Blog

Type 1 Diabetes Has Never Had a Disease-Modifying Therapy That Works After Diagnosis. Tzield Just Changed That. Here Is What the PROTECT Trial Data Shows.

June 25, 2026

📌 The essentials On June 12, 2026 (announced June 13), the FDA granted accelerated approval to Tzield (teplizumab-mzwv, Sanofi) for a new indication: to delay the decline in endogenous (the patient’s own) insulin production in pediatric patients aged 8 through 17 years recently diagnosed with Stage 3 type 1 diabetes (T1D). This is the first FDA-approved disease-modifying therapy for recently diagnosed Stage 3 type 1 diabetes. Prior to this approval, there was no treatment capable of altering the course of T1D after clinical diagnosis. Critical time window: treatment must be initiated within 8 weeks of Stage 3 T1D diagnosis. This is an acute clinical opportunity: families and pediatric endocrinologists need to be aware that this window exists and act accordingly. Regulatory pathway: accelerated approval based on C-peptide (a surrogate marker of beta-cell function reasonably likely to predict clinical benefit). A post-approval confirmatory study, the Phase 3 BETA-PRESERVE trial, is ongoing. The clinical basis: Phase 3 PROTECT trial (NCT03875729), 328 youth with Stage 3 T1D enrolled within 6 weeks of diagnosis. Two 12-day IV infusion courses (at baseline and at week 26). Primary endpoint: stimulated C-peptide AUC at 78 weeks, a validated surrogate of beta-cell function. Teplizumab significantly preserved C-peptide versus placebo at 78 weeks. Clinically meaningful beta-cell function maintained in 94.9% of teplizumab-treated patients versus 79.2% of controls. Supporting outcomes: better HbA1c, more time-in-range, less insulin use, and lower hypoglycemia favored teplizumab numerically, though without statistical significance for each. Tzield is not effective as a disease-modifying therapy in non-autoimmune dysglycemic conditions: it only works when the underlying cause is immune-mediated beta-cell destruction. Key safety warnings: cytokine release syndrome (CRS), lymphopenia, viral reactivation including EBV and CMV (most serious cases in patients who continued treatment despite persistent severe lymphopenia). Tzield’s complete indication picture after June 2026: Stage 2 T1D (delay of Stage 3 onset) in patients aged 1 year and older; Stage 3 T1D (delay of insulin production decline) in patients aged 8 to 17 years recently diagnosed.

Type 1 diabetes is an autoimmune disease in which the immune system destroys the insulin-producing beta cells of the pancreas. For almost the entirety of its known history, nothing in medicine could change that course after it began. Insulin was discovered in 1921 and saved countless lives, but it did not address the underlying immune attack. Immunosuppressive agents reduced beta-cell destruction in small studies but caused unacceptable side effects. The disease progressed. Eventually, the beta cells were gone.

Teplizumab (Tzield) was the first drug to change any part of that story. Its original approval in November 2022 for Stage 2 T1D (the pre-symptomatic stage, before diagnosis) demonstrated that a 14-day course of IV treatment could delay the onset of clinical diabetes by approximately two years in at-risk individuals. That was extraordinary. But it left open a question: what about the children who were already diagnosed?

On June 12, 2026, the FDA answered that question. Tzield received accelerated approval for use after diagnosis, specifically to delay the decline of the patient’s own insulin production in children and adolescents aged 8 to 17 who have been recently diagnosed with Stage 3 T1D. It is the first disease-modifying therapy ever approved for recently diagnosed type 1 diabetes. There has never been anything like it before.

This post covers the staged model of type 1 diabetes and why it matters clinically, how teplizumab’s CD3 mechanism works to modulate the autoimmune attack, what the PROTECT trial showed, what the accelerated approval pathway means for the evidence base, what the 8-week treatment window requires from families and clinicians, and what this approval means for the type 1 diabetes community.

The Staged Model of Type 1 Diabetes: Why the Stage Matters

Type 1 diabetes is not a single event. It is a continuum of progressive autoimmune destruction of pancreatic beta cells that begins years before clinical diagnosis and continues afterward. The staged model, developed by the American Diabetes Association and JDRF (now Breakthrough T1D), provides a framework that has reshaped how clinicians and researchers understand and now treat the disease.

Stage	Definition	What it means clinically
Stage 1 T1D	Two or more positive islet autoantibodies; normoglycemia; no symptoms	Beta-cell autoimmunity established; at high risk for progression; no metabolic dysfunction yet
Stage 2 T1D	Two or more positive islet autoantibodies; dysglycemia (glucose abnormalities without meeting diabetes criteria); no symptoms	Beta-cell loss accelerating; progression to Stage 3 virtually certain without intervention; Tzield approved here (Stage 2 in patients aged 1 year and older)
Stage 3 T1D	Two or more positive autoantibodies plus symptomatic hyperglycemia meeting diabetes diagnostic criteria	Clinical diabetes: the stage families recognize as “diagnosis.” Beta-cell function still partially preserved at this point; Tzield now approved here in patients aged 8 to 17 years recently diagnosed

The critical insight embedded in this staging model, and the reason the June 2026 approval matters so much, is that Stage 3 T1D does not begin with zero remaining beta cells. At the time of clinical diagnosis, a meaningful fraction of insulin-producing capacity is still present. The autoimmune attack has been ongoing for years, but it has not yet completed its work. There is a window, measured in weeks to months after clinical diagnosis, during which intervention to slow or interrupt the immune destruction of the remaining beta cells is still biologically possible and clinically meaningful.

That window is exactly what teplizumab’s new indication targets.

Why preserving residual beta-cell function matters clinically Even partial preservation of the patient’s own insulin production, measured as C-peptide secretion, translates into tangible clinical advantages that insulin therapy alone cannot replicate. Patients with measurable residual beta-cell function consistently show better HbA1c levels, more time in glycemic range, lower insulin requirements, and meaningfully reduced frequency of severe hypoglycemia compared to patients with no endogenous insulin production. The pancreas’s own insulin secretion is exquisitely responsive to real-time blood glucose fluctuations in a way that no external insulin replacement strategy, including advanced closed-loop systems, can fully replicate. This is the clinical rationale for C-peptide preservation as both a trial endpoint and a treatment goal: it is not an abstract biomarker. It is a direct predictor of quality of life, safety, and long-term diabetes outcomes.

How Teplizumab Works: The CD3 Mechanism

Teplizumab is a humanized monoclonal antibody that targets CD3, a protein complex on the surface of T cells. Understanding why blocking CD3 helps preserve beta cells requires a brief look at the immunology of type 1 diabetes.

In type 1 diabetes, autoreactive CD8+ cytotoxic T cells and CD4+ helper T cells infiltrate the pancreatic islets and selectively destroy the beta cells that produce insulin. These T cells recognize beta-cell antigens (such as glutamic acid decarboxylase and insulin itself) as foreign and mount a sustained immune attack. The attack is not a single event; it is an ongoing, progressive destruction that continues over years and accelerates toward the time of clinical diagnosis and beyond.

CD3 is a component of the T-cell receptor complex: it is the intracellular signaling module that transduces the activation signal when a T cell’s antigen receptor binds its target. By binding CD3, teplizumab modulates T-cell activation without completely eliminating T cells from the circulation. This partial modulation is important: unlike conventional immunosuppressants that broadly suppress all T cell activity (creating broad susceptibility to infection), teplizumab’s mechanism selectively tolerizes the autoreactive T cells most responsible for beta-cell destruction while preserving broader immune function.

The proposed mechanism includes several complementary effects: induction of partially exhausted or tolerogenic T cells that suppress the autoimmune response; preferential depletion of effector T cells in the inflamed islets; and expansion of regulatory T cells that actively suppress autoimmunity. The net result, observed in both the original Stage 2 trials and now in the Stage 3 PROTECT trial, is a slower rate of beta-cell destruction measurable as preserved C-peptide secretion over years of follow-up after the treatment is complete.

Teplizumab is administered as a 14-day intravenous infusion course, not as an ongoing therapy. Two courses are given: one at baseline (treatment initiation) and one at week 26 (6 months later). After that, no further doses are required. The immune reprogramming established by the two courses appears to produce durable benefit, as evidenced by the persistent C-peptide preservation observed in PROTECT through 78 weeks after enrollment.

The PROTECT Trial: What the Evidence Shows

Design

PROTECT (NCT03875729) was a Phase 3, randomized, double-blind, placebo-controlled multinational trial specifically designed to evaluate teplizumab in newly diagnosed Stage 3 T1D. The trial enrolled 328 children and adolescents (teplizumab n=217, placebo n=111) within 6 weeks of Stage 3 T1D diagnosis.

Treatment regimen: Two 12-day intravenous infusion courses of teplizumab or placebo: one at baseline and one at week 26, in addition to standard diabetes care (insulin therapy and glucose monitoring).

Primary endpoint: Stimulated C-peptide area under the curve (AUC) at 78 weeks, measured during a mixed meal tolerance test (MMTT). C-peptide is co-secreted with insulin from beta cells; its level in the blood is a direct measure of functional beta-cell mass, unaffected by exogenous insulin administration.

Primary endpoint results

Teplizumab significantly preserved stimulated C-peptide versus placebo at 78 weeks. C-peptide is a validated surrogate endpoint for beta-cell function that is reasonably likely to predict clinical benefit, which is the evidentiary standard for accelerated approval.

Secondary and supporting outcomes

Outcome	Teplizumab	Placebo	Notes
Clinically meaningful beta-cell function maintained at 78 weeks	94.9%	79.2%	Clinically significant difference; higher proportion preserved residual function
HbA1c	Numerically favored teplizumab	Reference	Did not reach statistical significance
Time in range	Numerically favored teplizumab	Reference	Did not reach statistical significance
Insulin dose	Numerically lower with teplizumab	Reference	Did not reach statistical significance
Hypoglycemia	Numerically lower with teplizumab	Reference	Did not reach statistical significance

Source: Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and beta-cell function in newly diagnosed type 1 diabetes. NEJM. 2023;389(23):2151–2161. doi:10.1056/NEJMoa2306691. PROTECT NCT03875729.

The finding that 94.9% of teplizumab-treated patients maintained clinically meaningful beta-cell function compared to 79.2% of controls at 78 weeks is clinically important. It means that a substantially higher proportion of treated children preserved enough of their own insulin production to realize the downstream glycemic benefits associated with residual beta-cell function.

The secondary outcome numerical trends (better HbA1c, more time in range, less insulin needed, less hypoglycemia) are directionally consistent with what prior research has shown about the clinical value of C-peptide preservation, even without reaching individual statistical significance. They support the clinical plausibility of the C-peptide surrogate endpoint.

Dr. Kevan Herold, MD, C.N.H. Long Professor of Immunobiology and Medicine at Yale School of Medicine and co-author of the PROTECT trial, has stated that practically all patients with new-onset Stage 3 T1D should be offered therapy unless there is an underlying condition that would prevent drug administration, describing the absence of other disease-modifying alternatives for T1D as the defining context for this recommendation.

The accelerated approval basis and confirmatory study

The FDA granted this approval under the accelerated approval pathway, based on C-peptide as a surrogate endpoint reasonably likely to predict clinical benefit. This is the same pathway used for many rare disease and serious condition approvals where waiting for long-term clinical outcome data would delay access to potentially beneficial therapies.

The BETA-PRESERVE trial (NCT05902884), a Phase 3 confirmatory study, is ongoing to verify the clinical benefit of C-peptide preservation in terms of direct patient outcomes including HbA1c, time in range, insulin requirements, and hypoglycemia frequency. Continued approval is contingent on the confirmatory study verifying this clinical benefit.

The 8-Week Treatment Window: What This Means Practically

The approved indication specifies patients recently diagnosed with Stage 3 T1D. Breakthrough T1D has clarified this as within the last 8 weeks of Stage 3 diagnosis. This is not an administrative convenience: it is a biological reality. The earlier treatment is initiated after clinical diagnosis, the more residual beta-cell function remains to preserve. Waiting months after diagnosis substantially reduces the potential benefit.

This 8-week window creates a specific and urgent clinical requirement: families and pediatric endocrinologists must be aware of Tzield’s availability at the time of diagnosis, not months later. For families receiving a new T1D diagnosis in a child or adolescent, this means:

Ask the diagnosing pediatric endocrinologist at the initial appointment whether Tzield is appropriate for your child
If your child is aged 8 to 17, was diagnosed within the past 8 weeks, and has confirmed autoimmune T1D, the conversation about Tzield should happen now, not at the 3-month follow-up visit
A referral to an academic center or JDRF-connected care team with experience in disease-modifying therapy may be appropriate if the diagnosing center is not yet familiar with the treatment protocol

The two 12-day IV infusion courses require IV access and monitoring during infusions, which means this is not a home therapy. It requires an infusion center or hospital setting, coordination of insurance authorization, and scheduling. These logistics take time, making awareness at diagnosis critical for staying within the treatment window.

Tzield’s Complete Indication Picture After June 2026

Two approvals and one significant expansion have occurred in 2026:

Indication	Population	Approval date
Delay onset of Stage 3 T1D	Adults and pediatric patients aged 1 year and older with Stage 2 T1D	November 2022 (original); expanded to ages 1 to 7 in April 2026 (previously 8 and older)
Delay decline in insulin production in recently diagnosed Stage 3 T1D	Pediatric patients aged 8 to 17 years within 8 weeks of Stage 3 T1D diagnosis	June 12, 2026 (accelerated approval)

The Stage 2 expansion to children as young as 1 year (April 2026, based on PETITE-T1D study data) and the Stage 3 approval (June 2026, PROTECT) together mean that teplizumab is now available across the full spectrum of high-risk and newly diagnosed pediatric T1D, from presymptomatic at-risk toddlers through adolescents at clinical diagnosis.

Safety: What the Prescribing Information and Trial Data Show

Teplizumab’s safety profile is driven by its mechanism of CD3-directed T-cell modulation during 12-day IV infusion courses. The adverse event profile in PROTECT was consistent with the previously characterized teplizumab dataset from over 900 patients across the development program.

Warnings and key adverse events:

Cytokine release syndrome (CRS): A class effect of CD3-directed therapies. CRS occurs during the infusion course and is characterized by fever, nausea, headache, fatigue, myalgia, and other systemic symptoms. In teplizumab trials, CRS is generally mild to moderate and managed with premedication (acetaminophen and antihistamines) and supportive care during infusion. Severe CRS has been reported and requires prompt management. Infusion settings must be equipped to manage CRS.

Lymphopenia: T-cell depletion is expected with teplizumab and is part of its mechanism. Severe lymphopenia requires close monitoring. The most serious viral reactivation events observed in the clinical program occurred in patients who continued therapy despite persistent, severe lymphopenia. Current guidance requires dose interruption or discontinuation in the setting of persistent severe lymphopenia.

Viral reactivation: Serious, life-threatening cases of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation have been reported. Most serious cases occurred in patients with persistent, severe lymphopenia who continued treatment. Viral reactivation surveillance before and during treatment is essential.

Other adverse events reported in PROTECT: Lymphopenia (expected), cytopenias (reductions in other blood cell types), gastrointestinal symptoms, rash, transaminase elevations, and headache. These were generally consistent with the expected immunomodulatory effects of the drug.

Pre-treatment requirements:

Screening for EBV and CMV serostatus before initiating treatment
Complete blood count monitoring before and during treatment courses
Premedication before infusions to reduce CRS severity
Avoid live vaccines during and after treatment until lymphocyte recovery is confirmed

Contraindications:

Active serious infection
Immunocompromised patients are at increased risk; careful benefit-risk assessment required
Tzield is not effective as a disease-modifying therapy in non-autoimmune dysglycemic conditions: laboratory confirmation of autoimmune etiology (positive islet autoantibodies) is a clinical prerequisite

What This Means for Families and Clinicians

For families of a child recently diagnosed with T1D

If your child is aged 8 to 17 and has been diagnosed with type 1 diabetes within the past 8 weeks, Tzield is now an FDA-authorized option that deserves immediate discussion with your pediatric endocrinologist. This is not a therapy to consider “later.” The 8-week window is real and it closes.

Questions to ask your endocrinology team:

Has my child had autoantibody testing that confirms autoimmune T1D?
Are we within 8 weeks of diagnosis?
Is Tzield appropriate for my child given their health history?
Where can we receive the infusion courses?
What is the prior authorization process with our insurance?

The Breakthrough T1D website and JDRF Tzield resources provide current information for families navigating this decision. Sanofi’s Tzield support program (1-800-633-1610) provides information about access, insurance navigation, and referral to treatment centers.

For pediatric endocrinologists

This approval creates a new, urgent clinical protocol: at the time of Stage 3 T1D diagnosis in any patient aged 8 to 17, the Tzield conversation should occur within the first visit or at minimum within the first week of diagnosis. This is the same urgency model used for conditions like acute lymphoblastic leukemia, where initiating disease-modifying treatment in the correct window fundamentally alters long-term outcomes.

The treatment infrastructure requirements (IV infusion over 12 consecutive days, monitoring for CRS and lymphopenia, EBV/CMV screening) mean that systems-level readiness at pediatric endocrinology centers is important. Centers not currently equipped to administer teplizumab should establish referral pathways to centers that are.

The broader significance

Dr. Aaron J. Kowalski, PhD, CEO of Breakthrough T1D, described the approval as providing “a novel therapy that targets the autoimmune and progressive nature of stage 3 type 1 diabetes,” noting that approximately 64,000 people are diagnosed with T1D every year in the United States. For the pediatric portion of that population, a brief window of opportunity now exists to alter the course of the disease in a way that was not previously possible.

Type 1 diabetes has been managed for over 100 years with increasingly sophisticated insulin replacement. This is the first time a treatment has been approved that goes beyond replacement to address the underlying autoimmune destruction. It is a genuinely historic moment for the T1D community.

For related HED coverage on other disease-modifying therapies and autoimmune conditions, see our post on Ocrevus (ocrelizumab) receiving pediatric approval for relapsing-remitting multiple sclerosis, another CD20-directed therapy that alters the course of an autoimmune disease, and our post on Awiqli, the first once-weekly basal insulin for type 2 diabetes, for context on how the insulin therapy landscape continues to evolve alongside disease-modifying approaches.

Sources

FDA approval announcement: FDA approves new indication for Tzield (teplizumab) for certain pediatric patients with recently diagnosed Stage 3 type 1 diabetes. FDA.gov. June 12 (announced June 15), 2026.

Sanofi press release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes. Sanofi. June 12, 2026.

Drugs.com approval news: Sanofi’s Tzield Approved in the US as the First Disease-Modifying Therapy for Patients Recently Diagnosed with Stage 3 Type 1 Diabetes. drugs.com. June 13, 2026.

FDA plain language summary: FDA approves drug for pediatric stage 3 type I diabetes. FDA.gov. June 2026.

Pharmacy Times clinical review: FDA Approves Teplizumab-mzwv for Children With Newly Diagnosed Stage 3 Type 1 Diabetes. pharmacytimes.com. June 2026.

Patient Care Online clinical summary (with investigator cautions): FDA Expands Teplizumab Approval for Pediatric Stage 3 Type 1 Diabetes. patientcareonline.com. June 2026.

Healio endocrinology coverage: FDA approves Tzield to treat children and adolescents with stage 3 type 1 diabetes. healio.com. June 2026.

Pediatric Endocrine Society clinical summary: Teplizumab Approval Expanded to Stage 3 Type 1 Diabetes (Ages 8-17). pedsendo.org. June 2026.

Breakthrough T1D community update: Tzield approved for stage 3 T1D in the U.S. breakthrought1d.org. June 2026.

BioPharm International coverage: FDA Expands Pfizer’s Hympavzi Approval… (note: cross-reference; not directly cited for Tzield)

Sanofi Stage 2 expansion (April 2026, ages 1-7): Sanofi’s Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children. sanofi.com. April 22, 2026.

PROTECT trial primary publication: Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and beta-cell function in newly diagnosed type 1 diabetes. NEJM. 2023;389(23):2151–2161. doi:10.1056/NEJMoa2306691.

PROTECT trial registration: NCT03875729. ClinicalTrials.gov.

BETA-PRESERVE confirmatory trial registration: NCT05902884. ClinicalTrials.gov.

Teplizumab mechanism review: Teplizumab in Type 1 Diabetes. PMC9356435.

T1D staging scientific statement: Staging Presymptomatic Type 1 Diabetes. Diabetes. 2015;64(8):2541–2550.

T1D StatPearls: Type 1 Diabetes Mellitus. StatPearls. NCBI.

NIDDK T1D overview: Type 1 Diabetes. NIDDK.

Accelerated approval pathway: Accelerated Approval. FDA.gov.

EBV: Epstein-Barr Virus. StatPearls. NCBI.

CMV: Cytomegalovirus. StatPearls. NCBI.

Tzield prescribing information: TZIELD (teplizumab-mzwv) Prescribing Information. Sanofi. 2026.

Patient resources: Breakthrough T1D (JDRF) | American Diabetes Association: Type 1 | Sanofi Tzield patient support: 1-800-633-1610 | NIDDK Type 1 Diabetes

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Tzield (teplizumab-mzwv) is indicated for recently diagnosed Stage 3 T1D in pediatric patients aged 8 to 17 years within 8 weeks of diagnosis. It is not effective in non-autoimmune dysglycemic conditions. Treatment requires IV infusion and monitoring in a qualified clinical setting. Families should consult with a board-certified pediatric endocrinologist immediately after a child’s Stage 3 T1D diagnosis to determine eligibility and timing within the treatment window.

Ebglyss Can Now Be Given Every 8 Weeks Instead of Every 4. For Patients With Moderate-to-Severe Atopic Dermatitis, That Is a Meaningful Change. Here Is What the Science Shows.

June 24, 2026

📌 The essentials On June 9, 2026, the FDA approved a new maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz, Eli Lilly): one injection of 250 mg every 8 weeks (Q8W) for adults and adolescents aged 12 years and older weighing at least 40 kg (approximately 88 lbs) with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical prescription therapies. This is a new dosing regimen approval, not a new drug or new indication. Ebglyss was originally approved in September 2024 for the same population with a once-every-4-weeks (Q4W) maintenance regimen. The complete dosing schedule with the Q8W option: induction with 500 mg (two 250 mg injections) at weeks 0 and 2, then 250 mg every 2 weeks through week 16 or until adequate clinical response is achieved, followed by maintenance dosing of either 250 mg Q4W or 250 mg Q8W. What makes the Q8W approval clinically notable: Ebglyss is now the only FDA-approved biologic for atopic dermatitis that offers as few as 6 maintenance injections per year without a mandatory requirement for concomitant topical therapy from treatment initiation. No other approved AD biologic currently combines both of these features. The evidence basis: longitudinal exposure-response modeling and the Q8W ADjoin extension (NCT04392154), a 32-week open-label study evaluating Q8W and Q4W dosing in patients who had completed the 100-week ADjoin long-term study. No new safety signals were identified. No patients discontinued due to adverse events through 32 weeks. Important interpretive caveat: extension participants had already received approximately 100 weeks of lebrikizumab therapy before entering the Q8W study. The real-world applicability to newly initiating patients who transition to Q8W earlier has not been directly studied.

Atopic dermatitis is not a rash. It is a chronic, relapsing immune-mediated inflammatory disease of the skin that affects an estimated 16 million adults in the United States, more than 10% of the adult population, and a substantially higher proportion of children. At its severe end, atopic dermatitis produces relentless itch, disrupted sleep, cracked and weeping skin, and a psychological burden documented to rival conditions such as psoriasis and chronic pain. For adults and adolescents with moderate-to-severe disease inadequately controlled by topical therapies, systemic treatments including biologics are increasingly the standard of care.

Ebglyss (lebrikizumab), an IL-13 inhibitor, was approved in September 2024 with a once-monthly (Q4W) maintenance dosing schedule. On June 9, 2026, the FDA approved an expanded maintenance option: one injection every 8 weeks (Q8W), allowing eligible patients to reduce their annual injection burden from 13 to as few as 6 after completing induction. That numerical change from 13 to 6 injections per year is not a trivial reduction in the context of a disease that will require ongoing management for most patients indefinitely.

This post covers what atopic dermatitis is, how IL-13 drives its pathology and why blocking it works, what the ADjoin extension data supports, what the competitive significance of the Q8W approval is, and what patients and prescribers need to know about the dosing schedule in practice.

What Atopic Dermatitis Is and Why Moderate-to-Severe Disease Requires Systemic Therapy

Atopic dermatitis is a chronic inflammatory skin disease driven by dysfunction in both the skin barrier and the immune system. The two abnormalities are interconnected: a defective epidermal barrier, often related to mutations in the gene encoding filaggrin, allows allergens, irritants, and microorganisms to penetrate the skin, triggering and sustaining a type 2 (Th2-skewed) immune response. The resulting cytokine cascade, dominated by IL-4, IL-13, and IL-31, drives ongoing skin inflammation, barrier disruption, and the hallmark symptom of atopic dermatitis: intense, persistent itch.

The Th2-skewed immune response in atopic dermatitis is what has made this disease amenable to targeted biologic therapy. The first approved biologic for AD, dupilumab (Dupixent), targets both IL-4 and IL-13 by blocking the shared IL-4 receptor alpha chain. Lebrikizumab takes a more targeted approach: it binds specifically and exclusively to IL-13.

Why moderate-to-severe atopic dermatitis requires more than topical therapy

Topical corticosteroids and calcineurin inhibitors (tacrolimus, pimecrolimus) are effective for mild to moderate disease but have significant limitations in moderate-to-severe disease. Long-term topical corticosteroid use carries risks of skin atrophy, striae, and hypothalamic-pituitary-adrenal axis suppression with extensive application. The emotional and logistical burden of applying topical agents to extensive, inflamed skin multiple times daily is substantial, particularly for patients with involvement of difficult-to-treat areas such as the face, neck, and skin folds.

For patients whose disease is not adequately controlled by topical prescription therapies, systemic options including biologics targeting IL-4/IL-13 signaling (dupilumab, tralokinumab, lebrikizumab) and the JAK inhibitor class (upadacitinib, abrocitinib, baricitinib) represent the current standard. No mandatory concomitant topical therapy requirement at treatment initiation is a practical advantage for patients with extensive or difficult-to-treat distribution.

The Science: How IL-13 Drives Atopic Dermatitis and Why Blocking It Works

Interleukin-13 (IL-13) is a cytokine produced primarily by activated Th2 T cells, innate lymphoid cells type 2 (ILC2), and mast cells in atopic skin. It is the dominant driver of multiple pathological processes in atopic dermatitis:

Skin barrier disruption: IL-13 suppresses the expression of filaggrin, loricrin, and other structural proteins essential for the epidermal barrier. By reducing barrier protein synthesis, IL-13 perpetuates the permeability defect that allows allergen penetration and drives the cycle of sensitization and immune activation.

Itch: IL-13 directly stimulates sensory nerve fibers and primes skin-resident cells to release histamine and other pruritogens, contributing directly to the intense itch that is the defining symptom of atopic dermatitis.

Inflammation: IL-13 activates keratinocytes, fibroblasts, and other skin cells to produce chemokines and adhesion molecules that recruit additional immune cells to the skin, amplifying the local inflammatory response.

IgE production: IL-13 cooperates with IL-4 to drive B cell class switching to IgE production, the antibody class responsible for atopic sensitization.

Lebrikizumab is a high-affinity human monoclonal antibody that binds specifically to IL-13 itself, rather than to the IL-4/IL-13 shared receptor that dupilumab targets. By capturing circulating IL-13 before it can engage its receptor, lebrikizumab blocks downstream signaling through both the IL-13Rα1/IL-4Rα heterodimer (the signaling receptor for IL-13 in skin cells) and the IL-13Rα2 decoy receptor. The high binding affinity and specificity for IL-13 means the drug does not affect IL-4 signaling, which distinguishes it from dupilumab pharmacologically, though clinical outcomes in pivotal trials have been broadly comparable in terms of efficacy endpoints.

The structural basis for lebrikizumab’s IL-13 binding has been characterized crystallographically: the antibody binds at a distinct epitope on IL-13 that prevents both IL-13Rα1 and IL-13Rα2 engagement, explaining the completeness of its IL-13 blockade.

The Approved Dosing Schedule: Complete and Correct

With the June 9, 2026 approval, the complete Ebglyss dosing schedule for the approved population (adults and adolescents aged 12 years and older, weight at least 40 kg) is:

Phase	Dose	Frequency
Induction (weeks 0 and 2)	500 mg (two 250 mg injections administered at the same visit)	Two doses, two weeks apart
Maintenance (weeks 2 through 16 or until adequate response)	250 mg single injection	Every 2 weeks (Q2W)
Maintenance (after adequate response achieved, ongoing)	250 mg single injection	Every 4 weeks (Q4W) OR every 8 weeks (Q8W) — patient and clinician choice

The decision between Q4W and Q8W maintenance should be individualized. Patients with robust and sustained response who prefer a less frequent injection schedule are candidates for Q8W. Patients with a history of more frequent flares or less complete response may be better maintained on Q4W. This is a clinical judgment discussion between the patient and their dermatologist.

Annual injection count summary:

Induction (2 visits, 4 injections total across weeks 0 and 2, plus Q2W phase)
Q4W maintenance: approximately 13 injections per year
Q8W maintenance: as few as 6 injections per year

The ADjoin Extension Data: What Supported the Q8W Approval

The Q8W approval was based on two complementary data sources: longitudinal exposure-response modeling and the Q8W ADjoin extension study.

Exposure-response modeling

The pharmacokinetic and pharmacodynamic data from the original lebrikizumab development program, including ADvocate 1 and ADvocate 2 (the pivotal Phase 3 trials), demonstrated that lebrikizumab’s long half-life and sustained IL-13 suppression at Q8W dosing supported the hypothesis that every-8-week dosing could maintain therapeutic drug levels and clinical response in patients who had achieved adequate disease control. Longitudinal exposure-response modeling provides the mechanistic rationale for the regimen; the ADjoin extension provided the confirmatory clinical data.

ADjoin extension (NCT04392154)

The Q8W ADjoin extension was a 32-week open-label study evaluating Q8W and Q4W dosing in adult and adolescent patients who had completed the 100-week ADjoin long-term study. ADjoin itself enrolled completers from four prior Phase 3 trials: ADvocate 1 and 2 (52-week trials), ADore (52-week trial), and ADopt-VA (16-week trial). Patients in the extension received open-label Ebglyss 250 mg, Q8W or Q4W, regardless of their prior dosing interval (Q2W or Q4W) or response status at extension baseline.

Extension safety findings:

No new safety signals identified through 32 weeks of Q8W dosing
No patients discontinued due to adverse events through 32 weeks
Safety profile consistent with the established lebrikizumab dataset

Efficacy:

Disease control was maintained through 32 weeks in both Q8W and Q4W dosing groups
Long-term data from the broader lebrikizumab program show durable disease control for up to 4 years of continuous treatment

Dr. Peter Lio, MD, primary investigator of the ADjoin study and Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University, noted that extending maintenance dosing to every eight weeks represents an important option for patients living with moderate-to-severe atopic dermatitis.

The important interpretive caveat

The patients in the Q8W ADjoin extension had already completed approximately 100 weeks of lebrikizumab therapy before entering the extension. They were therefore a population with demonstrated long-term tolerability and sustained response, representing a selected, treatment-experienced group. The real-world applicability of Q8W dosing in newly initiating patients who have completed induction and transitioned earlier to Q8W maintenance has not been directly studied in a de novo population. Dermatologists should discuss this with patients: the 6-injections-per-year figure applies to patients who have achieved and maintained adequate response; the long-term profile of Q8W in newly initiated patients should be monitored as real-world experience accumulates.

Competitive Context: Where This Places Ebglyss in the AD Biologic Landscape

The atopic dermatitis biologic market in 2026 is the most competitive it has ever been. The approved biologics for moderate-to-severe AD include:

Drug	Target	Approval	Dosing (maintenance)	Mandatory topical
Dupixent (dupilumab, Sanofi/Regeneron)	IL-4Rα (blocks IL-4 and IL-13)	2017 (adults); expanded	Q2W	No
Adbry (tralokinumab, LEO Pharma)	IL-13	2021	Q2W; Q4W option available	No
Ebglyss (lebrikizumab, Lilly)	IL-13	2024	Q4W or Q8W	No

The Q8W approval gives Ebglyss a dosing frequency advantage over dupilumab (Q2W mandatory maintenance) and tralokinumab (Q2W standard, Q4W available for responders). Ebglyss’s Q8W maintenance option of as few as 6 injections per year, without a mandatory concomitant topical therapy requirement, is a combination not currently available with any other approved AD biologic. That distinction is commercially meaningful for Lilly and clinically meaningful for the subset of patients who are well-controlled responders and for whom injection burden influences long-term adherence.

The practical comparison for prescribers: dupilumab has the most extensive long-term evidence base and the broadest approved indication range (including asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and prurigo nodularis in addition to AD). For patients whose primary driver is AD management and for whom injection frequency is a concern, Ebglyss’s Q8W option is now a differentiating factor worth discussing.

Safety: What Prescribers and Patients Need to Know

The safety profile of lebrikizumab with the Q8W dosing regimen is consistent with the established dataset from the full lebrikizumab clinical program. The most common adverse reactions (occurring in at least 1% of patients) are:

Conjunctivitis: The most characteristic class effect across all IL-4/IL-13 pathway targeting biologics. Conjunctivitis in the lebrikizumab trials occurs at lower rates than typically reported with dupilumab, which is a clinically relevant distinction for patients who have experienced significant eye symptoms on dupilumab. Mild to moderate conjunctivitis should be assessed and treated with ophthalmic supportive care; if severe or persistent, ophthalmology consultation and discussion of dose adjustment are appropriate.

Injection site reactions: Common, typically mild (redness, pain, swelling at the injection site), and generally not requiring discontinuation. Rotate injection sites; abdomen, thigh, and upper arm are acceptable locations.

Herpes zoster: IL-13 pathway inhibition has a low but documented association with herpes zoster (shingles) reactivation. Patients who have not been vaccinated against herpes zoster should discuss vaccination with their dermatologist before initiating long-term biologic therapy for atopic dermatitis.

Contraindications:

Hypersensitivity to lebrikizumab-lbkz or any ingredient in Ebglyss

Live vaccines: As with all biologic therapies, live attenuated vaccines should not be administered during lebrikizumab treatment. Update all vaccines, including zoster vaccine, before initiating therapy.

Pregnancy: The effect of lebrikizumab on a developing fetus is not fully established. Discuss contraception and pregnancy planning with patients of reproductive potential. A pregnancy exposure registry (1-800-545-6962) is available for patients who become pregnant while on Ebglyss.

What This Means for Patients

For patients currently on Ebglyss Q4W who are achieving good disease control, the Q8W option is now available to discuss with their dermatologist. If you have been well-controlled for an extended period on Q4W maintenance and would benefit from a less frequent injection schedule, this is a conversation worth initiating at your next dermatology appointment.

For patients newly initiating Ebglyss: the standard induction and Q2W maintenance schedule remains the starting point. The Q8W option comes after achieving adequate clinical response, which typically occurs by week 16. The dosing path is: start with induction, achieve response, then discuss with your dermatologist whether Q4W or Q8W maintenance fits your response profile and lifestyle.

For patients who have experienced significant conjunctivitis on dupilumab: lebrikizumab’s IL-13-only mechanism (not blocking IL-4) is associated with lower conjunctivitis rates than dupilumab in clinical trials, making it a clinically reasonable alternative for patients where ocular side effects have been a management challenge.

For prescribers: the Q8W approval gives an additional tool for the conversation about long-term maintenance. Patient adherence to any chronic biologic therapy is improved by dosing schedules that fit into normal life rhythms. Six injections per year, administered at home without routine monitoring requirements, is a significantly lighter burden than monthly or biweekly regimens for patients who can achieve and sustain adequate disease control.

For related HED coverage on biologics for inflammatory conditions and the expanding IL-13 inhibitor class, see our post on Fasenra (benralizumab) receiving its new indication for hypereosinophilic syndrome and our post on Xolair (omalizumab) and its biosimilar transition as part of the 2026 LOE series, which covers the broader IgE/type-2 inflammation treatment landscape in which both drug classes operate.

Sources

Lilly FDA approval press release: FDA approves Lilly’s EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks. Eli Lilly. investor.lilly.com. June 9, 2026.

Drugs.com approval news: FDA Approves Lilly’s Ebglyss for One Maintenance Dose Every Eight Weeks. drugs.com. June 9, 2026.

HCPLive clinical coverage: FDA Approves Lebrikizumab 8-Week Maintenance Dosing in Atopic Dermatitis. hcplive.com. June 2026.

BioPharm International clinical coverage: FDA Approves Lebrikizumab Every-8-Week Maintenance Dosing for Moderate-Severe Atopic Dermatitis. biopharminternational.com. June 2026.

Contemporary Pediatrics (with investigator caveat): FDA approves lebrikizumab every-8-week maintenance dosing for moderate-to-severe atopic dermatitis. contemporarypediatrics.com. June 2026.

Dermatology Times coverage: Lebrikizumab Earns FDA Approval for Less Frequent, Every-8-Week Maintenance Dosing in AD. dermatologytimes.com. June 2026.

ADjoin extension (NCT04392154): NCT04392154. ClinicalTrials.gov.

Silverberg J et al. (ADjoin Q8W data; Fall Clinical Dermatology Conference 2025): Silverberg J, et al. Lebrikizumab every 8 weeks as maintenance dose provides long-lasting response in patients with moderate-to-severe atopic dermatitis. Fall Clinical Dermatology Conference. 2025.

4-year durability data (Almirall): Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis. Almirall press release. March 27, 2026.

Ebglyss original FDA approval (September 2024): FDA approves lebrikizumab-lbkz for atopic dermatitis. FDA.gov.

Dupixent FDA approval: FDA approves dupilumab for moderate to severe atopic dermatitis. FDA.gov.

Adbry FDA approval: FDA approves tralokinumab-ldrm for atopic dermatitis. FDA.gov.

IL-13 in atopic dermatitis: IL-13 in Atopic Dermatitis. PMC8908499.

Lebrikizumab IL-13 binding mechanism: Okragly A et al. Binding, neutralization and internalization of IL-13 antibody lebrikizumab. Dermatology and Therapy. 2023. doi:10.1007/s13555-023-00947-7.

Lebrikizumab structural basis: Ultsch M et al. Structural basis of signaling blockade by IL-13 antibody lebrikizumab. Journal of Molecular Biology. 2013;425(8):1330-1339. doi:10.1016/j.jmb.2013.01.024.

Atopic dermatitis epidemiology: Atopic Dermatitis. StatPearls. NCBI.

Atopic dermatitis quality of life burden: AD Quality of Life and Burden. PMC7305275.

NIAMS atopic dermatitis overview: Atopic Dermatitis. NIAMS.

Ebglyss prescribing information: EBGLYSS (lebrikizumab-lbkz) Prescribing Information. Eli Lilly. 2026.

Patient resources: National Eczema Association | American Academy of Dermatology: Find a Dermatologist | Lilly Ebglyss patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about biologic therapy for atopic dermatitis, including the choice between Q4W and Q8W maintenance dosing for Ebglyss, should be made in close consultation with a board-certified dermatologist or allergist familiar with the patient’s disease history, prior treatment response, and overall health profile.

Hympavzi Just Became Available to Children as Young as 6 and to Patients With Hemophilia Inhibitors — Two of the Groups Who Have Needed It Most. Here Is What the BASIS Trial Data Shows.

June 23, 2026

📌 The essentials On June 8, 2026, the FDA approved an expanded indication for Hympavzi (marstacimab-hncq, Pfizer) to include two additional patient populations: patients aged 12 years and older with hemophilia A or B who have inhibitors, and pediatric patients aged 6 to 11 years with hemophilia A or B with or without inhibitors. Hympavzi was originally approved in October 2024 for patients aged 12 years and older without inhibitors. The complete current indication: routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 6 years and older with hemophilia A (congenital factor VIII deficiency) or hemophilia B (congenital factor IX deficiency), with or without inhibitors. First-in-class designations from the expanded approval: Hympavzi is now the first subcutaneous non-factor therapy available for children aged 6 to 11 years with hemophilia B. Mechanism: Hympavzi targets the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI), a natural anticoagulant that brakes the initiation of coagulation. By inhibiting TFPI, marstacimab restores the coagulation pathway in a way that works regardless of whether the patient is deficient in factor VIII or factor IX, and regardless of whether inhibitory antibodies are present against those factors. This is why it works in both hemophilia A and B, and in patients with inhibitors. The clinical basis: Phase 3 BASIS trial (NCT03938792) inhibitor cohort and Phase 3 BASIS KIDS trial (NCT05611801). BASIS inhibitor cohort: 93% reduction in mean treated annualized bleeding rate (ABR) versus on-demand bypassing agent therapy (1.4 [95% CI 0.9 to 2.3] versus 19.8 [95% CI 16.1 to 24.3]; ratio 0.07 [95% CI 0.04 to 0.12]; p less than 0.0001). BASIS KIDS (ages 6 to 17): mean ABR 1.8 versus historical model-based mean ABR 3.6 with prior routine prophylaxis. Pediatric inhibitor subgroup (ages 6 to under 18; n=14): mean ABR 1.4 (99% CI 0.5 to 4.5) versus historical mean ABR 18.9 (99% CI 14.2 to 25.2). Ages 6 to 11 cohort (n=7): mean ABR 1.3 (99% CI 0.5 to 3.4). Warnings: thromboembolic events occurred in 2 of 259 patients in the open-label extension study; hypersensitivity reactions; embryo-fetal toxicity; increased laboratory values of fibrin D-dimer and prothrombin fragment 1.2. Dosing: once weekly subcutaneous injection; available as 75 mg/0.5 mL and 150 mg/mL prefilled syringe or autoinjector pen. No routine treatment-related laboratory monitoring required.

Hemophilia is, at its core, a disease of imbalance. The coagulation cascade that allows blood to clot and stop bleeding is a tightly regulated system of amplification, and in hemophilia A or B, a critical amplifier is missing or deficient. The consequences, when left untreated or inadequately treated, are relentless: joint bleeds that destroy cartilage and deform limbs, muscle hemorrhages that compress nerves and blood vessels, and intracranial bleeding that can be fatal. For patients with a specific complication called inhibitors, even the standard replacement therapy stops working, leaving them in a position where a category of medications designed to save their lives has become ineffective against their own immune response.

Hympavzi (marstacimab-hncq), originally approved in October 2024, takes an entirely different approach to hemophilia prophylaxis. Rather than replacing the deficient clotting factor, it blocks a natural brake on the coagulation system: tissue factor pathway inhibitor (TFPI). On June 8, 2026, the FDA expanded Hympavzi’s approved indication to two of the groups most in need of this approach: patients with hemophilia A or B who have inhibitors (where factor replacement therapy either cannot work or works inadequately), and children aged 6 to 11 years, the youngest pediatric age group that can benefit from a once-weekly subcutaneous prophylactic therapy.

This post covers what hemophilia is, why inhibitors represent such a significant clinical challenge, how the TFPI mechanism works and why it is effective across both hemophilia types and inhibitor-positive patients, what the BASIS and BASIS KIDS trial data shows, and what the expanded approval means for families and clinicians managing these patients.

What Hemophilia Is: A Brief Overview

Hemophilia is a rare, X-linked recessive bleeding disorder caused by deficiency or dysfunction of specific coagulation factors. Two major types are recognized:

Hemophilia A is caused by deficiency or dysfunction of factor VIII (FVIII). It is the more common type, affecting approximately 1 in 5,000 male births.

Hemophilia B is caused by deficiency or dysfunction of factor IX (FIX). It affects approximately 1 in 25,000 male births.

Both conditions result in a dysfunctional coagulation cascade, the sequential activation of clotting proteins that ultimately converts fibrinogen to fibrin and forms a stable blood clot. Without adequate FVIII or FIX activity, the intrinsic pathway of coagulation cannot amplify adequately, resulting in delayed, insufficient clot formation. Minor injuries that healthy individuals handle without consequence become prolonged bleeding events in hemophilia. Spontaneous joint and muscle bleeds, which occur without obvious trauma, are a hallmark of severe hemophilia and are responsible for the progressive arthropathy (joint destruction) that historically defined the long-term morbidity of the disease.

The standard of care for moderate to severe hemophilia has been prophylactic factor replacement: infusing FVIII or FIX concentrate on a scheduled basis, typically two to three times per week for IV formulations or less frequently for extended half-life products, to maintain factor levels high enough to prevent spontaneous bleeding. This approach has dramatically improved outcomes over the past four decades. It requires, however, venous access and intravenous administration, which is particularly challenging in young children whose veins are small and who may require port placement.

The inhibitor problem

Inhibitors are neutralizing antibodies against the infused clotting factor, most commonly FVIII in hemophilia A. They develop in approximately 30% of patients with severe hemophilia A and in a smaller proportion of hemophilia B patients, typically early in treatment. When inhibitors are present, the infused factor is rapidly neutralized before it can participate in clotting, and standard prophylaxis becomes ineffective.

Managing hemophilia with inhibitors has historically required bypassing agents, products that activate the coagulation cascade at steps downstream of where FVIII and FIX normally act: recombinant factor VIIa (NovoSeven) and activated prothrombin complex concentrate (aPCC, FEIBA). These agents work differently from standard factor replacement and are less precisely dosed, making achieving predictable bleeding protection more challenging. Their use is also expensive, requires intravenous administration, and when used on-demand (only when bleeding occurs) rather than prophylactically, leaves patients with significant residual bleeding burden.

Why non-factor therapies are a breakthrough for inhibitor patients The development of non-factor hemostatic therapies, which restore hemostasis by mechanisms that bypass the deficient factor entirely, represents one of the most significant advances in hemophilia management in decades. Emicizumab (Hemlibra), approved in 2017 for hemophilia A with inhibitors, was the first such therapy and demonstrated dramatic reductions in bleeding rates in a population that had previously had very limited prophylactic options. It works by bridging FIXa and FX, mimicking the co-factor function of FVIII specifically. However, because emicizumab bridges FIXa (factor IX in activated form), it works only in hemophilia A: it provides no benefit in hemophilia B because FIX is not a bridging partner for its mechanism. Marstacimab’s TFPI inhibition mechanism is active in both hemophilia A and hemophilia B regardless of inhibitor status, because it restores hemostasis upstream of where either FVIII or FIX deficiency disrupts the cascade. This is why Hympavzi’s expanded indication covers both hemophilia types and both inhibitor-positive and inhibitor-negative patients.

The Science: How Marstacimab Works

Tissue factor pathway inhibitor (TFPI) is a naturally occurring anticoagulant protein. It functions as a feedback inhibitor of the extrinsic pathway of coagulation: after tissue factor and factor VIIa initiate clotting in response to vascular injury, TFPI rapidly inhibits the TF-FVIIa-FXa complex, effectively braking the initial clotting signal after it has had time to initiate.

In healthy individuals, this brake is appropriate. The extrinsic pathway generates only a small initial burst of thrombin, and the intrinsic pathway (which requires FVIII and FIX) amplifies this initial signal to generate the large amounts of thrombin needed for stable clot formation. When FVIII or FIX is deficient, the initial thrombin burst generated by the extrinsic pathway is inadequate, and the amplification step through the intrinsic pathway cannot compensate. TFPI’s braking of the extrinsic pathway further limits the already insufficient hemostatic response.

Marstacimab is a human monoclonal antibody that targets the Kunitz 2 (K2) domain of TFPI with high specificity. The K2 domain is the site through which TFPI inhibits FXa, a critical downstream clotting protein. By blocking the K2 domain, marstacimab prevents TFPI from inhibiting FXa as efficiently. This allows the coagulation cascade to generate more thrombin from the extrinsic pathway initiation step, partially compensating for the deficient intrinsic amplification. The result is a shift in the coagulation balance toward clot formation even in the absence of adequate FVIII or FIX.

Critically, this mechanism functions regardless of:

Whether the patient is deficient in FVIII (hemophilia A) or FIX (hemophilia B)
Whether inhibitory antibodies are present against FVIII or FIX
The severity of the underlying factor deficiency

Because marstacimab acts on a checkpoint in the coagulation cascade that is common to both hemophilia types and is entirely upstream of where inhibitors act against replacement factors, it provides hemostatic coverage across the full breadth of the expanded indication.

The Original Approval and What the Expansion Adds

Original approval (October 2024)

Hympavzi was initially approved in October 2024 for routine prophylaxis in patients aged 12 years and older with hemophilia A without FVIII inhibitors or hemophilia B without FIX inhibitors, based on the Phase 3 BASIS trial in the non-inhibitor cohort.

The June 2026 expansion

The June 8, 2026 expansion adds two critically important populations:

Population 1: Patients aged 12 years and older with hemophilia A or B who have inhibitors. This is the group with the most limited treatment options prior to this approval, for whom on-demand bypassing agents were often the only recourse for bleeding management.

Population 2: Pediatric patients aged 6 to 11 years with hemophilia A or B, with or without inhibitors. This extends Hympavzi’s reach to younger children, a population in whom venous access for IV therapy is a significant practical challenge, and for whom a once-weekly subcutaneous injection is potentially far more manageable than frequent IV infusions.

Together, the expanded and original indications give Hympavzi a single consolidated label: routine prophylaxis for adults and pediatric patients aged 6 years and older with hemophilia A or B, with or without inhibitors.

The Clinical Evidence: BASIS Inhibitor Cohort and BASIS KIDS

BASIS trial (NCT03938792): the inhibitor cohort data

BASIS (NCT03938792) was a Phase 3, global, open-label trial evaluating marstacimab in patients with hemophilia A or B with and without inhibitors. The trial included an inhibitor cohort of patients who had previously received on-demand (OD) bypassing agent therapy for bleeding episodes. This population represents the clinical severity of inhibitor disease: patients who had not been on prophylaxis and were relying on reactive treatment when bleeds occurred.

The primary efficacy comparison in the inhibitor cohort was marstacimab prophylaxis versus on-demand bypassing agent therapy. The results were striking:

Outcome	Marstacimab prophylaxis	On-demand bypassing agent (historical)	Comparison
Mean treated annualized bleeding rate (ABR)	1.4 (95% CI 0.9 to 2.3)	19.8 (95% CI 16.1 to 24.3)	93% reduction; ratio 0.07 (95% CI 0.04 to 0.12); p less than 0.0001

Source: Clinical Advisor. Hympavzi Gains Expanded FDA Approval for Hemophilia A and B. June 2026. Hematology Advisor. June 2026. Pfizer press release, June 8, 2026.

A 93% reduction in mean treated annualized bleeding rate compared to on-demand bypassing therapy is a clinically substantial finding. Patients going from a mean treated ABR of approximately 19.8 bleeds per year to 1.4 bleeds per year is a transformation in disease burden. The most devastating consequence of hemophilia with inhibitors has always been the inability to prevent spontaneous joint bleeds because on-demand therapy, by definition, does not begin until bleeding has already started. Each prevented bleed under prophylaxis is a joint or muscle or organ that did not bleed.

This comparison is against on-demand therapy because patients in the inhibitor cohort had not previously been on prophylaxis. An interpretive note: comparing against on-demand is a favorable comparison for the active treatment; a head-to-head comparison against existing prophylactic bypassing agent regimens would be more demanding. Nonetheless, the magnitude of the reduction is substantial and clinically meaningful.

BASIS KIDS trial (NCT05611801): the pediatric data

BASIS KIDS (NCT05611801) was a Phase 3, global, open-label trial evaluating the safety and efficacy of marstacimab in children aged 1 to 17 years with hemophilia A or B, with or without inhibitors. Interim results from this trial supported the FDA’s expanded approval for the 6-to-11-year age group.

Population	Mean ABR with marstacimab	Comparison (historical model-based)
Ages 6 to 17, all patients (overall BASIS KIDS)	1.8	3.6 (prior routine prophylaxis)
Ages 6 to under 18 with inhibitors (n=14)	1.4 (99% CI 0.5 to 4.5)	18.9 (99% CI 14.2 to 25.2)
Ages 6 to 11 cohort (n=7)	1.3 (99% CI 0.5 to 3.4)	—

Source: Clinical Advisor. CheckRare. BASIS KIDS NCT05611801.

The pediatric inhibitor subgroup data is particularly notable: children with hemophilia and inhibitors achieved a mean ABR of 1.4 with marstacimab prophylaxis compared to a historical model-based mean of 18.9 with on-demand bypassing therapy. For the youngest cohort (ages 6 to 11), the mean ABR of 1.3 indicates that the same degree of bleeding rate reduction is achievable in younger children.

The comparison in BASIS KIDS against historical model-based rates (rather than a randomized parallel arm) is appropriate for a pediatric rare disease trial, where randomizing young children to a control arm receiving inferior therapy would be ethically difficult and practically challenging. The historical modeling approach uses well-characterized natural history data from the hemophilia population to provide a reference benchmark.

What Makes This Approval Particularly Significant

The hemophilia B inhibitor gap

The most significant first-in-class designation from this expansion is that Hympavzi is now the first subcutaneous non-factor therapy available for children aged 6 to 11 years with hemophilia B. This deserves specific explanation.

Emicizumab (Hemlibra), the landmark non-factor therapy approved for hemophilia A with inhibitors in 2017, works by bridging activated factor IXa and factor X, mimicking the cofactor function of FVIII. This mechanism is specific to hemophilia A: it does not provide any benefit in hemophilia B because factor IXa is not the relevant enzyme that needs a cofactor. Patients with hemophilia B and inhibitors have therefore had no approved subcutaneous prophylactic non-factor therapy option. For them, marstacimab’s TFPI inhibition mechanism, which is indifferent to whether the underlying deficiency is in FVIII or FIX, represents the first approval in this category.

Once-weekly subcutaneous administration without routine laboratory monitoring

Hympavzi is administered once weekly by subcutaneous injection. The therapy does not require routine treatment-related laboratory monitoring, which distinguishes it from many hemophilia treatments that require regular factor level measurement or trough level testing to guide dosing. For families managing pediatric hemophilia, reducing the blood draw burden alongside simplifying the injection schedule to once weekly is a meaningful quality-of-life improvement.

Patients aged 12 years and older may self-inject after proper training. For children aged 6 to 11, caregiver administration is expected.

Safety: What the Prescribing Information Covers

The prescribing information for Hympavzi includes several important warnings:

Thromboembolic events: Two thromboembolic events occurred among 259 patients in the open-label extension study. Because marstacimab shifts the coagulation balance toward clot formation by removing the TFPI brake on the extrinsic pathway, the theoretical risk of thrombosis is inherent to its mechanism of action. Monitor patients for signs and symptoms of thromboembolic events. The absolute rate was low (2 of 259 patients in the extension), but the mechanism-based concern means clinical vigilance is appropriate.

Laboratory changes: Increases in fibrin D-dimer and prothrombin fragment 1.2 have been observed with marstacimab. These are laboratory markers of coagulation activation and fibrin turnover. They are consistent with the drug’s mechanism (enhanced coagulation pathway activity) but require awareness in clinical monitoring. Do not interpret elevated D-dimer as diagnostic for thrombosis without clinical correlation in patients receiving marstacimab.

Hypersensitivity reactions: As with all monoclonal antibodies, hypersensitivity reactions including anaphylaxis may occur. Patients should be informed of the symptoms and instructed to seek immediate medical attention if they occur.

Embryo-fetal toxicity: Based on the mechanism of action (promoting coagulation), there is a potential for fetal harm. Females of reproductive potential should use effective contraception during treatment.

Common adverse reactions (2% or greater): Injection site reactions, headache, pyrexia, arthralgia, diarrhea, pruritus, and rash.

What This Means for Patients and Families

For patients with hemophilia A or B who have inhibitors

This is the population for whom this expansion matters most urgently. Inhibitor-positive patients, particularly those with hemophilia B inhibitors, have had no approved subcutaneous non-factor prophylactic therapy before this date. The BASIS inhibitor cohort’s 93% reduction in treated ABR compared to on-demand bypassing therapy represents a shift from a reactive management strategy to an active preventive one, with the bleed rate reduction that entails.

If you or a family member has hemophilia with inhibitors and has been managed with on-demand bypassing agents, a conversation with your hematologist about whether Hympavzi is an appropriate prophylactic option is warranted.

For families of children aged 6 to 11

For young children with hemophilia, IV access for factor infusions has historically been the most practically difficult aspect of management, often requiring port placement and the risks that entails. A once-weekly subcutaneous injection administered by a caregiver at home, without routine blood draws for monitoring, represents a materially simpler treatment paradigm for this age group. The BASIS KIDS data showing a mean ABR of 1.3 in the 6-to-11 cohort supports the clinical adequacy of this approach.

For children with hemophilia B specifically, this is the first approved subcutaneous non-factor prophylactic therapy in this age group, filling a gap that emicizumab’s mechanism could not address.

For clinicians managing hemophilia

The complete current Hympavzi indication covers hemophilia A and B, with or without inhibitors, in patients aged 6 years and older. This is a single once-weekly subcutaneous platform applicable across the majority of the hemophilia population. For patients who are appropriate candidates, the elimination of routine treatment-related laboratory monitoring removes a significant ongoing management burden.

The thromboembolic warning and the D-dimer/prothrombin fragment 1.2 elevations associated with marstacimab require clinical awareness, particularly in patients who may develop thrombotic risk factors over time (surgery, immobilization, pregnancy). Risk-benefit discussions individualized to each patient’s circumstances remain the appropriate framework.

For related HED coverage on other rare hematologic disease approvals in 2026, see our post on KRESLADI, the first gene therapy approved for severe leukocyte adhesion deficiency type I and our post on Decnupaz (pivekimab sunirine) approved for blastic plasmacytoid dendritic cell neoplasm.

Sources

Pfizer FDA approval press release: U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. Pfizer. June 8, 2026.

Drugs.com approval news: U.S. FDA Approves Pfizer’s Hympavzi for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. drugs.com. June 8, 2026.

BioPharm International clinical coverage: FDA Expands Pfizer’s Hympavzi Approval to Pediatric Hemophilia Patients and Those with Inhibitors. biopharminternational.com. June 2026.

Hematology Advisor (BASIS inhibitor data): Hympavzi Gains Expanded FDA Approval for Hemophilia A and B. hematologyadvisor.com. June 2026.

Clinical Advisor detailed summary: Hympavzi Gains Expanded FDA Approval for Hemophilia A and B. clinicaladvisor.com. June 2026.

Conexiant clinical summary: FDA Expands Marstacimab Indication in Hemophilia A and B. conexiant.com. June 2026.

CheckRare clinical coverage: FDA Expands Approval of Hympavzi (Marstacimab) for Patients With Hemophilia. checkrare.com. June 2026.

BASIS trial registration: NCT03938792. ClinicalTrials.gov.

BASIS KIDS trial registration: NCT05611801. ClinicalTrials.gov.

Priority Review grant (sBLA): FDA Grants Priority Review for HYMPAVZI sBLA. Pfizer. 2026.

Hympavzi original approval (October 2024): Hympavzi FDA Approval History. drugs.com.

Hympavzi prescribing information: HYMPAVZI (marstacimab-hncq) Prescribing Information. Pfizer. 2026.

TFPI biology and marstacimab mechanism: Tissue Factor Pathway Inhibitor. PMC6126283.

Coagulation cascade: Coagulation Studies. StatPearls. NCBI.

Hemophilia A overview: Hemophilia A. StatPearls. NCBI.

Hemophilia B overview: Hemophilia B. StatPearls. NCBI.

Hemophilia inhibitors: Factor VIII Inhibitors in Hemophilia A. PMC7155173.

CDC hemophilia overview: Hemophilia. CDC.

Patient resources: National Hemophilia Foundation | World Federation of Hemophilia | Pfizer Hympavzi patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Hemophilia management is complex and requires individualized assessment by a hematologist experienced in bleeding disorders. Decisions about switching to or initiating Hympavzi should be made in consultation with a treating hematologist who can assess the patient’s inhibitor status, bleeding history, current prophylaxis regimen, and individual risk-benefit profile.

The Only Oral Carbapenem in the World Just Got FDA Approved. Here Is What Utebzi Is and Why It Changes How Drug-Resistant Urinary Tract Infections Can Be Treated.

June 22, 2026

📌 The essentials On June 17, 2026, the FDA approved Utebzi (tebipenem pivoxil, GSK/Spero Therapeutics) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms in adult patients who have limited or no alternative oral treatment options. This is the first and only oral carbapenem antibiotic approved anywhere in the United States. Previously, every carbapenem available to U.S. clinicians required intravenous administration, meaning that patients with drug-resistant cUTIs requiring carbapenem-level coverage had no oral option and needed hospitalization, a peripherally inserted central catheter (PICC) line, or infusion center visits. Approved organisms: Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca, and Enterococcus faecalis. The clinical basis: Phase 3 PIVOT-PO trial (NCT06059846), 1,690 hospitalized adults with cUTI or acute pyelonephritis, double-blind, randomized 1:1 oral tebipenem pivoxil versus intravenous imipenem-cilastatin. Trial stopped early for efficacy at interim analysis (May 2025). Primary endpoint: overall response (composite of clinical cure plus microbiological eradication) at test-of-cure visit. Result: 58.5% (261/446) with tebipenem pivoxil versus 60.2% (291/483) with IV imipenem-cilastatin (adjusted difference −1.3%; 95% CI −7.5% to 4.8%), meeting non-inferiority. ESBL-producing Enterobacterales subgroup: composite response 52.2% versus 56.8% with IV imipenem-cilastatin. Regulatory designations: Qualified Infectious Disease Product (QIDP), Fast Track. Regulatory history: GSK resubmitted the NDA in December 2025 after an earlier Complete Response Letter; PIVOT-PO data supported the resubmission. Dosing: 600 mg (two 300 mg tablets) orally every 6 hours for 7 to 10 days, with or without food. Important dosing limits: dose adjustment required for eGFR 15 to below 60 mL/min; use not recommended in patients with eGFR above 150 mL/min due to predicted reduced tebipenem exposure.

For the past several decades, carbapenems have represented the antibiotic class of last resort in infectious disease medicine. When bacteria have developed resistance to penicillins, cephalosporins, and fluoroquinolones, carbapenems are frequently the agents that still work. They are critically important, routinely used in hospitalized patients with serious infections, and until June 17, 2026, every single carbapenem available in the United States required intravenous administration.

That meant something specific and consequential for patients with complicated urinary tract infections caused by multidrug-resistant organisms: no matter how well they felt, no matter how stable their condition, they needed a hospital bed, an IV line, or an outpatient infusion arrangement to receive the only effective treatment available to them. The United States has more than 3 million cUTI cases treated annually, and a substantial proportion involve organisms resistant to standard oral agents. For those patients, the arrival of an oral carbapenem is not a minor convenience. It is a clinically meaningful expansion of outpatient treatment options.

Utebzi (tebipenem pivoxil, GSK/Spero Therapeutics) was approved June 17, 2026, as the first oral carbapenem in the U.S. for cUTI in patients with limited or no alternative oral treatment options. The Phase 3 PIVOT-PO trial compared oral tebipenem pivoxil head-to-head against intravenous imipenem-cilastatin, the gold-standard IV carbapenem, and stopped early for efficacy. This post covers what complicated UTIs are, how carbapenems work and why an oral formulation required a novel prodrug approach, what PIVOT-PO data showed, what the regulatory backstory was, and what this approval means for patients and clinicians managing resistant gram-negative infections.

What Complicated Urinary Tract Infections Are and Why Drug Resistance Makes Them Harder to Treat

Complicated urinary tract infections are defined by the presence of structural or functional abnormalities in the urinary tract, or by host factors that impair the normal defenses against infection. They include pyelonephritis (kidney infection), infections associated with urinary catheters or stents, infections in patients with obstructive uropathy or neurogenic bladder, and infections in immunocompromised hosts. Unlike uncomplicated UTIs, which can typically be treated with short courses of oral antibiotics in otherwise healthy outpatient women, cUTIs require more intensive management, longer treatment courses, and often hospitalization.

The most common organisms causing cUTI are gram-negative Enterobacterales, principally E. coli and Klebsiella pneumoniae. These same organisms are at the center of one of the most serious antimicrobial resistance crises in contemporary medicine.

Extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales have developed enzymes that inactivate most penicillins and cephalosporins. They are resistant to trimethoprim-sulfamethoxazole in many cases and frequently resistant to fluoroquinolones. In the PIVOT-PO trial, approximately 35 to 39% of Enterobacterales isolates in both arms were ESBL producers, reflecting the real-world prevalence of this resistance pattern in hospitalized patients with cUTI. For patients whose infection is caused by an ESBL-producing organism, the standard outpatient oral antibiotics (ciprofloxacin, trimethoprim-sulfamethoxazole, nitrofurantoin) are often not options. Until now, that left no oral carbapenem alternative.

Carbapenem-resistant Enterobacterales (CRE), which are resistant even to standard IV carbapenems, are designated by the CDC as an urgent threat. Utebzi’s approved indication specifically covers susceptible organisms, meaning it is not intended for CRE infections where even IV carbapenems would fail. Its value is in the ESBL-producing and fluoroquinolone-resistant Enterobacterales space, where it provides a first oral carbapenem-class option.

The Science: How Tebipenem Works and Why an Oral Carbapenem Required a Prodrug Approach

Carbapenem mechanism of action

Carbapenems belong to the beta-lactam antibiotic class, which also includes penicillins and cephalosporins. All beta-lactams share a core mechanism: they bind to penicillin-binding proteins (PBPs) in bacterial cell walls, inhibiting the transpeptidation reaction that cross-links the peptidoglycan strands that give the cell wall its structural integrity. Without proper peptidoglycan cross-linking, the bacterial cell wall cannot withstand osmotic pressure, the cell lyses, and the bacterium dies.

What distinguishes carbapenems from other beta-lactams is their stability against beta-lactamase enzymes. Most gram-negative bacteria that cause serious infections produce beta-lactamases, enzymes that hydrolyze the beta-lactam ring of penicillins and cephalosporins, rendering those antibiotics inactive. Carbapenems have a unique bicyclic structure that makes them resistant to the most common beta-lactamases, including ESBLs. This is why carbapenems remain active where penicillins and cephalosporins have failed, and it is the mechanistic basis for their clinical importance as last-resort antibiotics.

Tebipenem specifically exhibits broad-spectrum activity against gram-negative Enterobacterales by binding with high affinity to PBP2 and PBP3, the penicillin-binding proteins primarily responsible for cell wall elongation and septation during bacterial cell division. Its activity is bactericidal and is optimized against the organisms most commonly implicated in cUTI.

Why carbapenems were IV-only until now: the oral bioavailability problem

The reason all previously approved carbapenems required intravenous administration is oral bioavailability. Carbapenem molecules are hydrophilic (water-loving) and polar, characteristics that make them excellent at distributing through aqueous tissues but also make it difficult for them to cross the lipid-rich intestinal epithelium and reach the bloodstream when swallowed. Most carbapenem molecules taken orally would simply pass through the gut without being absorbed.

Tebipenem pivoxil solves this through a prodrug strategy. “Tebipenem pivoxil” is the prodrug form: the active carbapenem molecule tebipenem is chemically modified with a pivoxil ester group that makes the compound more lipophilic (fat-soluble) and significantly improves oral absorption across the intestinal epithelium. After absorption, intestinal esterases rapidly cleave the pivoxil ester, releasing the active tebipenem molecule into systemic circulation. The active tebipenem then distributes into renal tissue and urine, where it achieves the concentrations needed to kill the causative organisms.

This prodrug approach is the same chemical strategy used in several other orally administered antibiotics, most notably the cephalosporin prodrugs cefuroxime axetil and cefpodoxime proxetil, where ester modification similarly improves gut absorption of molecules that would otherwise be poorly bioavailable. For carbapenems, engineering this chemistry without compromising the stability of the beta-lactam ring and without producing a molecule with unfavorable pharmacokinetics was a substantial pharmaceutical development challenge.

Why the pivoxil ester matters beyond oral bioavailability The pivoxil moiety that enables tebipenem’s oral absorption is the same group used in pivampicillin and pivmecillinam, and its hydrolysis releases pivalic acid as a byproduct. Pivalate can conjugate with carnitine and impair carnitine metabolism, particularly with long-term or repeated use. This class effect of pivoxil-containing antibiotics is relevant for patients receiving concurrent carnitine supplementation and for patients with carnitine metabolism disorders. The short course of Utebzi (7 to 10 days) limits this concern in most clinical settings, but it is worth noting as a mechanistic consideration of the prodrug chemistry.

The PIVOT-PO Trial: Design and Full Results

Design

PIVOT-PO (NCT06059846) was a global, randomized, double-blind, non-inferiority Phase 3 trial enrolling 1,690 hospitalized adult patients with cUTI or acute pyelonephritis. The double-blind design was maintained using a double-dummy approach: patients in each arm received both an active oral tablet and a matching IV placebo, or an active IV infusion and a matching oral placebo tablet, maintaining blinding while comparing true oral versus true IV administration.

Randomization: 1:1 to:

Tebipenem pivoxil 600 mg orally (two 300 mg tablets) every 6 hours for 7 to 10 days
Imipenem-cilastatin 500 mg intravenously every 6 hours for 7 to 10 days (standard of care comparator)

Imipenem-cilastatin (Primaxin) was chosen as the comparator because it is a well-established IV carbapenem with robust efficacy data in cUTI, appropriate as the active reference standard for a non-inferiority comparison against an oral carbapenem.

Primary endpoint: Overall response at the test-of-cure (TOC) visit, defined as a composite of clinical cure plus microbiological eradication in the intent-to-treat (ITT) efficacy cohort.

The trial was stopped early for efficacy at a planned interim analysis in May 2025, indicating that the pre-specified criteria for early stopping based on demonstrated non-inferiority were met ahead of the planned full enrollment.

Primary endpoint results

Outcome	Tebipenem pivoxil (oral)	Imipenem-cilastatin (IV)	Comparison
Overall response (clinical cure plus microbiological eradication) at TOC	58.5% (261/446)	60.2% (291/483)	Adjusted difference −1.3% (95% CI −7.5% to 4.8%)
Non-inferiority demonstrated	Yes	Reference	Lower CI bound within pre-specified margin

Source: Spero Therapeutics/GSK press release. GlobeNewswire. June 17, 2026. PIVOT-PO NCT06059846. Presented at IDWeek 2025.

The adjusted difference of −1.3 percentage points, with a 95% confidence interval ranging from −7.5% to +4.8%, demonstrates that oral tebipenem pivoxil was non-inferior to intravenous imipenem-cilastatin in achieving the composite endpoint of clinical cure plus microbiological eradication. The upper bound of the confidence interval is positive (favoring oral tebipenem in the best-case scenario) and the lower bound remains within whatever non-inferiority margin was pre-specified. This is the evidentiary standard the FDA required to demonstrate that oral tebipenem delivers comparable efficacy to the IV comparator.

ESBL-producing pathogen subgroup

In the PIVOT-PO trial, 35.1% of Enterobacterales isolates in the tebipenem arm and 38.9% in the imipenem arm were ESBL producers, reflecting the real-world prevalence of ESBL-producing cUTI in hospitalized patients. Among patients infected with ESBL-producing organisms, the composite response rates at TOC were 52.2% with tebipenem pivoxil and 56.8% with IV imipenem-cilastatin. Comparable response rates were also observed among patients infected with fluoroquinolone-not-susceptible and trimethoprim-sulfamethoxazole-resistant Enterobacterales.

This subgroup data is clinically important because the ESBL-producing patient population represents precisely the group for whom no oral treatment was previously available. That composite response rates in this resistance-characterized subgroup were broadly consistent with the overall ITT population supports the use of tebipenem pivoxil specifically in these patients.

Safety in PIVOT-PO

The safety profile of tebipenem pivoxil was consistent with the carbapenem class. The most common adverse events were diarrhea and headache. Additional adverse events reported included mild to moderate nausea, abdominal pain, transaminase elevations, and Clostridioides difficile-associated diarrhea (CDAD), which is a class effect associated with broad-spectrum antibiotics. No new or unexpected safety signals were identified.

The Regulatory Backstory: A Prior CRL and the Path to Approval

The path to Utebzi’s June 2026 approval was not linear. GSK and Spero had submitted an earlier NDA for tebipenem pivoxil for cUTI, supported by a prior Phase 3 trial. That application received a Complete Response Letter from the FDA, which identified deficiencies that needed to be addressed before approval could be granted. The PIVOT-PO trial, which compared oral tebipenem directly against intravenous imipenem-cilastatin (a more demanding head-to-head non-inferiority design than the prior trial), was specifically designed and conducted to address the FDA’s concerns and generate the evidence package required for resubmission.

GSK filed the NDA resubmission in December 2025, supported by the PIVOT-PO data that had been presented at IDWeek 2025 weeks prior. The PDUFA date was set for June 18, 2026, and the FDA approved one day ahead of the deadline on June 17, 2026.

The tebipenem pivoxil program has received QIDP (Qualified Infectious Disease Product) designation and Fast Track designation from the FDA, both reflecting the agency’s recognition of the serious unmet need in drug-resistant cUTI.

Approved Organisms, Dosing, and Critical Prescribing Guidance

Approved organisms

Utebzi is approved for cUTI caused by the following susceptible organisms:

Escherichia coli
Klebsiella pneumoniae
Enterobacter cloacae species complex
Klebsiella oxytoca
Enterococcus faecalis

Culture and susceptibility testing are essential before prescribing. Utebzi is indicated for organisms confirmed or strongly suspected to be susceptible. It is not effective against CRE (carbapenem-resistant Enterobacterales), and empiric use without culture data should be guided by institutional stewardship protocols and local epidemiology.

Dosing

Parameter	Details
Standard dose	600 mg (two 300 mg tablets) orally every 6 hours
Duration	7 to 10 days
Administration	With or without food
Renal adjustment	Required for eGFR 15 to below 60 mL/min; consult full prescribing information for specific dose
eGFR above 150 mL/min	Use not recommended (predicted reduced tebipenem exposure may reduce efficacy; if necessary, monitor clinical response closely)
Not recommended	eGFR below 15 mL/min (end-stage renal disease without dialysis); data insufficient

The eGFR above 150 mL/min restriction is an unusual and clinically notable prescribing caution. Patients with hyperfiltration (augmented renal clearance), which can occur in younger patients, pregnant patients, and critically ill patients with preserved kidney function, may clear tebipenem faster than typical patients, potentially reducing urinary drug concentrations below the threshold needed for bactericidal activity. This pharmacokinetic consideration is specific to a renally-excreted antibiotic being used for a urinary tract indication and should be considered when prescribing in patients whose renal function is known to be substantially above normal.

Antibiotic stewardship

Consistent with antimicrobial stewardship principles, Utebzi should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria. The approved labeling specifically addresses this: use should follow culture and susceptibility data whenever possible, and empiric use should be reserved for patients with strong clinical suspicion of a resistant organism based on prior culture history, risk factors, or local epidemiology.

What This Approval Means in Clinical Practice

Before June 17, 2026, a hospitalized patient with pyelonephritis caused by an ESBL-producing E. coli, who was otherwise stable and could be managed as an outpatient, had essentially no oral option. Every carbapenem required IV access. Sending such a patient home required either arranging home IV infusion (expensive, logistically complex, and uncomfortable for the patient) or keeping them in the hospital longer than their clinical condition strictly required (expensive and exposing them to hospital-acquired infection risk).

As Dr. Debra L. Fromer, MD, of Hackensack Meridian Health, explained: the advent of an oral carbapenem reduces the strain on the healthcare system by enabling earlier discharge and allowing outpatient treatment of patients who previously required hospitalization or PICC line placement. A pill taken at home every 6 hours is not identical in convenience to a once-daily oral antibiotic, but compared to an IV infusion it is transformative for appropriate patients.

The key phrase in the approved indication is “limited or no alternative oral treatment options.” Utebzi is not positioned as a first-line or empiric therapy for all cUTIs. It is a targeted option for the resistance gap: patients with culture-confirmed or highly suspected resistant organisms where standard oral agents have failed or are expected to fail. The approved patient population is specific, the culture requirement is clinical standard, and the antibiotic stewardship framing is appropriately conservative.

For patients with cUTI or recurrent UTI who are managing resistant infections: Utebzi is a prescription medication that requires a clinician experienced in managing complicated UTIs. The starting point for access is a discussion with a urologist, urogynecologist, or infectious disease specialist who can review culture results and determine whether tebipenem pivoxil is appropriate for the specific organism and clinical situation.

For related HED coverage on other resistant-organism antibiotic approvals in 2026, see our post on Zaynich (cefepime-zidebactam), the first antibiotic combination in which the beta-lactamase inhibitor also independently targets PBP2, approved for drug-resistant cUTI just weeks earlier.

Sources

FDA approval / GSK press release: Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections. GSK. June 17, 2026.

Spero Therapeutics press release: Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections. Spero Therapeutics/GlobeNewswire. June 17, 2026.

Drugs.com approval news: FDA Approves Utebzi (tebipenem pivoxil) for Adults with Complicated Urinary Tract Infections. drugs.com. June 17, 2026.

Utebzi approval history: Utebzi FDA Approval History. drugs.com.

Urology Times clinical coverage (with Dr. Fromer quote): FDA approves tebipenem pivoxil for complicated urinary tract infections. urologytimes.com. June 2026.

AJMC detailed trial coverage: FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs. ajmc.com. June 2026.

Renal and Urology News clinical summary: Utebzi Approved as First Oral Carbapenem Antibiotic for cUTIs. renalandurologynews.com. June 2026.

Contagion Live detailed coverage: FDA Approves Tebipenem Pivoxil as First Oral Carbapenem For Complicated Urinary Tract Infections. contagionlive.com. June 2026.

Contemporary OB/GYN clinical coverage: FDA approves tebipenem pivoxil as first oral carbapenem antibiotic for complicated urinary tract infections. contemporaryobgyn.net. June 2026.

PIVOT-PO trial registration: NCT06059846. ClinicalTrials.gov.

Complicated UTI overview: Complicated Urinary Tract Infections. StatPearls. NCBI.

Beta-lactam antibiotics and PBPs: Beta-Lactam Antibiotics. StatPearls. NCBI.

ESBL and beta-lactamases: Beta-Lactamase Inhibitors. PMC7279573.

Enterobacterales infections: Gram-Negative Bacterial Infections. StatPearls. NCBI.

C. diff associated diarrhea: Clostridioides Difficile. StatPearls. NCBI.

CRE threat designation: Antibiotic Resistance Threats in the United States. CDC.

Antibiotic stewardship core elements: Core Elements of Antibiotic Stewardship. CDC.

QIDP and GAIN Act: GAIN Act FAQ. FDA.gov.

Fast Track designation: Fast Track. FDA.gov.

CRL overview: FDA Drug Review Process. FDA.gov.

Utebzi prescribing information: UTEBZI (tebipenem pivoxil) Prescribing Information. GSK. 2026.

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Utebzi is a prescription antibiotic indicated specifically for adult patients with complicated urinary tract infections caused by susceptible organisms who have limited or no alternative oral treatment options. Antibiotic selection should be guided by culture and susceptibility data and made in consultation with a qualified healthcare provider.

Every Gadolinium MRI Contrast Agent Exposes Patients to Gadolinium Deposition Risk. Ambelvist Just Became the First Approved in the U.S. That Does It With 60% Less Gadolinium. Here Is What the Science and the QUANTI Trial Data Show.

June 21, 2026

📌 The essentials On June 12, 2026, the FDA approved Ambelvist (gadoquatrane, Bayer) for use with MRI to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system) in adult and pediatric patients, including term neonates. What makes it distinctive: gadoquatrane is a next-generation macrocyclic gadolinium-based contrast agent (mGBCA) with a novel tetrameric structure that achieves high image quality at substantially reduced gadolinium doses. With this approval, Ambelvist becomes the lowest-dose macrocyclic GBCA approved in the United States. Recommended dose: 0.01 mmol/kg actual body weight, which delivers 0.04 mmol Gd/kg body weight. This represents 60% less gadolinium than the standard macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight, and 20% less gadolinium than gadopiclenol (Vueway), which delivers 0.05 mmol Gd/kg. The clinical basis: Phase 3 QUANTI program (three studies: QUANTI CNS, QUANTI OBR, and QUANTI Pediatric), 808 patients including 93 children, across 15 countries. QUANTI CNS and QUANTI OBR were randomized, double-blind, active-comparator crossover trials. Key results: gadoquatrane met the primary endpoint of non-inferiority to comparator mGBCAs (gadobutrol, gadoterate, gadoteridol) in visualization parameters and lesion detection using 60% less gadolinium. Post-contrast MRI with gadoquatrane was superior to unenhanced MRI alone. In descriptive analyses, visualization scores and lesion counts per blinded independent reader were comparable to comparator mGBCAs dosed at 0.1 mmol Gd/kg. No new safety signals. Boxed warnings: intrathecal administration risk; nephrogenic systemic fibrosis (NSF). Contraindicated in patients with a history of severe hypersensitivity reactions to gadoquatrane.

Every year, more than 40 million MRI examinations with contrast are performed in the United States. The contrast agents used in the majority of those scans are gadolinium-based, and they are among the most important diagnostic tools in modern medicine. They light up tumors, strokes, vascular malformations, inflammatory lesions, and infections in brain tissue, spinal cord, joints, liver, and virtually every region of the body, making otherwise invisible pathology visible and informing clinical decisions that affect surgical planning, treatment selection, and disease monitoring.

Gadolinium-based contrast agents are also, as the FDA has required to be prominently stated in prescribing information since 2017, associated with gadolinium retention: gadolinium is retained for months or years in several organs, including the brain, even in patients with normal kidney function. The clinical significance of that retention in patients without renal impairment has not been definitively established, but the concern is real enough that the FDA, the American College of Radiology, and radiological societies worldwide have consistently encouraged the use of the lowest gadolinium dose that provides the necessary diagnostic information.

Ambelvist (gadoquatrane, Bayer), approved June 12, 2026, is the first MRI contrast agent to reach that lowest-dose standard among the macrocyclic class in the United States. Its novel tetrameric molecular structure achieves high image quality at 60% less gadolinium than standard macrocyclic agents, and clinical trial data demonstrated equivalent diagnostic performance to comparator agents dosed at 2.5 times the gadolinium content.

This post covers what gadolinium-based contrast agents do and why gadolinium retention matters, how gadoquatrane’s tetrameric structure produces high-quality imaging at lower gadolinium doses, what the QUANTI Phase 3 program showed, what the safety profile means in practice, and where Ambelvist fits in the current MRI contrast landscape.

What Gadolinium-Based Contrast Agents Do and Why Gadolinium Retention Is a Clinical Concern

How contrast-enhanced MRI works

MRI produces images by detecting the radiofrequency signals emitted by hydrogen nuclei (protons) in water and fat molecules as they return to equilibrium after being excited by a magnetic field and radiofrequency pulses. The speed of that return, characterized by relaxation times called T1 and T2, varies across different tissue types and creates the intrinsic contrast that makes MRI valuable even without exogenous contrast agents.

Gadolinium-based contrast agents (GBCAs) enhance this further. Gadolinium (Gd) is a paramagnetic metal ion that shortens the T1 relaxation time of nearby water protons, causing tissues that take up the contrast agent to appear brighter on T1-weighted MRI sequences. The enhancement is selective: gadolinium distributes into tissues with abnormal vascularity or disrupted blood-brain barrier, which is precisely the characteristic of tumors, inflammatory lesions, abscesses, demyelinating plaques, and vascular malformations. Normal brain parenchyma is protected by an intact blood-brain barrier and does not enhance.

This is why contrast-enhanced MRI is so diagnostically powerful: the gadolinium signal provides a spatial map of pathological vascular abnormality superimposed on the exquisite anatomical detail of the unenhanced MRI sequence.

Why gadolinium retention matters

Since the first GBCA was introduced in 1988, these agents have generally been considered safe for patients with normal renal function. That perception began to evolve in 2006 when nephrogenic systemic fibrosis (NSF), a serious and potentially fatal fibrosing condition, was firmly linked to GBCA administration in patients with severely impaired renal function. NSF is now largely eliminated through screening practices and the preferential use of more stable macrocyclic GBCAs over less stable linear agents.

A separate and distinct concern emerged around 2014 when researchers identified gadolinium deposition in brain tissue in patients with normal renal function who had received multiple GBCA-enhanced MRI scans. Signal changes in the dentate nucleus and globus pallidus on T1-weighted MRI were found to correlate with cumulative gadolinium exposure. This deposition occurs with all GBCAs but is substantially greater with linear agents than with macrocyclic agents. At equivalent doses, macrocyclic GBCAs show the lowest and most similar retention profiles among all GBCA classes, because their cyclic molecular cage structure holds gadolinium more tightly and releases it less readily than the open-chain structure of linear agents.

The clinical consequences of gadolinium deposition in the brain of patients with normal renal function have not been definitively established, but the regulatory response has been clear: minimize gadolinium dose while preserving diagnostic quality. The ACR Manual on Contrast Media recommends using the lowest gadolinium dose necessary to provide adequate diagnostic information.

The gadolinium problem in plain terms Every dose of gadolinium-based contrast agent leaves some gadolinium behind in the body, including in the brain. The macrocyclic cage structure of agents like gadobutrol, gadoterate, and gadoteridol holds gadolinium more tightly, reducing this retention compared to linear agents. But even macrocyclic agents deposit some gadolinium at standard doses. The logical next step, which gadoquatrane’s development pursued, was to engineer a macrocyclic agent that achieves equivalent image quality using substantially less gadolinium. Less gadolinium administered means less gadolinium available for retention, regardless of the agent’s stability profile. The tetrameric structure of gadoquatrane was designed specifically to achieve this: four times the relaxivity enhancement per gadolinium atom, enabling a 60% dose reduction while maintaining comparable imaging performance.

How Gadoquatrane Works: The Tetrameric Structure and High Relaxivity

The key to understanding why gadoquatrane can deliver equivalent diagnostic performance at 60% less gadolinium than standard macrocyclic agents lies in its molecular architecture.

Conventional GBCAs, including the macrocyclic agents gadobutrol (Gadavist), gadoterate (Dotarem), and gadoteridol (ProHance), are monomeric molecules: one gadolinium ion chelated by one organic ligand. The magnetic effect of a single gadolinium ion on surrounding water protons, measured as relaxivity, is determined by how efficiently the paramagnetic gadolinium shortens the T1 relaxation time of nearby water molecules in a given concentration and magnetic field strength.

Gadoquatrane has a tetrameric structure: four gadolinium-chelate units are covalently linked in a single molecular framework. This arrangement substantially increases the molecule’s relaxivity. Each gadoquatrane molecule carries four gadolinium ions, and the molecular size and tumbling rate created by this tetrameric architecture are optimized for more efficient interaction with surrounding water protons. The result is that each molecule of gadoquatrane produces greater T1 enhancement per unit of gadolinium than conventional monomeric GBCAs.

This higher relaxivity per gadolinium atom is what allows gadoquatrane to produce comparable image quality at a substantially reduced gadolinium dose. The principle is analogous to a more efficient engine producing the same power output from less fuel: the tetrameric architecture extracts more MRI signal enhancement per gadolinium ion administered.

Gadoquatrane retains the macrocyclic cage structure of the established macrocyclic agents, with each of the four gadolinium ions held within a macrocyclic ligand unit. This means gadoquatrane’s thermodynamic and kinetic stability properties, the characteristics that minimize gadolinium release and retention, are consistent with the macrocyclic class. The same structural feature that produces low gadolinium retention in gadobutrol and gadoterate is present in each of gadoquatrane’s four chelate units.

The QUANTI Clinical Program: Three Trials, 808 Patients, 15 Countries

Gadoquatrane’s FDA approval is based on the QUANTI clinical development program, which consisted of three trials designed to evaluate efficacy and safety across the full body scope of the approved indication.

Program design

QUANTI CNS (NCT05915702): A multinational, randomized, prospective, double-blind, active-comparator crossover Phase 3 trial in adult patients with known or suspected CNS pathologies (brain, spine, associated tissues) undergoing contrast-enhanced MRI. Patients received gadoquatrane at 0.01 mmol/kg body weight (delivering 0.04 mmol Gd/kg) in one crossover period and one of three comparator macrocyclic GBCAs (gadobutrol, gadoterate, or gadoteridol) at 0.1 mmol Gd/kg in the other period. The crossover design meant each patient served as their own control, strengthening the comparison.

QUANTI OBR (NCT05915728): The same design applied to non-CNS body regions (head and neck, thorax, abdomen, pelvis, musculoskeletal system) in adult patients.

QUANTI Pediatric: A separate study evaluating the pharmacokinetics and safety of gadoquatrane in pediatric patients from birth to below 18 years of age across all body regions. This study supported the pediatric indication, including term neonates.

In total, 808 patients including 93 children participated across 15 countries. All three trials investigated gadoquatrane at the same 0.04 mmol Gd/kg dose, which represents a 60% reduction compared to the 0.1 mmol Gd/kg dose used by standard macrocyclic GBCAs.

Primary and secondary endpoint results

The primary endpoints of QUANTI CNS and QUANTI OBR assessed visualization parameters (border delineation, internal morphology, and contrast enhancement) as rated by blinded independent readers comparing gadoquatrane-enhanced MRI to comparator-enhanced MRI.

Outcome	Result
Primary endpoint: non-inferiority of gadoquatrane versus comparator mGBCAs in visualization parameters (CNS and body)	Met in both QUANTI CNS and QUANTI OBR
Key secondary endpoint: superiority of post-contrast MRI with gadoquatrane versus unenhanced MRI alone	Met: increased lesion visualization confirmed
Descriptive comparison: visualization scores and lesion counts per blinded independent reader	Gadoquatrane comparable to comparator mGBCAs dosed at 0.1 mmol Gd/kg
Secondary endpoints: sensitivity and specificity for lesion detection	Non-inferiority to comparator mGBCAs demonstrated
Pediatric pharmacokinetics	Pharmacokinetic behavior in children consistent with adult data; efficacy from adult data applicable to pediatric population
Overall safety profile (all ages)	Consistent with prior gadoquatrane data and macrocyclic GBCAs class; no new safety signals

Source: Bayer press release, June 15, 2026. QUANTI CNS NCT05915702. QUANTI OBR NCT05915728. QUANTI CNS ECR 2025 presentation.

The crossover design is worth emphasizing for its evidentiary strength. Because each patient received both gadoquatrane and a comparator macrocyclic agent in separate MRI sessions (with blinded independent reading of all images), the comparison is unusually rigorous: the same patient’s pathology is being imaged with different agents, eliminating the patient-level variability that can confound parallel-group designs in imaging trials.

The pediatric finding that pharmacokinetic behavior of gadoquatrane in children is similar to that in adults allowed the FDA to establish pediatric efficacy through pharmacokinetic/pharmacodynamic bridging, a standard approach for contrast agents where it is not ethical or practical to run fully powered efficacy trials in all pediatric subpopulations.

Where Ambelvist Fits in the GBCA Landscape

The U.S. MRI contrast agent market in 2026 includes multiple approved GBCAs across the linear and macrocyclic classes, with recent additions specifically at lower doses:

Agent	Class	Dose	Gd content	FDA approval
Gadobutrol (Gadavist, Bayer)	Macrocyclic	0.1 mmol/kg	0.1 mmol Gd/kg	2011
Gadoterate meglumine (Dotarem, Guerbet)	Macrocyclic	0.1 mmol/kg	0.1 mmol Gd/kg	2013
Gadoteridol (ProHance, Bracco)	Macrocyclic	0.1 mmol/kg	0.1 mmol Gd/kg	1992
Gadapentetate dimeglumine (Magnevist)	Linear	0.1 mmol/kg	0.1 mmol Gd/kg	1988
Gadopiclenol (Vueway, Bracco)	Macrocyclic	0.05 mmol/kg	0.05 mmol Gd/kg	2022
Gadoquatrane (Ambelvist, Bayer)	Macrocyclic	0.01 mmol/kg	0.04 mmol Gd/kg	June 2026

Gadopiclenol (Vueway), approved in 2022, was the first high-relaxivity macrocyclic GBCA to achieve reduced-dose approval in the U.S., delivering 0.05 mmol Gd/kg versus the standard 0.1 mmol Gd/kg used by earlier macrocyclic agents. Gadoquatrane extends this further, delivering 0.04 mmol Gd/kg, 20% less gadolinium than gadopiclenol and 60% less than standard macrocyclic agents.

The competitive distinction between Ambelvist and Vueway will be evaluated by radiologists based on imaging performance data, institutional formulary decisions, practical acquisition considerations, and any head-to-head data that emerges in the coming years. Neither drug has been compared directly to the other in a randomized trial; both have been compared to the same standard-dose macrocyclic agents.

For radiology departments and institutions with established ACR or local protocols encouraging minimum gadolinium dose, Ambelvist provides an additional option in the macrocyclic class with the lowest Gd dose approved in the U.S. For patients who undergo contrast-enhanced MRI repeatedly over years of disease monitoring, such as patients with multiple sclerosis, brain metastases, or chronic inflammatory conditions requiring serial imaging, the cumulative gadolinium dose reduction across many scans is the practical benefit.

Safety: What the Prescribing Information Covers

Ambelvist’s safety profile is consistent with the macrocyclic GBCA class, with the same class-level concerns that apply to all gadolinium-based contrast agents.

Boxed warnings:

Intrathecal administration: Gadolinium-based contrast agents are not approved for intrathecal injection, and accidental intrathecal administration has resulted in serious adverse reactions including seizures, cardiorespiratory arrest, and death. This is a class-wide warning for all GBCAs. Ambelvist must be administered intravenously only.

Nephrogenic systemic fibrosis (NSF): Ambelvist, like all approved GBCAs, carries a boxed warning for NSF, a serious, debilitating, and potentially fatal fibrosing disorder of the skin and other tissues that has been observed in patients with impaired elimination of GBCAs, primarily those with chronic, severe kidney disease. As a macrocyclic agent, gadoquatrane is classified in the lower-NSF-risk group (ACR Group II/III), but the class warning remains on the label. Screen patients for acute kidney injury or other conditions that may reduce renal clearance before administering any GBCA.

Contraindication:

Ambelvist is contraindicated in patients with a history of severe hypersensitivity reactions to gadoquatrane.

Warnings and precautions:

Hypersensitivity reactions: As with all GBCAs, acute allergic-type reactions ranging from mild (urticaria, pruritus) to severe (anaphylaxis, bronchospasm, cardiovascular collapse) can occur. These are uncommon but can be immediate or delayed. Assess patient allergy history before administration. Maintain resuscitation capability during administration.

Gadolinium retention: As described above, gadolinium is retained for months or years in the brain and other organs following GBCA administration. Linear GBCAs cause greater retention than macrocyclic GBCAs. At equivalent doses, retention is lowest and most similar among macrocyclic agents. The lower administered dose of gadoquatrane means less total gadolinium is available for potential retention compared to standard-dose macrocyclic agents. The clinical consequences of gadolinium retention in the brain of patients with normal renal function have not been established.

Acute kidney injury: GBCAs may increase the risk of acute kidney injury. Screen patients for reduced renal function before administration. In patients with chronic kidney disease, use the lowest dose necessary and avoid repeat dosing unless the diagnostic benefit clearly outweighs the risk.

Interference with lesion visualization: Certain lesion types may not enhance reliably with Ambelvist. Some lesions visible with other GBCA types may not be detectable with gadoquatrane at the approved dose. Blinded reading of MRI examinations should consider the dose and agent used.

Dosing:

Administered as an intravenous injection of 0.01 mmol/kg actual body weight (which delivers 0.04 mmol Gd/kg body weight). Ambelvist is supplied as a 0.1 mmol/mL solution in single-dose vials, single-dose prefilled syringes, imaging bulk packages, and pharmacy bulk packages.

What This Means for Patients Who Receive Contrast-Enhanced MRI

Most patients receiving contrast-enhanced MRI will not choose their contrast agent: the radiology department or ordering institution determines which agent to use based on formulary, protocol, and clinical judgment. What patients can do is understand why the conversation about gadolinium matters and ask informed questions about contrast use.

For patients who undergo contrast-enhanced MRI repeatedly, such as those with multiple sclerosis being monitored for disease activity, patients with brain metastases under treatment, and patients with chronic inflammatory conditions like Crohn’s disease requiring serial cross-sectional imaging, cumulative gadolinium exposure from repeated scans is the most relevant concern. Lower-dose agents at equivalent diagnostic performance represent a genuine clinical benefit for these populations over a lifetime of imaging.

For patients with chronic kidney disease, the NSF boxed warning is the priority concern. Any patient with significantly impaired renal function should discuss with their ordering physician whether contrast enhancement is necessary for their specific clinical question, and if so, which agent and dose minimize the NSF risk while providing the needed diagnostic information.

For patients undergoing a single diagnostic MRI as part of an acute clinical evaluation, such as evaluation for stroke, initial workup of a brain mass, or staging of a newly diagnosed cancer, the cumulative dose concern is less relevant. The diagnostic adequacy of the scan is the priority.

For clinicians and radiologists: the ACR Manual on Contrast Media, updated in 2026, provides the current framework for GBCA selection and dose minimization. Ambelvist’s addition to the macrocyclic formulary options gives departments a lowest-dose macrocyclic choice for protocols where gadolinium minimization is a priority alongside diagnostic adequacy.

For related HED coverage on neurological conditions commonly evaluated with contrast-enhanced MRI, see our post on Ocrevus (ocrelizumab) approved for pediatric relapsing-remitting MS and our post on the FDA’s acceleration of psychedelic drug programs for treatment-resistant depression and PTSD, the latter of which covers conditions where neuroimaging plays a growing role in clinical research.

Sources

Bayer FDA approval press release: Bayer’s AMBELVIST (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI. BusinessWire. June 15, 2026.

Bayer Ambelvist page: AMBELVIST (gadoquatrane) FDA approval. bayer.com.

BioSpace approval coverage: Bayer’s Ambelvist Receives FDA Approval for Contrast-Enhanced MRI. biospace.com. June 15, 2026.

CancerNetwork clinical summary: FDA Approves Gadoquatrane to Detect CNS and Non-CNS Body Region Lesions. cancernetwork.com. June 2026.

Renal and Urology News coverage: FDA Approves Lower-Dose Gadolinium Contrast Agent Ambelvist. renalandurologynews.com. June 2026.

Neurology Advisor coverage: FDA Approves Lower-Dose Gadolinium Contrast Agent Ambelvist. neurologyadvisor.com. June 2026.

Axis Imaging News coverage: FDA Approves Bayer’s Low-Dose MRI Contrast Agent. axisimagingnews.com. June 2026.

QUANTI CNS Phase 3 topline results (Bayer/ECR 2025): Positive results from Phase III study for Bayer’s investigational contrast agent gadoquatrane. Bayer/BusinessWire. February 26, 2025.

QUANTI program pivotal topline results (all studies): Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints. BusinessWire. January 10, 2025.

QUANTI Pediatric (RSNA 2025): RSNA25: Pediatric Study for Bayer’s Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints. biospace.com. December 2025.

QUANTI CNS trial registration: NCT05915702. ClinicalTrials.gov.

QUANTI OBR trial registration: NCT05915728. ClinicalTrials.gov.

Ambelvist prescribing information: AMBELVIST (gadoquatrane) Prescribing Information. Bayer. labeling.bayerhealthcare.com.

GBCA safety update (AJR): Update on Gadolinium-Based Contrast Agent Safety. AJR. doi:10.2214/AJR.23.30036.

Gadolinium retention brain review: MRI contrast agents and retention in the brain: review. PMC11282029.

Linear versus macrocyclic gadolinium CNS gene expression: Long-term effects of linear versus macrocyclic GBCAs on gene expression in CNS of mice. PMC11723877.

Gadolinium toxicity mechanisms review: Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role. PMC12454587.

NSF overview: Nephrogenic Systemic Fibrosis. StatPearls. NCBI.

ACR Manual on Contrast Media (2026): ACR Manual on Contrast Media. acr.org.

MRI overview: Magnetic Resonance Imaging. NIBIB.

Vueway (gadopiclenol) prescribing information (comparator reference): Vueway (gadopiclenol) package insert. Bracco.

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Ambelvist (gadoquatrane) carries a boxed warning for risks associated with intrathecal administration and nephrogenic systemic fibrosis. Decisions about contrast agent selection for MRI examinations are made by qualified radiologists and ordering clinicians based on the clinical question, patient characteristics, and institutional protocols. Patients with renal impairment should discuss the use of gadolinium-based contrast agents with their physician before undergoing contrast-enhanced MRI.

Xeljanz Was the First Oral JAK Inhibitor Approved in the U.S. And Then a Mandatory Safety Trial Changed How the Entire Class Is Used. Its Generic Is Already Here. Here Is What the Science, the Safety Data, and the LOE Mean for Patients.

June 20, 2026

📌 The essentials Xeljanz (tofacitinib, Pfizer) was the first-in-class oral JAK inhibitor approved in the world, receiving FDA approval in November 2012 for rheumatoid arthritis. Five indications now: moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC), ankylosing spondylitis (AS), and polyarticular course juvenile idiopathic arthritis (pcJIA). Mechanism: oral small-molecule inhibitor of JAK1, JAK2, JAK3, and to a lesser extent TYK2, blocking the intracellular signaling pathway that dozens of pro-inflammatory cytokines share. Xeljanz generated approximately $625 million in U.S. sales in 2025. The pivotal safety trial: ORAL Surveillance (NCT02092467), a mandated post-marketing Phase 3b/4 trial (n=4,362), found tofacitinib was associated with higher rates of MACE, malignancy, and all-cause mortality compared to TNF inhibitors in RA patients aged 50 and older with cardiovascular risk factors. This resulted in a boxed warning encompassing serious infections, mortality, malignancy, MACE, and thrombosis, and repositioned tofacitinib as a second-line option only after TNF inhibitor failure in RA and PsA. The FDA extended this class-level boxed warning to all JAK inhibitors. Generic entry: the FDA approved the first generic tofacitinib citrate from Ajanta Pharma in August 2025. Full generic competition is now underway. Current Xeljanz list price: approximately $5,000 to $6,000 per month for standard 5 mg twice-daily RA dosing. Expected generic price with multi-source competition: approximately $1,000 to $1,200 per month initially, declining further as competition deepens. The safety warning applies to generic tofacitinib identically to the brand. Generic availability does not make the drug safer for high-cardiovascular-risk patients.

📚 About this series: the 2026 Loss of Exclusivity Watch This is the final post of HED’s 2026 Loss of Exclusivity series, tracking the ten major drugs losing U.S. exclusivity this year. The full series covers: Xolair (omalizumab) • Pomalyst (pomalidomide) • Opsumit (macitentan) • Januvia/Janumet (sitagliptin) • Simponi (golimumab) • Mavenclad (cladribine) • Gattex (teduglutide) • Trintellix (vortioxetine) • Briviact (brivaracetam) • Xeljanz (tofacitinib). Each post follows the same format: what the drug is and how it works, what the clinical evidence shows, who uses it and why, and what the entrance of competition means for patients, prescribers, and the market.

When tofacitinib received FDA approval in November 2012, it was the first oral small-molecule disease-modifying antirheumatic drug approved in the United States in more than a decade and the first-in-class JAK inhibitor anywhere in the world. The approval was the culmination of a genuinely novel drug discovery effort: identifying a target inside the immune cell rather than outside it, designing a molecule small enough to cross cell membranes and block the enzyme, and demonstrating that blocking this enzyme could match the efficacy of the injectable biologics that had dominated inflammatory disease treatment for the preceding decade.

The JAK inhibitor class built on the Xeljanz foundation quickly became one of the most scientifically exciting and clinically contested drug classes in modern medicine. The excitement came from oral administration, rapid onset, broad efficacy across multiple autoimmune diseases, and a reversible mechanism that offered a different risk-benefit profile from continuous biologic immunosuppression. The controversy came from a mandatory post-marketing safety trial, ORAL Surveillance, whose results landed in 2021 and fundamentally reshaped how the entire class is prescribed.

The FDA concluded, based on its completed review of the ORAL Surveillance trial data, that there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death with tofacitinib, and required a boxed warning for major adverse cardiovascular events, mortality, malignancy, and thrombosis.

Xeljanz generated approximately $625 million in U.S. sales in 2025, down substantially from its peak, with the revenue decline driven by both the prescribing restrictions that followed the safety warning and the early entry of generic competition. The first generic tofacitinib was approved by Ajanta Pharma in August 2025. As of 2026, full generic entry is underway, with prices expected to fall approximately 80%, mirroring the trajectory seen with JAK inhibitor generics in international markets.

This final post in the 2026 LOE series covers tofacitinib’s path from first-in-class JAK inhibitor to a heavily scrutinized drug now entering a generic market, the JAK-STAT pathway it targets, what the ORAL Surveillance data actually says and what it does not say, what it means to prescribe or take tofacitinib in the context of those safety findings, how it compares to the newer and more selective JAK inhibitors that followed it, and what the generic transition means for patients who have been well-controlled on it for years.

What Tofacitinib Treats: Five FDA-Approved Indications

Tofacitinib is FDA-approved for five indications. The breadth of that indication portfolio reflects the JAK-STAT pathway’s central role across multiple immune-mediated inflammatory diseases: the same molecular bottleneck drives inflammation in RA synovium, psoriatic joints, ulcerative colitis mucosa, and the axial skeleton in ankylosing spondylitis.

Rheumatoid arthritis is the primary indication and the one with the deepest evidence base. Since the ORAL Surveillance safety update in December 2021, tofacitinib is specifically indicated for adults with moderate to severe active RA who have had inadequate response or intolerance to one or more TNF blockers. It is no longer a first-line option for RA.

Psoriatic arthritis follows the same post-TNF-failure positioning. Tofacitinib is approved for adults with active PsA who have had inadequate response or intolerance to one or more TNF blockers.

Ulcerative colitis is approved at a higher induction dose (10 mg twice daily for the induction phase, then 5 mg twice daily maintenance, or 10 mg maintenance in patients who do not achieve adequate control), making the UC indication pharmacologically distinct from RA and PsA in terms of dose management.

Polyarticular course juvenile idiopathic arthritis (pcJIA) extends the approved population to children aged 2 years and older, one of the few JAK inhibitor indications in a pediatric population.

Ankylosing spondylitis received its U.S. approval in 2021, positioning tofacitinib as an oral alternative to the TNF inhibitor and IL-17 inhibitor biologics that had previously been standard for biologic-eligible axial spondyloarthritis patients.

The JAK-STAT Pathway: How Tofacitinib Works

To understand tofacitinib’s mechanism and why blocking it suppresses inflammation so broadly, it helps to understand the JAK-STAT signaling pathway, one of the most fundamental communication systems in the immune cell.

When cytokines bind to their receptors on the surface of immune cells, they trigger a cascade of intracellular signaling events. The first step after receptor activation is the cross-phosphorylation of Janus kinase (JAK) proteins, which are bound to the intracellular portion of the cytokine receptor. There are four JAK family members: JAK1, JAK2, JAK3, and TYK2. Different cytokine receptors pair different JAK family members; the specific JAK pair activated determines which downstream signaling molecules are engaged.

Once activated, JAKs phosphorylate STAT proteins, signal transducers and activators of transcription. Phosphorylated STATs form dimers, translocate to the nucleus, and directly activate transcription of genes involved in immune cell proliferation, survival, differentiation, and cytokine production. The result is rapid amplification of the inflammatory signal that began at the cell surface.

Tofacitinib exerts its mechanism by inhibiting intracellular nonreceptor tyrosine kinase JAK enzymes. It inhibits JAK1, JAK2, JAK3, and to a lesser extent TYK2. In cellular settings where JAK kinases signal in pairs, tofacitinib preferentially inhibits signaling by heterodimeric receptors associated with JAK3 and JAK1, with functional selectivity over receptors that signal via pairs of JAK2.

Inhibition of JAK1 and JAK3 blocks signaling through the common gamma chain-containing receptors for several cytokines, including interleukin-2, -4, -7, -9, -15, and -21. These cytokines are integral to lymphocyte activation, development, proliferation, and function. Rather than targeting one cytokine extracellularly the way a biologic monoclonal antibody does, tofacitinib enters the cell and blocks a signaling enzyme that multiple cytokine pathways share. The breadth of that blockade is both the source of its efficacy across multiple diseases and the mechanistic explanation for some of its safety concerns.

JAK pair inhibited	Cytokines affected	Clinical relevance
JAK1/JAK3 (primary targets)	IL-2, IL-4, IL-7, IL-9, IL-15, IL-21	Lymphocyte activation and proliferation; adaptive immunity modulation
JAK1/JAK2	IL-6, IL-10, IL-11, IFN-alpha, IFN-beta	Acute phase response, inflammatory signaling, innate immunity
JAK2/TYK2	IL-12, IL-23	T-helper cell differentiation; relevant in psoriasis and IBD
JAK1/TYK2	Type I interferons	Antiviral defense; relevant to infection risk

The ORAL Surveillance Story: What the Data Actually Shows

No discussion of tofacitinib in 2026 can be complete without a thorough and honest account of ORAL Surveillance. It is the single most consequential clinical trial in the history of the JAK inhibitor class and the source of the boxed warning that now governs every tofacitinib prescription.

What the trial was: ORAL Surveillance (NCT02092467) was a Phase 3b/4 open-label, randomized post-marketing safety study mandated by the FDA. The trial enrolled 4,362 patients with moderate to severe rheumatoid arthritis on methotrexate background therapy, all aged 50 years or older and with at least one additional cardiovascular risk factor. Patients were randomized to tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, or a TNF inhibitor (adalimumab in North America, etanercept elsewhere).

What the primary endpoint was: Non-inferiority of tofacitinib to TNF inhibitors for two co-primary endpoints: major adverse cardiovascular events (MACE, defined as cardiovascular death, myocardial infarction, and stroke) and malignancy (excluding non-melanoma skin cancer). The pre-specified non-inferiority margin was an upper bound of 1.8 for the hazard ratio confidence interval.

What the results showed: ORAL Surveillance failed to demonstrate non-inferiority of tofacitinib to TNF inhibitors for both MACE and malignancy. Tofacitinib was associated with numerically higher rates of MACE and malignancy than TNF inhibitors in this high-cardiovascular-risk population.

At the FDA-approved 5 mg twice-daily dose, the number needed to harm was 567 patient-years for MACE and 276 patient-years for malignancy, translating to one additional MACE per approximately 113 patients and one additional cancer per approximately 55 patients treated with tofacitinib instead of a TNF inhibitor over a five-year period. Cancer risk was higher in patients over age 65 (HR 1.70; 95% CI 1.00 to 2.90) than in younger patients (HR 1.36; 95% CI 0.85 to 2.17).

The critical limitations that honest interpretation requires:

First, ORAL Surveillance enrolled a deliberately high-risk population, patients aged 50 and older with established cardiovascular risk factors. The trial lacked a group that was neither a JAK inhibitor nor a TNF inhibitor, meaning it can only compare tofacitinib to TNF blockers, not to placebo or to the underlying disease-related risk. The results therefore quantify the difference in risk between tofacitinib and TNF inhibitors in high-risk patients, not the absolute risk in a typical tofacitinib patient population.

Second, the FDA’s decision to extend the boxed warning to all patients and all JAK inhibitors, not just the high-risk RA population in ORAL Surveillance, was a policy judgment that has been debated in the rheumatology community. Real-world registry data from the Corrona registry, comparing the safety of tofacitinib to other biologics in a broader patient population, found no differences in MACE, serious infection events, malignancy, or death, representing some of the longest-term real-life safety data available for tofacitinib.

Third, the 10 mg twice-daily dose showed more pronounced safety signals than the 5 mg dose, specifically for pulmonary embolism and all-cause mortality. The 10 mg dose is not approved for RA or PsA; its use is limited to the ulcerative colitis induction period. The class warning effectively applied findings from a dose used in RA only in the trial to clinical contexts where that dose would never be used.

The honest clinical summary: ORAL Surveillance demonstrated a real safety signal for cardiovascular events and malignancy in a high-cardiovascular-risk population of RA patients aged 50 and older when comparing tofacitinib to TNF inhibitors. That signal is clinically meaningful for patient selection. It does not characterize the risk-benefit profile in all patients across all indications, and the magnitude of risk in lower-risk patients is substantially less certain.

The Safety Profile: What the Prescribing Information Requires

The Xeljanz prescribing information contains one of the most extensive boxed warning sections in rheumatology, encompassing six distinct categories of serious risk. The infection screening requirements parallel those for the biologic TNF inhibitors discussed in Post 5 of this series on golimumab and the Simponi LOE: tuberculosis screening before initiating, hepatitis B screening, and updated vaccination status are all required. Live vaccines are contraindicated during tofacitinib therapy.

Safety category	Details	Clinical guidance
Serious infections (boxed warning)	Increased risk of bacterial, fungal, viral, and opportunistic infections including tuberculosis. Risk is elevated with concomitant immunosuppressives.	Screen for latent TB before initiating. Evaluate for active infection before each refill. Hold tofacitinib during active serious infection.
Mortality (boxed warning)	Higher rate of all-cause mortality including sudden cardiovascular death compared to TNF blockers in ORAL Surveillance RA patients.	Use only after failure of TNF inhibitor in RA and PsA. Avoid in patients at high cardiovascular risk unless no suitable alternatives exist.
Malignancy (boxed warning)	Higher rates of lymphoma and lung cancer with tofacitinib versus TNF blockers. Risk increased in patients 65 and older, current or past smokers, and those with known malignancy risk factors.	Avoid in patients with known malignancy other than treated non-melanoma skin cancer. Consider alternatives in patients with significant cancer risk factors, especially current or past smokers over 65.
MACE (boxed warning)	Higher rate of MACE (cardiovascular death, MI, stroke) versus TNF blockers in ORAL Surveillance, particularly in patients 65 and older, smokers, and those with cardiovascular risk factors.	Use with caution in patients with cardiovascular disease. Avoid in patients at high CV risk unless no suitable alternatives are available.
Thrombosis (boxed warning)	Increased incidence of pulmonary embolism, venous thrombosis, and arterial thrombosis, primarily at the 10 mg twice-daily dose.	Use with caution in patients with risk factors for VTE. Promptly evaluate patients reporting signs of DVT or PE.
Herpes zoster reactivation	Rates of herpes zoster higher with tofacitinib than with TNF inhibitors.	Ensure zoster vaccination before starting tofacitinib where possible. Monitor during treatment.
Hyperlipidemia	Dose-dependent increases in total cholesterol, LDL, and HDL.	Monitor lipid levels 4 to 8 weeks after initiating. Manage dyslipidemia per standard clinical guidelines.
Anemia	Hemoglobin decreases observed; avoid initiating in patients with hemoglobin below 9 g/dL.	Monitor CBC during treatment.
GI perforations	Cases of GI perforation reported, particularly in patients with Crohn’s disease or diverticulitis.	Use with caution in patients at increased risk for GI perforations.
Renal and hepatic impairment	Dose reduction required in moderate renal impairment (eGFR 30 to 60 mL/min) or moderate hepatic impairment. Avoid in severe impairment.	Assess renal and hepatic function at baseline and periodically.

How Tofacitinib Compares to the Newer JAK Inhibitors

Tofacitinib’s approval opened the door to a JAK inhibitor generation that has continued to evolve. Baricitinib (Olumiant), upadacitinib (Rinvoq), and filgotinib (Jyseleca, approved in Europe but not the U.S.) are more selective for specific JAK isoforms, primarily JAK1, compared to tofacitinib’s broader JAK1/JAK2/JAK3 inhibition.

Agent	Primary target	Key indications	Selectivity profile	Safety class warning
Tofacitinib (Xeljanz)	JAK1/JAK3	RA, PsA, UC, AS, pcJIA	Broad: inhibits JAK1, 2, 3	Full boxed warning (class)
Baricitinib (Olumiant)	JAK1/JAK2	RA, alopecia areata, COVID-19	Preferential JAK1/JAK2	Full boxed warning (class)
Upadacitinib (Rinvoq)	JAK1-selective	RA, PsA, AS, AD, UC, Crohn’s	Highest JAK1 selectivity in class	Full boxed warning (class)

The theoretical advantage of JAK1 selectivity is that JAK3 inhibition disrupts common gamma chain cytokine signaling (IL-2, IL-7, IL-15) more dramatically and may contribute to a broader immunosuppressive effect that is not necessary for anti-inflammatory benefit in most autoimmune diseases. Whether this translates to meaningful real-world safety differences between agents in the class is still being studied. The FDA extended the class-level boxed warning to all JAK inhibitors in 2021 based on ORAL Surveillance findings, pending further evidence from the class.

For patients: the arrival of generic tofacitinib does not make it the automatic choice over newer, still-branded JAK inhibitors. The prescribing decision should still be driven by individual patient characteristics, cardiovascular risk, prior treatment history, specific indication, and comorbidities, with the rheumatologist or gastroenterologist making a risk-stratified recommendation. What the generic does mean is that tofacitinib becomes far more accessible for patients in whom it is the appropriate choice and for whom cost has been a barrier.

The Generic Entry: What Has Already Happened

The primary composition-of-matter patent for tofacitinib expired in December 2025. In August 2025, the FDA approved the first generic tofacitinib citrate from Ajanta Pharma, Ltd., marking the first generic entry into the Xeljanz market.

As of 2026, full generic entry is underway. Multiple manufacturers have filed ANDAs for generic tofacitinib tablets and extended-release tablets (Xeljanz XR). The immediate-release 5 mg and 10 mg tablets are the highest-volume products; the extended-release 11 mg once-daily tablet has its own separate patent profile and may follow a slightly different generic timeline.

As a small molecule, Xeljanz is far more straightforward to replicate than the monoclonal antibodies used in similar indications. Unlike the biologics covered in this series, golimumab (Simponi) and omalizumab (Xolair), which require complex manufacturing, stability verification, and specialized storage, generic tofacitinib tablets are produced through conventional pharmaceutical chemistry and distributed through standard pharmacy channels. This raises the prospect of rapid substitution, particularly in healthcare systems under cost pressure.

The current Xeljanz list price is approximately $5,000 to $6,000 per month for standard 5 mg twice-daily RA dosing. At approximately 80% price erosion, generic tofacitinib would reach approximately $1,000 to $1,200 per month initially, falling further as competition deepens. For health systems globally where JAK inhibitors have often been reserved for patients with access to payer-negotiated or government-reimbursed pricing, generic availability may meaningfully expand treatment reach.

Pfizer’s response to the LOE includes a branded copay assistance program. As with most specialty drug LOE events in this series, commercial copay assistance for insured patients slows but does not prevent market conversion, with the main beneficiaries of the generic being uninsured patients, Medicare patients, and health systems negotiating formulary contracts.

What Patients Currently on Xeljanz Should Know

If you are currently taking Xeljanz and your disease is well controlled, the generic transition is clinically straightforward. Generic tofacitinib citrate is the same molecule, at the same dose, with the same mechanism. Your disease-modifying benefit, your infection risk, and your safety monitoring requirements are unchanged by the switch from brand to generic.

What does change is cost, in your favor, as formularies transition to preferring the lower-cost generic. Expect formulary notifications about generic tofacitinib in 2026 and into 2027. When that notification arrives, discuss it with your rheumatologist or gastroenterologist at your next visit, not as a cause for alarm, but to confirm your dose and monitoring schedule remain appropriate.

If you are in the high-cardiovascular-risk population that ORAL Surveillance studied, aged 65 or older with cardiovascular risk factors, or a current or past smoker, the prescribing conversation with your rheumatologist should specifically address whether tofacitinib remains the best option for you given the ORAL Surveillance findings, or whether a TNF inhibitor might be more appropriate for your individual risk profile. Generic availability does not change the safety data. It does not make the drug safer for high-risk patients. The boxed warning applies to the generic exactly as it applies to the brand.

For patients newly diagnosed with RA, PsA, or AS: the label now requires demonstrating inadequate response or intolerance to at least one TNF blocker before starting tofacitinib. The generic’s arrival does not change that positioning. It remains a drug for the second-line and later autoimmune treatment setting.

For related HED coverage on other JAK inhibitor approvals and autoimmune disease treatment developments in 2026, see our post on the Simponi (golimumab) LOE and the Immgolis biosimilar litigation and our post on Fasenra (benralizumab) receiving a new indication for hypereosinophilic syndrome.

📌 A note on the completed series This post closes out HED’s 2026 Loss of Exclusivity Watch, a 10-post series covering drugs that generated over $17 billion in combined annual U.S. sales now entering the competitive generic and biosimilar market. The series spanned four therapeutic areas and three drug modalities: small molecules (sitagliptin, cladribine, vortioxetine, brivaracetam, tofacitinib, macitentan), a peptide biologic (teduglutide), and injectable biologics (golimumab, omalizumab, pomalidomide). What runs through every post — from Xolair’s interchangeable biosimilar to generic cladribine’s patent invalidation to Xeljanz’s generic entry — is the same fundamental tension in pharmaceutical markets. The periods of exclusivity that fund drug development are real and often necessary. The prices those exclusivity periods produce are frequently out of reach for the patients who need the drugs most. And the generic and biosimilar transitions that eventually bring prices down are complicated, incomplete, and slower in the U.S. than in most other developed health systems. The 2026 patent cliff does not resolve that tension. But for millions of patients currently priced out of Januvia, Trintellix, Mavenclad, Briviact, and Xeljanz, it moves the needle in a meaningful direction.

Sources

Xeljanz FDA approval: FDA approves tofacitinib for rheumatoid arthritis. FDA.gov. November 2012.

FDA boxed warning update (December 2021): FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors. FDA.gov. December 2021.

First generic tofacitinib approval (Ajanta Pharma, August 2025): ANDA Drug Approval Database. FDA.gov.

Patent expiry and generic pricing: XELJANZ patent and generic information. DrugPatentWatch. | The next pharma patent cliff: how 2026 to 2032 will reshape revenue. Labiotech. March 2026.

ORAL Surveillance trial registration: NCT02092467. ClinicalTrials.gov.

ORAL Surveillance primary publication: Ytterberg SR et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. NEJM. 2022;386(4):316–326. doi:10.1056/NEJMoa2109927.

ORAL Surveillance NNH analysis: JAK inhibitors and black box warnings: what is the future for JAK inhibitors? PMC10615860.

Lancet Rheumatology editorial (FDA class warning debate): FDA expands JAK inhibitors warning: going beyond the data? Lancet Rheumatology. 2021.

Corrona registry real-world safety data: Curtis JR et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2021. PMID 34185363.

Tofacitinib mechanism (StatPearls): Tofacitinib. StatPearls. NCBI.

JAK-STAT pathway review: JAK-STAT Signaling Pathway. PMC8440069.

Tofacitinib JAK selectivity in RA: Tofacitinib Suppresses Several JAK-STAT Pathways in RA In Vivo. Frontiers in Immunology. 2021.

JAK inhibitor selectivity comparison: Molecular Modeling Insights into Upadacitinib Selectivity. PMC8778839.

Baricitinib FDA approval: FDA approves baricitinib for moderately to severely active rheumatoid arthritis. FDA.gov.

Upadacitinib FDA approval: FDA approves upadacitinib for moderate to severe rheumatoid arthritis. FDA.gov.

Latent TB screening: Testing for Latent TB Infection. CDC.

Herpes zoster: Herpes Zoster. StatPearls. NCBI.

Xeljanz prescribing information: XELJANZ (tofacitinib) Prescribing Information. Pfizer.

NIAMS disease overviews: Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis | Juvenile Arthritis

NIDDK ulcerative colitis: Ulcerative Colitis. niddk.nih.gov.

HED internal references: LOE Post 5: Simponi (golimumab) | Fasenra HES approval post

Patient resources: Arthritis Foundation | Crohn’s and Colitis Foundation | Pfizer RxPathways patient assistance | Good Days Patient Assistance

Disclaimer: Health Evidence Digest provides general information about FDA approvals, loss of exclusivity events, and health research for educational purposes. This content is not a substitute for professional medical advice. Tofacitinib carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. Decisions about initiating, continuing, or transitioning from brand-name to generic tofacitinib must be made in close collaboration with a board-certified rheumatologist or gastroenterologist who can assess the patient’s individual cardiovascular risk, infection history, and overall benefit-risk profile. Never stop a DMARD without medical guidance.

Briviact Is the Better-Tolerated Descendant of One of Epilepsy’s Most Prescribed Drugs. Its Generics Are Already in Pharmacies. Here Is What the SV2A Science Behind It Actually Shows and What the LOE Means for 3.4 Million Americans With Epilepsy.

June 19, 2026

📌 The essentials Briviact (brivaracetam, UCB) is an oral antiseizure medication (ASM) approved in February 2016 for adjunctive treatment of focal (partial-onset) seizures in patients aged 1 month and older. It is available as tablets (10 mg, 25 mg, 50 mg, 75 mg, 100 mg), an oral solution (10 mg/mL), and an intravenous solution. Mechanism: SV2A (synaptic vesicle protein 2A) inhibitor. Brivaracetam shares its mechanism class with levetiracetam (Keppra) but binds SV2A with 15 to 30 times higher affinity and penetrates the brain faster. At therapeutic doses it is predicted to occupy more than 80% of SV2A in the human brain. The key clinical differentiation from levetiracetam: substantially lower rates of behavioral and psychiatric side effects (irritability, aggression, mood disturbance), the most clinically significant limitation of levetiracetam in practice. Briviact generated approximately $652 million in U.S. sales in 2025. Generic status: generics are already entering the U.S. market. UCB’s own patient-facing materials acknowledge this directly. At least one full FDA approval for generic brivaracetam was issued as early as June 2022 (Sunshine Lake Pharma); twelve companies have filed for generic approval; five tentative approvals exist. Brand list price: approximately $650 to $800 per month for 100 mg twice daily. Expected generic price with multi-source competition: $50 to $100 per month. Phase 3 pivotal trials: approximately 38 to 42% of patients achieved a 50% or greater reduction in seizure frequency at 100 mg per day. Statistically significant seizure reduction was demonstrated even in patients who had failed five or more prior antiseizure medications. Critical prescribing caution: brivaracetam and levetiracetam should not be co-administered at therapeutic doses. Both compete for the same SV2A binding site, reducing brivaracetam efficacy. Cross-taper required when transitioning.

📚 About this series: the 2026 Loss of Exclusivity Watch This is Post 9 of HED’s 2026 Loss of Exclusivity series, tracking the ten major drugs losing U.S. exclusivity this year. The full series covers: Xolair (omalizumab) • Pomalyst (pomalidomide) • Opsumit (macitentan) • Januvia/Janumet (sitagliptin) • Simponi (golimumab) • Mavenclad (cladribine) • Gattex (teduglutide) • Trintellix (vortioxetine) • Briviact (brivaracetam) • Xeljanz (tofacitinib). Each post follows the same format: what the drug is and how it works, what the clinical evidence shows, who uses it and why, and what the entrance of competition means for patients, prescribers, and the market.

Epilepsy is one of the most common serious neurological conditions in the world. Approximately 3.4 million Americans live with active epilepsy, and roughly 150,000 new cases are diagnosed each year in the United States alone. For the majority of patients, antiseizure medications manage the condition well enough to allow normal daily functioning. For about one-third, however, seizures remain inadequately controlled despite multiple medication trials, a population with enormous unmet need and, for many, a daily reality shaped by unpredictable neurological events that affect their ability to drive, work, care for their families, and move through the world safely.

Briviact (brivaracetam), developed by the Belgian biopharmaceutical company UCB, was FDA-approved in February 2016 for the adjunctive treatment of focal (partial-onset) seizures in patients aged 1 month and older. It belongs to the same drug class as levetiracetam (Keppra), one of the most widely prescribed antiseizure medications globally, but is not the same drug. Brivaracetam displays higher selectivity and affinity for synaptic vesicle protein 2A (SV2A) in the brain than levetiracetam. That distinction in receptor pharmacology translates into meaningful clinical differences, particularly in the behavioral and psychiatric side effect profile that has long been levetiracetam’s most significant clinical limitation.

Briviact generated approximately $652 million in U.S. sales in 2025. Generics are already entering the U.S. market. UCB’s own patient-facing website acknowledges this directly, stating that patients may notice generic versions of Briviact becoming available because the medicine’s patent is expiring.

The LOE story for brivaracetam is less dramatic than some others in this series: no litigation standoff, no manufacturing CRL, no biosimilar complexity. Generics are arriving. For patients currently on Briviact at brand-name prices, the cost relief is real and the transition should be clinically straightforward. But to understand what is being preserved when a patient transitions to generic brivaracetam, and why the drug’s specific receptor pharmacology was worth developing in the first place, requires going inside the science of SV2A, one of the more unusual drug targets in all of neurology.

What Epilepsy Is and Why Focal Seizures Are the Focus

Epilepsy is defined by the International League Against Epilepsy as a disease characterized by at least two unprovoked seizures occurring more than 24 hours apart, or one unprovoked seizure with a high probability of further seizures based on brain imaging or other factors. Seizures are the visible manifestation of abnormal, synchronous electrical activity across networks of neurons, either a localized discharge that remains focal or one that spreads to involve the entire brain.

The classification of seizure types has clinical importance because different seizure types respond to different drug mechanisms, and because the experience of a seizure is highly variable depending on where in the brain the discharge originates:

Seizure type	Origin	Common experience	Key treatment consideration
Focal onset (aware)	Localized cortical region, consciousness preserved	Strange feelings, déjà vu, unusual smells or tastes, repetitive movements, emotional changes	Brivaracetam, levetiracetam, lacosamide, lamotrigine, carbamazepine
Focal onset (impaired awareness)	Localized region, consciousness affected	Automatisms (lip smacking, hand movements), confusion, amnesia for the event	Same class options; seizure impact on daily function significant
Focal to bilateral tonic-clonic	Focal onset spreading to both hemispheres	Convulsions, loss of consciousness, post-ictal fatigue	Multiple agents; drug-resistant disease common
Generalized onset	Both hemispheres simultaneously from onset	Absence, myoclonic jerks, tonic-clonic episodes	Different drug profile; some focal ASMs ineffective

Brivaracetam is indicated for focal (partial-onset) seizures specifically. It is not approved for generalized epilepsy syndromes such as juvenile myoclonic epilepsy or absence epilepsy in the same way as some broader-spectrum agents. This specificity matters when evaluating its place in the treatment landscape.

The one-third of epilepsy patients with drug-resistant disease, defined as failure of two adequate trials of appropriately chosen and tolerated antiseizure medications, face a different clinical and quality-of-life reality from those who achieve seizure freedom early. For this population, the ongoing search for better-tolerated, more effective adjunctive agents is the difference between driving and not driving, working and not working, independent living and supervised care.

The SV2A Target: What It Is and Why It Matters

The mechanism shared by both levetiracetam and brivaracetam is one of the more scientifically unusual in clinical neuroscience. Both drugs bind to synaptic vesicle protein 2A (SV2A), a protein embedded in the membrane of synaptic vesicles inside neurons. Understanding what SV2A does, and why binding to it controls seizures, requires a brief look at how synaptic transmission works.

Neurons communicate at synapses by releasing neurotransmitters into the synaptic cleft. These neurotransmitters are stored in small membrane-bound packages called synaptic vesicles. When an action potential arrives at the presynaptic terminal, voltage-gated calcium channels open, calcium flows in, and the vesicles fuse with the presynaptic membrane to release their contents into the cleft in a process called exocytosis.

SV2A is a transmembrane glycoprotein expressed in virtually all neurons throughout the central nervous system. It contributes to calcium-sensitive exocytosis of transmitters through interaction with synaptotagmin, vesicular transport, stabilization of vesicular neurotransmitter loading, and regulation of calcium sensitivity. In practical terms: SV2A is part of the molecular machinery regulating how readily vesicles release neurotransmitter in response to neuronal activity.

In epilepsy, the problem is neuronal hyperexcitability: networks of neurons that fire too synchronously and too readily, creating the electrical storm of a seizure. By modulating SV2A, levetiracetam and brivaracetam dampen the readiness of vesicles to release neurotransmitter during high-frequency neuronal firing, selectively reducing the excessive synaptic transmission that characterizes seizure activity without broadly suppressing normal neuronal communication.

Both drugs bind selectively to SV2A with at least 100-fold higher affinity compared to SV2B and SV2C, the two related isoforms. This selectivity for the A isoform is thought to be central to the antiseizure effect, since SV2A is expressed in excitatory glutamatergic and inhibitory GABAergic neurons throughout the brain while SV2B and SV2C have more restricted distributions.

What Makes Brivaracetam Different From Levetiracetam

This is the central clinical pharmacology question, because levetiracetam has been generically available since 2008 and costs only a few dollars per month. If brivaracetam were simply levetiracetam with a slightly different structure, its development and $652 million in annual sales would be difficult to justify. The evidence says it is meaningfully different in three ways.

First: substantially higher SV2A affinity. Brivaracetam is a selective, high-affinity SV2A ligand with 15 to 30 times higher affinity than levetiracetam. Based on its affinity and pharmacokinetic parameters, at therapeutic concentrations brivaracetam is predicted to occupy more than 80% of SV2A in the human brain. Higher receptor occupancy at therapeutic doses means more complete target engagement, which may translate into efficacy at lower doses and in patients who have shown partial or incomplete response to levetiracetam.

Second: faster and more complete brain penetration. Brivaracetam has high lipid solubility and rapid brain penetration, with engagement of SV2A within minutes of administration. Levetiracetam’s brain penetration is slower. This pharmacokinetic difference is particularly relevant for intravenous use in acute seizure management, where speed of action matters, and may help explain why brivaracetam can work in some patients where levetiracetam does not achieve adequate SV2A occupancy.

Third: a more favorable behavioral side effect profile. This is the most clinically significant differentiation from a prescriber and patient perspective. Levetiracetam has a well-established adverse effect profile involving irritability, aggression, mood disturbance, and behavioral changes, sometimes severe enough to require drug discontinuation. The mechanism behind this behavioral toxicity is not fully elucidated but is thought to involve off-target effects beyond SV2A.

Brivaracetam’s exceptional selectivity for SV2A and its higher affinity suggest it exhibits superior clinical tolerability compared to levetiracetam. The increased possibility of behavioral abnormalities associated with levetiracetam has driven clinical interest in brivaracetam as an alternative with a cleaner receptor profile.

In clinical practice, the most common reason a neurologist prescribes brivaracetam over levetiracetam is either a patient with prior levetiracetam intolerance due to behavioral effects, or a patient with inadequate seizure control on levetiracetam who the clinician believes may achieve better SV2A occupancy with the higher-affinity compound.

There is one important prescribing caution arising from this relationship: the two drugs should not be used concurrently. Brivaracetam’s efficacy is reduced when levetiracetam is co-administered, because levetiracetam competes with brivaracetam for the same SV2A binding site. The clinical trials that evaluated brivaracetam efficacy excluded patients on concomitant levetiracetam from the efficacy analysis for exactly this reason.

The Clinical Evidence: Three Pivotal Phase 3 Trials

Brivaracetam’s FDA approval was supported primarily by three randomized, double-blind, placebo-controlled Phase 3 trials: N01252 (NCT00490035), N01253 (NCT00464269), and N01358 (NCT01261325), all evaluating adjunctive brivaracetam at doses of 50 to 200 mg per day in adults with uncontrolled focal seizures despite one to two existing antiseizure medications.

The primary endpoint across the pivotal trials was the percentage reduction over placebo in baseline-adjusted focal seizure frequency per 28 days during the 12-week treatment period.

Trial	N	Doses tested	Seizure frequency reduction versus placebo (100 mg/day)	50% responder rate (100 mg/day)	Notes
N01252	approximately 400	20, 50, 100 mg/day	Significant at 100 mg	approximately 40%	Conducted in Europe and India
N01253	approximately 400	5, 20, 50 mg/day	Significant at 50 mg (reduction 12.8%, p equals 0.025)	Dose-dependent improvement	Lower doses; 50 mg minimum effective
N01358	approximately 768	50, 100, 200 mg/day	Significant at 100 and 200 mg/day	approximately 38 to 42% at 100 to 200 mg/day	Largest pivotal trial; established dose range

Source: Klein P, Schiemann J. A review of the pharmacology and clinical efficacy of brivaracetam. PMC5783144. 2018.

The 50% responder rate, the proportion of patients achieving at least a 50% reduction in seizure frequency, is the benchmark most commonly used in clinical practice to assess whether an antiseizure medication is working meaningfully for an individual patient. Rates of approximately 38 to 42% at the 100 mg dose are consistent with what would be expected from an active adjunctive agent in a refractory focal epilepsy population.

The drug-resistant patient data is particularly informative. In patients with five or more previous antiseizure medications, a highly refractory population, the percentage reduction over placebo in 28-day adjusted focal seizure frequency was 18.1% for 100 mg per day (p equals 0.006) and 19.8% for 200 mg per day (p equals 0.004). Demonstrating statistically significant seizure reduction in patients who have already failed five or more previous medications is clinically meaningful, even if the absolute reduction is modest. For this population, any additional seizure control represents a real change in safety and quality of life.

A later Phase 3 study in adult Asian patients (EP0083) confirmed these findings across a different population: the percentage reduction over placebo was 24.5% (p equals 0.0005) for 50 mg per day and 33.4% (p less than 0.0001) for 200 mg per day. The 50% responder rate was 19.0% for placebo, 41.1% for 50 mg, and 49.3% for 200 mg per day.

The Safety Profile

Brivaracetam’s safety profile is a key part of its clinical story, and the comparison to levetiracetam is front and center.

Safety item	Details	Clinical guidance
Somnolence and fatigue	Most common adverse events; dose-dependent; occurred in approximately 15 to 25% of patients at therapeutic doses versus approximately 8 to 10% with placebo.	Counsel patients to avoid driving or operating heavy machinery until individual CNS effects are established. Often improves with continued treatment.
Dizziness	Common, dose-dependent; reported in approximately 10 to 12% at 100 to 200 mg/day.	Same caution regarding driving and machinery. Usually mild.
Behavioral and psychiatric effects	Substantially less common than with levetiracetam. Irritability, aggression, and mood disturbance reported at rates more comparable to other adjunctive antiseizure medications.	Monitor for mood changes, especially in patients with prior psychiatric history. Lower behavioral burden than levetiracetam is a key clinical differentiator.
Suicidal behavior and ideation	Class-level FDA warning for antiseizure medications: increased risk of suicidal thoughts and behavior.	Monitor all patients on antiseizure medications for emergence of new or worsening depressive symptoms, suicidal thoughts, or unusual behavioral changes.
Drug interactions: CYP2C19 inhibitors	Brivaracetam is metabolized by CYP2C19. Strong inhibitors (fluconazole, fluvoxamine) may increase brivaracetam plasma concentrations.	Reduce brivaracetam dose by half when co-administered with strong CYP2C19 inhibitors.
Drug interactions: rifampin	Strong CYP3A4 and CYP2C19 inducers (rifampin) can reduce brivaracetam levels by up to 45%.	Consider increasing brivaracetam dose when co-administered with rifampin or other strong inducers; monitor seizure control.
Drug interactions: levetiracetam	Concurrent use not recommended. Both compete for SV2A binding, reducing brivaracetam efficacy.	Cross-taper required when transitioning from levetiracetam: taper levetiracetam down while titrating brivaracetam up. Do not co-prescribe at therapeutic doses.
Renal impairment	Dose adjustment not required for mild to moderate impairment based on renal function alone.	Use with caution in severe renal impairment; monitor closely.
Pregnancy	Animal studies showed adverse developmental effects at high exposures. Human teratogenicity risk not fully established.	Discuss contraception and pregnancy planning with all patients of reproductive potential. Encourage pregnancy registry enrollment.
Abrupt discontinuation	As with all antiseizure medications, abrupt discontinuation risks seizure recurrence and status epilepticus.	Taper gradually when discontinuing. Never stop brivaracetam abruptly without medical supervision.

The behavioral tolerability advantage over levetiracetam deserves emphasis. Levetiracetam-induced irritability and aggression, sometimes called “Keppra rage” in patient communities, is not a trivial side effect. It affects family functioning, occupational performance, and quality of life, and is the most commonly cited reason for levetiracetam discontinuation in clinical practice. Brivaracetam’s cleaner SV2A selectivity appears to substantially reduce this risk, making it a genuinely preferred option for patients with prior behavioral side effects on levetiracetam.

The Patent and Generic Landscape: What Has Already Happened

Unlike several other drugs in this series, Briviact’s generic transition is not a future event. It is already underway.

UCB won a patent litigation decision in 2023, with a federal judge upholding the validity of U.S. Patent No. 6,911,461 covering the brivaracetam compound and blocking generic copies until 2026. That protection has now expired. The FDA has approved a generic version of Briviact, and UCB’s own materials acknowledge that patients may see generic versions appearing at their pharmacy.

Twelve different companies have filed for generic approval of Briviact. The manufacturers that have received or are pursuing FDA approval include Aurobindo, Lupin, MSN Laboratories, Zydus Pharmaceuticals, and Sunshine Lake Pharma, among others. Five tentative approvals exist for generic brivaracetam indicating near-term availability, and Sunshine Lake Pharma received a full FDA approval on June 9, 2022, among the first generic approvals for this compound.

With multiple generic manufacturers in the market, the price trajectory follows the standard antiseizure generic pattern: 70 to 85% reductions from brand-name pricing over 12 to 24 months as competition deepens. Briviact’s current list price runs approximately $650 to $800 per month for 100 mg twice daily. Generic brivaracetam is expected to settle at $50 to $100 per month with multi-source competition established.

UCB’s response to the LOE includes a branded patient loyalty program. UCB’s own Briviact savings card page states that even as generic options become available, patients may choose to stay on branded Briviact, and that without specific written instructions pharmacies may automatically dispense a generic version. This is a standard brand retention strategy: copay assistance programs that make the brand financially competitive with the generic at the point of care for commercially insured patients, while the payer bears the higher system-level cost. It slows but does not prevent market conversion.

Where Brivaracetam Fits in the 2026 Epilepsy Treatment Landscape

The antiseizure medication landscape is one of the most crowded in neurology, with more than 30 approved agents in the United States. The SV2A class represents one of the most established modern mechanisms: levetiracetam became a first-line agent for many epilepsy syndromes after its 1999 approval, and brivaracetam has carved out a complementary niche as the higher-affinity, better-tolerated successor.

The key positioning questions for a neurologist in 2026:

Is brivaracetam preferable to levetiracetam as first-line adjunctive therapy for focal epilepsy? The clinical evidence supports brivaracetam’s tolerability advantage, particularly the reduced behavioral side effect burden. However, levetiracetam has decades of real-world safety data, an even broader approved indication range, and costs pennies per day as a generic. Many neurologists use levetiracetam first and reserve brivaracetam for patients who develop behavioral side effects or need a switch.

Is generic brivaracetam bioequivalent to Briviact? Yes. The FDA bioequivalence standard ensures that approved generic brivaracetam delivers the same active ingredient at the same concentration with the same pharmacokinetic profile as the brand. The clinical effect, SV2A binding, seizure suppression, and tolerability profile, is preserved in the generic.

What about the interaction with levetiracetam? This is the most important practical management point for transitions. If a patient is switching from levetiracetam to brivaracetam or generic brivaracetam, the two should not be co-prescribed at full doses. A structured cross-taper, reducing levetiracetam while introducing brivaracetam, is the appropriate approach, managed by the treating neurologist.

The arrival of affordable generic brivaracetam has a particular public health significance for the drug-resistant epilepsy population. Patients cycling through multiple agents in search of seizure control have historically faced barriers to accessing newer, better-tolerated antiseizure medications due to cost and formulary restrictions. With generic brivaracetam entering the market at a fraction of Briviact’s brand price, prescribers have more flexibility to choose the agent best suited to a patient’s tolerability profile rather than the agent most easily covered by their insurance formulary.

What Patients Should Know

If you are currently taking Briviact and your seizures are well controlled: nothing in the generic transition changes the clinical effect of your medication. Generic brivaracetam contains the same active ingredient, at the same dose, with the same pharmacokinetics. If your pharmacy substitutes the generic and you experience any perceived change, whether in tablet appearance, packaging, or tolerability, contact your neurologist. Changes in perception of medication effect are sometimes real and sometimes related to factors unrelated to the drug itself; either way, they are worth reporting.

If you are switching from levetiracetam due to behavioral side effects: generic brivaracetam, now broadly available and significantly less expensive than brand Briviact, may be the option that has been cost-prohibitive for you in the past. Discuss this specifically with your neurologist, not just as an inquiry about a brand-name drug, but as a request to evaluate whether generic brivaracetam is now a realistic option given its changed cost profile.

If you are managing epilepsy in a child: brivaracetam is approved for patients aged 1 month and older. The availability of an oral solution formulation (10 mg/mL) is particularly relevant for young children or patients with swallowing difficulties. Confirm with your pediatric neurologist whether generic versions of both the tablet and oral solution formulations are available and appropriate for your child’s dosing needs.

One final reminder that applies to every patient on any antiseizure medication: never stop or reduce the dose of brivaracetam without medical guidance. Abrupt discontinuation of antiseizure medications risks seizure recurrence, including status epilepticus, regardless of how long the patient has been seizure-free.

For related HED coverage on neurological drug LOE events and CNS approvals in 2026, see our post on Mavenclad (cladribine) losing its MS dosing regimen patents and what the science behind selective immune reconstitution actually shows, and our post on the FDA approval of Ocrevus (ocrelizumab) for pediatric relapsing-remitting MS.

Sources

Briviact FDA approval: FDA approves brivaracetam for partial-onset seizures. FDA.gov. February 2016.

Patent litigation and LOE timing: UCB Wins Patent Order Blocking Copies of Briviact Epilepsy Drug. Bloomberg Law. August 2023. | Top 10 Drugs Losing U.S. Patent Protection in 2026. FDCELL. March 2026.

Generic availability: Generic Briviact Availability. drugs.com. Updated May 7, 2026. | BRIVIACT patent and generic information. DrugPatentWatch.

UCB patient acknowledgment of LOE: Briviact Savings Card and Patient Support. briviact.com.

SV2A mechanism and brivaracetam pharmacology: Klein P, Schiemann J. A review of the pharmacology and clinical efficacy of brivaracetam. PMC5783144. 2018.

SV2A allosteric modulation structural basis: Mechanisms Underlying Allosteric Modulation of Antiseizure Medication Binding to SV2A. PNAS. 2025. doi:10.1073/pnas.2510239122.

Brivaracetam brain penetration and SV2A occupancy: Nicolas JM et al. Brivaracetam, a selective high-affinity SV2A ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57(2):201–209. PMID 26663401.

SV2A differential interaction (brivaracetam vs. levetiracetam): Wood MD et al. Evidence for a differential interaction of brivaracetam and levetiracetam with SV2A. Epilepsia. 2017.

Phase 3 pivotal trial program: Klein P, Schiemann J. PMC5783144.

N01252 trial registration: NCT00490035. ClinicalTrials.gov.

N01253 trial registration: NCT00464269. ClinicalTrials.gov.

N01358 trial registration: NCT01261325. ClinicalTrials.gov.

Drug-resistant patient subgroup analysis: Villanueva V et al. Effect of Number of Previous Antiseizure Medications on Efficacy and Tolerability of Adjunctive Brivaracetam. Advances in Therapy. 2021.

Asian patient Phase 3 trial (EP0083): Inoue Y et al. Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients. Epilepsia Open. 2024. PMC11145603.

Brivaracetam versus levetiracetam behavioral tolerability: Comparison of Effectiveness of Brivaracetam and Levetiracetam for Post-Traumatic Seizure Prophylaxis. PMC11588607.

FDA antiseizure medication suicidality warning: Information on Antiepileptic Drugs (AEDs) and Suicidality. FDA.gov.

Levetiracetam StatPearls: Levetiracetam. StatPearls. NCBI.

Epilepsy StatPearls: Epilepsy. StatPearls. NCBI.

CDC epilepsy data: Epilepsy Data and Statistics. CDC.

Briviact prescribing information: Briviact (brivaracetam) Prescribing Information, Schedule V. UCB, Inc.

Pregnancy registry: North American AED Pregnancy Registry. epilepsyregistry.org.

Patient resources: Epilepsy Foundation | American Epilepsy Society | UCB patient support: myuCARE

Disclaimer: Health Evidence Digest provides general information about FDA approvals, loss of exclusivity events, and health research for educational purposes. This content is not a substitute for professional medical advice. Epilepsy management requires individualized assessment by a board-certified neurologist. Antiseizure medications should never be stopped or adjusted without medical supervision. Drug pricing information reflects figures at time of publication and is subject to change.

Trintellix Is Not Just Another SSRI for MDD. Its Mechanism Touches Six Serotonin Receptors and Has Demonstrated Cognitive Benefits That Other Antidepressants Have Not. Now Its Core Patent Expires and What Happens Next Matters for Millions of Patients.

June 18, 2026

📌 The essentials Trintellix (vortioxetine, Lundbeck/Takeda) is an oral antidepressant with a multimodal mechanism of action, approved in September 2013 for adults with major depressive disorder (MDD). It is not an SSRI. It simultaneously inhibits the serotonin transporter (SERT) and acts as an agonist, partial agonist, or antagonist at five distinct serotonin receptor subtypes: 5-HT1A (full agonist), 5-HT1B (partial agonist), 5-HT3 (antagonist), 5-HT7 (antagonist), and 5-HT1D (antagonist). The clinical differentiation: vortioxetine produces antidepressant and anxiolytic effects comparable to SSRIs and better-tolerated than SNRIs, while demonstrating a direct pharmacological benefit on cognitive function (processing speed, working memory) that duloxetine and SSRIs have not shown in controlled trials. The cognitive benefit is real and pharmacologically independent of mood improvement, but effect sizes are modest (standardized effect size 0.24 to 0.35 after MADRS adjustment). Current list price: approximately $514 per 30-day supply. Generic timeline: the core compound patent (U.S. Patent No. 7,144,884) expired June 17, 2026. A six-month pediatric exclusivity period extends effective market protection to approximately February 2027. As of June 2026, the FDA has not issued final generic approval for vortioxetine; three tentative approvals exist (Alembic, Lupin, and others), which convert to final approvals when exclusivity ends. Generic launches are expected in early to mid-2027 at prices 70 to 85% below current list price.

📚 About this series: the 2026 Loss of Exclusivity Watch This is Post 8 of HED’s 2026 Loss of Exclusivity series, tracking the ten major drugs losing U.S. exclusivity this year. The full series covers: Xolair (omalizumab) • Pomalyst (pomalidomide) • Opsumit (macitentan) • Januvia/Janumet (sitagliptin) • Simponi (golimumab) • Mavenclad (cladribine) • Gattex (teduglutide) • Trintellix (vortioxetine) • Briviact (brivaracetam) • Xeljanz (tofacitinib). Each post follows the same format: what the drug is and how it works, what the clinical evidence shows, who uses it and why, and what the entrance of competition means for patients, prescribers, and the market.

Major depressive disorder is the leading cause of disability worldwide. An estimated 280 million people live with depression globally, and in the United States alone, approximately 21 million adults experienced at least one major depressive episode in the past year. Despite decades of drug development, treatment outcomes remain deeply unsatisfying for a large proportion of patients. About one-third of people with MDD do not achieve adequate response after trying multiple antidepressants, a population so large and so poorly served that it has its own clinical designation: treatment-resistant depression.

Even among patients who do respond to antidepressants, a significant and underappreciated problem persists: cognitive impairment. Depression is not only a disease of mood. Patients consistently report difficulties with concentration, memory, processing speed, and executive function, symptoms that often persist even after mood has improved on conventional antidepressant therapy. This cognitive dysfunction in depression is one of the most significant contributors to functional impairment, disability, and reduced quality of life in patients who are otherwise considered treatment responders.

Vortioxetine is a novel antidepressant with multimodal activity that provides improvements in cognitive function alongside antidepressant and anxiolytic effects. In head-to-head comparisons it has been found to be one of the most tolerable options for MDD and demonstrates a direct cognitive benefit that comparators including duloxetine have not replicated in controlled trials.

Trintellix (vortioxetine), developed by Lundbeck and commercialized in the U.S. by Takeda, was FDA-approved in September 2013. The current list price is approximately $514 for a 30-day supply. A 2021 study of Medicare beneficiaries on antidepressants found 16.6% had cost-related medication nonadherence, and separate analyses have linked antidepressant nonadherence to more hospitalizations, more emergency room visits, and higher total medical costs, meaning high out-of-pocket costs can worsen the very condition these medications are meant to treat.

The core patent expired June 17, 2026. With pediatric exclusivity extending effective protection to approximately February 2027, generic vortioxetine is expected to reach U.S. pharmacies in early to mid-2027 at 70 to 85% below current list price.

What Major Depressive Disorder Is and Why It Remains So Hard to Treat

Major depressive disorder is diagnosed when a person experiences at least five of nine specific symptoms for two weeks or longer, with at least one of those symptoms being either depressed mood or loss of interest or pleasure. The other diagnostic criteria include changes in weight or appetite, sleep disturbances, psychomotor changes observable by others, fatigue, feelings of worthlessness or excessive guilt, difficulty thinking or concentrating, and recurrent thoughts of death or suicidal ideation.

What this clinical description obscures is the heterogeneity of the disease in practice. Two patients who both meet criteria for MDD may have almost entirely different symptom profiles: one with profound psychomotor slowing, hypersomnia, and appetite increase; another with insomnia, agitation, and severe cognitive dysfunction. The neurobiological mechanisms driving these different phenotypes are not identical, which helps explain why no single antidepressant works for all patients and why treatment often requires multiple trials.

The antidepressant treatment landscape has been dominated since the late 1980s by SSRIs, fluoxetine, sertraline, escitalopram, paroxetine, and subsequently by SNRIs such as venlafaxine and duloxetine. These drugs block the reuptake transporters for serotonin, and in the case of SNRIs, norepinephrine, increasing the available concentration of these neurotransmitters in the synaptic cleft. They are effective for many patients, reasonably well tolerated, and generically available at very low cost.

The unmet need they leave behind is twofold: the treatment-resistant patients who do not respond, and the responders who achieve better mood but not better thinking. Vortioxetine was specifically designed to address the second of these gaps, and the clinical evidence suggests it does so in a meaningful way.

The Science: What Makes Vortioxetine’s Mechanism Different

Most antidepressants approved over the past three decades have a single primary mechanism: blocking one or two neurotransmitter transporters. Vortioxetine does something fundamentally different. It simultaneously acts on multiple serotonin receptor subtypes while also blocking the serotonin transporter, creating what pharmacologists call a multimodal mechanism of action.

Vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, a 5-HT1B receptor partial agonist, a 5-HT1A receptor full agonist, and an inhibitor of the serotonin transporter (SERT), leading to modulation of neurotransmission in several systems simultaneously. This multimodal activity is considered responsible for the antidepressant and anxiolytic effects and the improvement of cognitive function observed with vortioxetine.

SERT inhibition — blocking the serotonin reuptake transporter, just as SSRIs do — is the foundation. It increases serotonin availability in the synapse.

5-HT1A receptor full agonism activates receptors on serotonergic neurons in the raphe nuclei, increasing serotonin firing and release. SSRIs do not directly activate 5-HT1A; they increase serotonin, which then stimulates 5-HT1A indirectly. Vortioxetine’s direct agonism augments this effect.

5-HT3 receptor antagonism is arguably the most pharmacologically interesting element. 5-HT3 receptors are ion channels located on inhibitory interneurons throughout the brain. When activated, they inhibit the release of multiple neurotransmitters including serotonin, dopamine, norepinephrine, and acetylcholine. Blocking 5-HT3 removes this inhibitory brake on multiple neurotransmitter systems simultaneously, which may explain the pro-cognitive effects of vortioxetine.

5-HT7 receptor antagonism regulates circadian rhythms, sleep architecture, and learning and memory processes. Blocking these receptors enhances serotonin release and affects glutamatergic neurotransmission in the hippocampus, a region critical for memory consolidation.

The downstream consequence of this receptor profile is that vortioxetine increases not only serotonin but also dopamine, norepinephrine, acetylcholine, histamine, and glutamate in specific brain regions. Enhanced release of glutamate from increased pyramidal neuron activity could enhance long-term potentiation, neuronal plasticity, and memory formation. This is not theoretical: the cognitive benefit is measured and quantified in clinical trials with objective neuropsychological instruments.

Receptor target	Vortioxetine action	Downstream effect
SERT (serotonin transporter)	Inhibitor	Increases synaptic serotonin: the SSRI foundation
5-HT1A receptor	Full agonist	Increases serotonin firing from raphe nuclei; anxiolytic effects
5-HT1B receptor	Partial agonist	Further increases serotonin, glutamate, acetylcholine, histamine release
5-HT3 receptor	Antagonist	Removes inhibitory brake on multiple neurotransmitters; key pro-cognitive contribution
5-HT7 receptor	Antagonist	Affects circadian regulation, hippocampal glutamate, memory processes
5-HT1D receptor	Antagonist	Modulates serotonin autoreceptors; contributes to net serotonin increase

The Clinical Evidence: Mood, Cognition, and What the Head-to-Head Data Shows

Antidepressant efficacy

Across the pivotal clinical trials, vortioxetine consistently outperformed placebo on the Montgomery-Asberg Depression Rating Scale (MADRS), the primary outcome measure for MDD trials. A systematic review and meta-analysis of 20 studies involving 8,547 participants found that vortioxetine outperformed placebo in response (RR 1.35; 95% CI 1.23 to 1.48; p less than 0.001), remission (RR 1.33; 95% CI 1.17 to 1.52; p less than 0.001), and cognitive function (SMD 0.34; 95% CI 0.16 to 0.52; p less than 0.001).

Head-to-head comparisons with SSRIs and SNRIs require honest framing. Compared with SNRIs, vortioxetine had better tolerability (RR 0.90; 95% CI 0.86 to 0.94; p less than 0.001) but no significant difference in response or remission rates. Compared with SSRIs, vortioxetine showed no difference in response or remission. Vortioxetine is not more effective at treating depression symptoms than SSRIs or SNRIs. It is comparably effective and better tolerated than SNRIs. The clinical differentiation lies in what it does to cognition, not in superior mood outcomes.

The cognitive benefit: what the evidence actually shows

The cognitive evidence for vortioxetine is the most scientifically distinctive part of the drug’s story. The primary instrument used across trials to measure cognitive function was the Digit Symbol Substitution Test (DSST), a validated, objective neuropsychological test of processing speed, attention, and working memory.

A meta-analysis across three randomized, double-blind, placebo-controlled 8-week trials of vortioxetine in MDD found that before adjustment for MADRS score, vortioxetine separated from placebo on DSST in all individual trials and statistically improved DSST performance versus placebo in meta-analysis (standardized effect size [SES] 0.35; p less than 0.0001). After adjustment for MADRS score, controlling for the possibility that cognitive improvement was simply a consequence of mood improvement, vortioxetine maintained DSST improvement with separation from placebo maintained in meta-analysis (SES 0.24; p less than 0.0001). By contrast, duloxetine failed to separate from placebo on DSST in either individual trials or meta-analyses. Vortioxetine statistically favored duloxetine on DSST after MADRS adjustment.

The MADRS adjustment is the critical methodological point. A drug that improves mood will often improve cognition as a secondary consequence: patients think more clearly when they feel less depressed. By controlling statistically for the degree of mood improvement and still finding a cognitive benefit, the analysis establishes that vortioxetine’s cognitive effect has a direct pharmacological component beyond its antidepressant effect. Duloxetine, a widely used SNRI, did not demonstrate this.

A separate meta-analysis of six placebo-controlled trials confirmed that vortioxetine significantly improved cognitive function compared with placebo as measured by both DSST and PDQ (Perceived Deficit Questionnaire, a patient-reported cognitive outcomes measure) scores, with improvements not related to vortioxetine dosage.

Outcome measure	Effect versus placebo	Effect versus duloxetine	Independence from mood improvement
MADRS (depression severity)	Significant (p less than 0.001)	Comparable	Not applicable
DSST (objective cognitive processing)	Significant (SES 0.35; p less than 0.0001)	Statistically superior (SES 0.16 favoring vortioxetine; p=0.04)	Maintained after MADRS adjustment (SES 0.24)
PDQ (patient-reported cognition)	Significant improvement	Better than SNRIs	Direct pharmacological component established
Response rate	RR 1.35 versus placebo	Comparable to SSRIs/SNRIs	—
Remission rate	RR 1.33 versus placebo	Comparable to SSRIs/SNRIs	—

The honest framing: the cognitive benefit is real, statistically robust, and pharmacologically independent. But effect sizes are modest (SES 0.24 to 0.35 after adjustment). This is not a dramatic cognitive rescue. It is a meaningful but incremental advantage in processing speed and working memory that may translate to real functional improvement for patients who find cognitive symptoms particularly impairing.

Where Vortioxetine Fits in the 2026 Antidepressant Landscape

The MDD treatment landscape in 2026 is broader than it has ever been, and vortioxetine’s niche is more specific than its general antidepressant label implies.

The first-line standard of care remains SSRIs, sertraline, escitalopram, fluoxetine, all generically available for under $20 per month. They work for a large proportion of patients and their cost-effectiveness at scale is excellent. SNRIs including venlafaxine and duloxetine are also generically available and appropriate for patients who need norepinephrine augmentation or have comorbid pain conditions.

Vortioxetine’s specific clinical home is patients for whom cognitive symptoms are a prominent part of their depression, either the primary complaint or a residual symptom that persists after adequate mood response on prior treatment. The evidence supports a direct pharmacological role in improving objective processing speed and subjective cognitive function that other antidepressants including duloxetine have not demonstrated. This is where a prescriber would reach for vortioxetine rather than a less expensive SSRI alternative.

The 2026 antidepressant landscape also includes newer entrants in adjacent spaces. Esketamine (Spravato), approved for treatment-resistant depression, targets the glutamate system through NMDA receptor antagonism. Auvelity (dextromethorphan/bupropion), approved for MDD and now also for Alzheimer’s agitation, also targets NMDA receptors. Gepirone (Exxua), an azapirone approved in 2023, is a selective 5-HT1A agonist. None overlap directly with vortioxetine’s specific receptor profile, and none are positioned for the cognition-focused use case in the same way.

The comparison that matters most for payers and formulary decision-makers is vortioxetine against the cheap SSRIs. Once generic vortioxetine is available, priced at 70 to 85% below the current list price, the formulary calculus changes and patients who have been prescribed Trintellix at $500 per month can access the same molecule for $30 to $50.

The Patent Timeline: When Generics Will Actually Arrive

The core compound patent, U.S. Patent No. 7,144,884, expired June 17, 2026. A six-month pediatric exclusivity period follows, extending to approximately December 17, 2026. However, accounting for the specific pediatric study completion timing and the precise triggering conditions for exclusivity, the effective protection extends to approximately February 2027, which is the date used by most legal and pharmaceutical analysts as the practical entry window.

While Trintellix’s Orange Book patent listings extend as far as March 2032, federal courts have ruled that the latest-expiring patents do not cover the use generic manufacturers are seeking approval for, which is treating MDD rather than the specialized cognitive impairment or adverse-event management methods those later patents claimed. The patents stretching to 2031 and 2032 do not block generic vortioxetine tablets approved for MDD. The only enforceable barrier to generic entry is the core compound patent and the pediatric exclusivity.

As of June 2026, the FDA has not issued final approval for a generic version of Trintellix, though three tentative approvals exist. Tentative approval means the FDA has determined the applications are approvable but cannot grant final approval while exclusivity protections remain active. When pediatric exclusivity expires in approximately February 2027, those tentative approvals convert to final approvals and manufacturers can launch.

Manufacturers with tentative approvals include Alembic, Lupin, Macleods, Sandoz, Sigmapharm, and Zydus, each of which filed ANDAs and participated in the patent proceedings. First-to-file status in Hatch-Waxman litigation may entitle one or more challengers to 180 days of market exclusivity, meaning for six months after the first generic launch only the first filer can sell generic vortioxetine. After that window, the full field enters and prices typically fall sharply.

Patients and prescribers should expect generic vortioxetine availability in U.S. pharmacies beginning in early to mid-2027, with prices expected to fall 70 to 85% below Trintellix’s current list price within 12 to 18 months of multi-generic competition.

The Safety Profile

Vortioxetine’s tolerability profile is one of its clinical selling points. It avoids several side effects common to other antidepressant classes, while introducing its own characteristic profile.

Safety item	Details	Clinical guidance
Nausea	Most common adverse event; reported in approximately 21 to 32% of patients across trials, dose-dependent, most prominent in the first 1 to 2 weeks.	Taking with food reduces severity. Starting at 5 mg and titrating to target dose may improve tolerability. Usually resolves within 2 weeks of continued treatment.
Sexual dysfunction	Less common than with SSRIs, a clinically meaningful advantage for many patients. However, decreased libido, delayed orgasm, and erectile dysfunction have been reported.	Discuss openly before initiating. The comparative advantage over SSRIs in this domain is meaningful for patients who have discontinued prior antidepressants due to sexual side effects.
Suicidality (boxed warning)	Class-level FDA boxed warning for all antidepressants: increased risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Not indicated in pediatric patients.	Monitor closely during the first weeks of treatment, particularly in patients aged 18 to 24. Clinical benefit in adults 25 and older outweighs risk.
Serotonin syndrome	Risk when combined with other serotonergic drugs: other antidepressants, tramadol, certain migraine medications, linezolid.	Do not use with MAOIs or within 21 days of stopping an MAOI. Allow 14 days after stopping vortioxetine before starting an MAOI. Educate patients about serotonin syndrome symptoms.
Discontinuation syndrome	Abrupt discontinuation can cause dizziness, sensory disturbances, irritability, anxiety, and confusion.	Taper gradually when discontinuing; titrate down over 2 to 4 weeks. Never stop abruptly.
Hyponatremia	Low sodium, primarily in older adults on diuretics: a class effect of SSRIs and SNRIs also seen with vortioxetine.	Monitor sodium levels in at-risk patients, especially elderly patients on diuretics.
Abnormal bleeding	Increased risk of GI bleeding, particularly when combined with NSAIDs, aspirin, or anticoagulants, from serotonin’s role in platelet function.	Caution with concurrent anticoagulant or antiplatelet use.
Weight	Weight-neutral in clinical trials. A meaningful advantage compared to TCAs, mirtazapine, and some atypical antipsychotics used as augmentation agents.	Reassure patients who have experienced weight gain on prior antidepressant therapy.
Sleep	Vortioxetine does not significantly impair sleep architecture and may be beneficial for certain sleep disturbances associated with depression, a consequence of its 5-HT7 antagonism and circadian effects.	Can generally be taken at any time of day; morning dosing may be preferred to minimize any activating effects.

The comparative tolerability data from meta-analyses is clinically important: vortioxetine showed better tolerability than SNRIs, with fewer discontinuations due to adverse events, while showing comparable tolerability to SSRIs. For patients who have discontinued duloxetine or venlafaxine due to side effects, including nausea, sweating, blood pressure elevation, or discontinuation symptoms, vortioxetine offers a mechanistically different profile worth considering.

What the Generic Arrival Means for Patients

The significance of generic vortioxetine for the MDD patient population is both economic and clinical. At $466 to $576 per month, Trintellix is out of reach as a sustainable long-term therapy for uninsured patients and represents a substantial burden for those with high-deductible insurance plans. Cost-related medication nonadherence in antidepressants has been directly linked to worse clinical outcomes including more hospitalizations and higher total healthcare costs.

Depression is not a disease where medication gaps are clinically neutral. Stopping an antidepressant prematurely is associated with relapse risk, and the period immediately following discontinuation carries elevated suicide risk in some patients. A drug that is too expensive to continue consistently is not just an economic problem. It is a clinical hazard.

When generic vortioxetine becomes available in early to mid-2027, the cost profile shifts dramatically. Patients currently maintained on Trintellix who have been managing significant cost-sharing will have access to the same molecule at a price comparable to other generic antidepressants. Prescribers who have been reluctant to start Trintellix due to prior authorization requirements and formulary friction will face a different landscape. And patients who have heard about the cognitive benefits but could not access the drug financially will have a realistic path to trying it.

For patients currently on Trintellix who are responding: nothing changes clinically in 2026. The drug is available, and payer formularies have not yet shifted to generic alternatives because none exist. In early to mid-2027, when your formulary sends a notification about transitioning to generic vortioxetine, the medication will be therapeutically identical to what you are taking today. The active ingredient, the dose, the mechanism, and the clinical effects are the same. A brief conversation with your prescriber at your next visit is appropriate, not a reason to delay transition.

If you are experiencing a mental health crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.

For related HED coverage on newer antidepressant and psychiatric drug approvals in 2026, see our post on Auvelity receiving its second FDA approval for agitation in Alzheimer’s disease and our coverage of the FDA’s psychedelic drug program accelerations, including psilocybin for treatment-resistant depression.

Sources

Trintellix FDA approval: FDA approves vortioxetine to treat major depressive disorder. FDA.gov. September 2013.

Patent expiry and litigation timeline: U.S. court issues decision in Trintellix patent litigation. Lundbeck press release. news.cision.com. October 1, 2021. | Trintellix Patent Expiration Date and Generic Timeline. LegalClarity. April 2026.

Federal Circuit non-infringement ruling: H. Lundbeck A/S v. Lupin Ltd, No. 22-1194 (Fed. Cir. 2023). A&O Shearman. January 2026.

Generic availability (current): Generic Trintellix Availability. drugs.com. Updated June 11, 2026.

Trintellix pricing: Trintellix (vortioxetine) prices. MedicalNewsToday. 2026.

Vortioxetine mechanism (StatPearls): Vortioxetine. StatPearls. NCBI.

Multimodal mechanism — receptor specifics: Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine: blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine. CNS Spectrums. 2015.

Cognitive effects meta-analysis (primary, PMC 2016): Vieta E et al. The Effects of Vortioxetine on Cognitive Function in Patients with MDD: A Meta-Analysis of Three Randomized Controlled Trials. PMC5091829.

Cognitive effects meta-analysis (2022): Li J et al. Effect of Vortioxetine on Cognitive Impairment in Patients with Major Depressive Disorder: A Systematic Review and Meta-analysis. Int J Neuropsychopharmacol. 2022;25(12):969. PMC9743961.

Efficacy versus SSRIs/SNRIs meta-analysis: Systematic Review and Meta-Analysis of Vortioxetine for MDD in Adults. PMC9263295.

Cognitive dysfunction in depression review: Cognitive dysfunction in MDD. PMC6416141.

Treatment-resistant depression: Treatment-Resistant Depression. StatPearls. NCBI.

MDD StatPearls: Major Depressive Disorder. StatPearls. NCBI.

SSRIs: Selective Serotonin Reuptake Inhibitors. StatPearls. NCBI.

SNRIs: Serotonin-Norepinephrine Reuptake Inhibitors. StatPearls. NCBI.

Serotonin syndrome: Serotonin Syndrome. StatPearls. NCBI.

Trintellix prescribing information: Trintellix (vortioxetine) Prescribing Information. Takeda Pharmaceuticals.

NIMH MDD statistics: Major Depression. NIMH.

WHO depression fact sheet: Depression. WHO.

Esketamine FDA approval: FDA approves esketamine nasal spray (Spravato) for treatment-resistant depression. FDA.gov.

988 Suicide and Crisis Lifeline: 988lifeline.org.

HED internal references: Auvelity Alzheimer’s agitation approval post | FDA psychedelic drug program post

Patient resources: National Alliance on Mental Illness (NAMI) | Mental Health America | 988 Suicide and Crisis Lifeline | SAMHSA National Helpline: 1-800-662-4357

Disclaimer: Health Evidence Digest provides general information about FDA approvals, loss of exclusivity events, and health research for educational purposes. This content is not a substitute for professional medical advice. Depression is a serious medical condition requiring individualized diagnosis and treatment by a qualified clinician. Decisions about antidepressant therapy, including transitions between brand-name and generic medications, should be made in consultation with a prescribing psychiatrist, primary care physician, or other qualified mental health provider. Never discontinue an antidepressant without medical guidance. If you or someone you know is experiencing a mental health crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.

Gattex Costs More Than $700,000 a Year and Is the Only Drug That Asks the Intestine to Grow Back. Its Pediatric Exclusivity Just Expired. Here Is What the Science Behind This Remarkable and Remarkably Expensive Therapy Actually Shows.

June 17, 2026

📌 The essentials Gattex (teduglutide, Takeda) is a GLP-2 analog approved for adults and children aged 1 year and older with short bowel syndrome (SBS) who are dependent on parenteral nutrition. Mechanism: teduglutide binds GLP-2 receptors on subepithelial myofibroblasts and enteric neurons, triggering paracrine release of growth factors that increase villus height, crypt depth, intestinal blood flow, and barrier integrity. The net result is increased absorptive surface area and reduced need for intravenous nutrition support. FDA approval: December 21, 2012 for adults; extended to pediatric patients aged 1 year and older in subsequent approvals. Last pediatric exclusivity expired May 16, 2026. Seven patent litigation cases have been filed by generic challengers. The STEPS pivotal trial: 63% of patients achieved at least a 20% reduction in parenteral nutrition volume at 24 weeks versus 30% with placebo (p less than 0.001). Long-term extension data: 16 of 134 patients (approximately 12%) achieved complete parenteral nutrition independence after a mean of 89 weeks of teduglutide treatment. Annual cost: exceeds $700,000 for adults at current list price. Cost-effectiveness modeling has found that teduglutide does not meet traditional cost-effectiveness thresholds except in subpopulations achieving maximum benefit. Mandatory colonoscopy surveillance: colonoscopy within 6 months before initiating Gattex and every 5 years thereafter is required due to the theoretical risk of accelerating growth of pre-existing colorectal polyps or neoplasia. Note on regulatory pathway: teduglutide is a recombinant 33-amino acid peptide. Follow-on products may proceed via biosimilar aBLA or via 505(b)(2) NDA or ANDA pathways depending on the FDA’s regulatory classification, a determination that may differ for individual manufacturers.

📚 About this series: the 2026 Loss of Exclusivity Watch This is Post 7 of HED’s 2026 Loss of Exclusivity series, tracking the ten major drugs losing U.S. exclusivity this year. The full series covers: Xolair (omalizumab) • Pomalyst (pomalidomide) • Opsumit (macitentan) • Januvia/Janumet (sitagliptin) • Simponi (golimumab) • Mavenclad (cladribine) • Gattex (teduglutide) • Trintellix (vortioxetine) • Briviact (brivaracetam) • Xeljanz (tofacitinib). Each post follows the same format: what the drug is and how it works, what the clinical evidence shows, who uses it and why, and what the entrance of competition means for patients, prescribers, and the market.

There is a small corner of clinical medicine where patients survive on bags of liquid nutrition delivered directly into a vein, every night, sometimes for the rest of their lives. A pump. A central line catheter tunneled under the skin. Hours tethered to an IV pole before they can sleep. The condition is called intestinal failure, and for patients with short bowel syndrome, it is not a temporary inconvenience. It is the permanent consequence of having lost so much of their small intestine that what remains cannot absorb enough nutrients to sustain life.

Short bowel syndrome (SBS) is a rare disorder with known physical, psychosocial, and economic burdens and significant morbidity and mortality. Many individuals with SBS require long-term home parenteral nutrition (PN). The most common etiologies in adults are Crohn’s disease and mesenteric ischemia. Intestinal anatomy and remnant bowel length are prognostic for parenteral nutrition dependency, and achieving enteral autonomy confers a meaningful survival advantage.

Gattex (teduglutide) is unusual even by orphan drug standards because its mechanism is not suppression, replacement, or blockade. It asks the intestine to grow. Teduglutide is a GLP-2 analog that reduces dependence on parenteral nutrition in patients with SBS by promoting enterocytic proliferation and increasing absorptive surface area. A drug that literally stimulates the remnant intestinal lining to expand, absorb more, and, for a meaningful fraction of patients, allow the eventual reduction or elimination of intravenous nutritional support. That is a fundamentally different therapeutic proposition from most drugs in medicine.

Gattex was approved by the FDA on December 21, 2012 for adult patients with SBS dependent on parenteral support, and later expanded to include pediatric patients aged 1 year and older. Its last pediatric exclusivity expired on May 16, 2026. Seven patent litigation cases have been filed by generic challengers, indicating strong commercial interest in launch. No follow-on product has yet been approved.

This post covers what short bowel syndrome and intestinal failure actually are, why teduglutide’s GLP-2 mechanism is scientifically distinctive, what the STEPS pivotal trial and long-term extension data show, what the mandatory colonoscopy surveillance requirement means and why it exists, the cost and access reality of a drug exceeding $700,000 per year, and what the LOE means for a patient population that is both tiny and profoundly treatment-dependent.

What Short Bowel Syndrome Is and What Living With It Looks Like

The small intestine in a healthy adult measures roughly six to seven meters in length. It is the primary site of nutrient and fluid absorption, where digested food crosses from the gut lumen into the bloodstream and where fats, proteins, carbohydrates, vitamins, and minerals are taken up to sustain every organ and process in the body.

SBS in adults is characterized by the European Society for Clinical Nutrition and Metabolism as the clinical condition associated with a remaining small bowel in continuity of less than 200 cm. When that much intestine is absent, either surgically removed or non-functional, what remains cannot absorb enough to sustain the person without supplemental support. The result is intestinal failure.

SBS can develop at any age and from multiple causes:

Cause	Population	Notes
Crohn’s disease with repeated resections	Adults	Cumulative surgical bowel loss over years of disease; most common adult SBS etiology
Mesenteric ischemia	Adults, often older	Vascular occlusion leading to extensive bowel necrosis; often acute and catastrophic
Volvulus (intestinal twisting)	Any age	Can occur in neonates (midgut volvulus) or adults
Necrotizing enterocolitis (NEC)	Premature neonates	Leading cause of SBS in pediatric populations; premature gut tissue undergoes inflammatory necrosis
Gastroschisis and congenital abnormalities	Neonates	Congenital bowel defects requiring extensive resection at birth
Trauma or radiation enteritis	Adults	Less common; direct physical injury or radiation damage to bowel

The clinical consequences of intestinal failure are multisystemic. Patients must receive total parenteral nutrition (TPN), intravenous delivery of all macronutrients, micronutrients, electrolytes, and fluids. Home PN typically requires 10 to 16 hours of infusion per night through a central venous catheter. The catheter is a permanent source of risk: central line-associated bloodstream infections (CLABSIs) are a leading cause of morbidity and death in this population. Long-term PN also causes parenteral nutrition-associated liver disease, cholestatic damage that can progress to cirrhosis and liver failure over years, particularly in children. It is this PN dependence that is responsible for the majority of morbidity and mortality associated with SBS, including catheter infections and PN-induced cholestatic liver dysfunction.

In the United States, the prevalence of SBS-associated intestinal failure requiring home PN is estimated at roughly 10,000 to 15,000 adults and several thousand children. It is genuinely rare, which is why Gattex received orphan drug designation and why its development took decades from the initial discovery of its target hormone.

The Science: What GLP-2 Does and Why Teduglutide Was Engineered the Way It Was

The story of teduglutide begins with a discovery made in the 1990s about a gut hormone most people have never heard of: glucagon-like peptide-2 (GLP-2).

GLP-2 is a 33-amino acid peptide secreted by L-cells in the distal small intestine and colon in response to food intake. It acts as a trophic hormone for the intestinal epithelium. When researchers administered GLP-2 to mice, the results were striking: GLP-2 produced a 50% increase in small bowel weight, significantly taller villi, and deeper crypts, with no effect on other organs. This identified GLP-2 as a specific intestinal growth factor and immediately suggested therapeutic potential for intestinal failure.

The problem with using native GLP-2 as a drug is its half-life: approximately 7 minutes. The enzyme DPP-4, the same dipeptidyl peptidase-4 that sitagliptin (covered in Post 4 of this LOE series) inhibits, rapidly cleaves and inactivates native GLP-2 in circulation. A drug with a 7-minute half-life would require continuous intravenous infusion, not a practical therapeutic option.

A single amino acid substitution, replacing glycine with alanine at position 2, renders teduglutide resistant to DPP-4 degradation, extending its half-life from approximately 7 minutes to approximately 2 hours. This single amino acid change is the molecular engineering that made teduglutide viable as a once-daily subcutaneous injection rather than a continuous infusion.

The mechanism through which GLP-2 and teduglutide promote intestinal growth is indirect: GLP-2 receptors are not expressed on intestinal epithelial cells themselves. Instead, GLP-2 binds receptors on subepithelial myofibroblasts and enteric neurons, triggering paracrine release of growth factors that promote villus growth, crypt proliferation, barrier repair, and reduced inflammation.

The downstream effects are multiple and coordinated: teduglutide reduces accelerated gastric emptying and gastric hypersecretion, increases intestinal blood flow, promotes the growth of enterocytes, increases villus height and crypt depth, improves intestinal barrier function, and accelerates the process of intestinal adaptation. The sum of these effects is an intestinal lining that is structurally larger, better perfused, and more functionally capable of absorbing fluid and nutrients, meaning the same length of remnant bowel can do more work than it could before teduglutide.

The STEPS Trial and Clinical Evidence

STEPS (Study of Teduglutide Effectiveness in Parenteral Nutrition-Dependent Short Bowel Syndrome) was the pivotal Phase 3 trial that supported Gattex’s 2012 FDA approval. It enrolled 86 adult patients with SBS-associated intestinal failure dependent on parenteral nutrition, randomizing them to teduglutide 0.05 mg/kg/day subcutaneous injection or placebo for 24 weeks.

Outcome	Placebo	Teduglutide 0.05 mg/kg/day	Significance
Achieved at least 20% PN volume reduction at Week 24	30% of patients	63% of patients	p less than 0.001
Mean PN volume reduction	approximately 2 liters per week	approximately 4.4 liters per week	Statistically significant
Patients achieving at least 1 day/week reduction in PN days	27%	54%	Statistically significant
Villus height increase	Not significant	Significant increase	Structural intestinal growth confirmed
Plasma citrulline increase	—	Significant increase	Citrulline as biomarker of functional enterocyte mass

Source: Jeppesen PB et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473–1481. doi:10.1053/j.gastro.2012.09.007.

The 20% PN volume reduction threshold used as the primary endpoint was specifically chosen because it represents a clinically meaningful reduction in infusion time and catheter infection risk. Reducing PN by 20% or more translates to roughly 1 to 2 fewer infusion nights per week for some patients, which has measurable quality-of-life implications.

Long-term extension data told a more complete story about what the drug can achieve over time. A post-hoc analysis of the teduglutide clinical trial program, including two Phase 3 trials and their extension studies, revealed that 16 of 134 patients (approximately 12%) gained complete oral or enteral autonomy from nutritional support after a median of 5 years of previous PN dependence, after a mean duration of 89 weeks of teduglutide treatment. Complete PN independence can occur later in the course of therapy, even after one to two years of administration, meaning that patients and clinicians who see partial benefit early should not discontinue prematurely before the full adaptive potential of the intestine has been realized.

Complete PN independence is the most profound outcome in SBS management: a patient who no longer needs nightly IV nutrition, no longer requires a central line catheter, and can eat and drink without fear that what they consume cannot sustain them. Achieving it in 12% of a population that has been PN-dependent for a median of 5 years is a clinically meaningful milestone, even if the majority of patients achieve meaningful PN reduction rather than full independence.

The Colonoscopy Requirement: Why It Exists and What It Means Clinically

This is the safety element most distinctive to teduglutide and the one most directly tied to its mechanism.

Because teduglutide stimulates intestinal epithelial cell proliferation, it also theoretically accelerates the growth of any pre-existing neoplastic or pre-neoplastic tissue. GLP-2 analog activity on intestinal crypts is not selective between normal mucosa and polyps. The FDA’s response to this theoretical risk is mandatory surveillance: colonoscopy of the entire colon with removal of polyps should be performed within 6 months prior to initiating Gattex therapy and every 5 years thereafter, or more frequently as clinically indicated.

The practical implications for patients are significant. In SBS patients, many of whom are older adults with multiple comorbidities, a history of extensive GI surgery, and significant differences in intestinal anatomy, colonoscopy preparation and procedure carries higher procedural risk than in the average screening population. The discussion of whether colonoscopy surveillance is feasible and appropriate for a given patient should be part of the informed consent process before initiating teduglutide.

Importantly, the clinical trial data showed that polyp rates on teduglutide were not dramatically elevated compared to placebo: a pilot study found the occurrence of polyps was similar before and after treatment and included only low-grade dysplastic lesions. The surveillance requirement is precautionary rather than based on an established excess malignancy signal. Nonetheless, it is mandatory per the prescribing information and should not be deferred.

The Safety Profile

Safety item	Details	Clinical guidance
Colorectal neoplasia (warning)	Potential for accelerated polyp or neoplasia growth due to GLP-2 intestinal proliferative mechanism. Colorectal polyps identified in clinical trials.	Colonoscopy within 6 months before initiating; every 5 years during therapy or more often as clinically indicated. Discontinue in patients with active GI malignancy.
Fluid and electrolyte disturbances	Improved intestinal absorption can alter fluid and electrolyte balance rapidly, particularly in patients concurrently receiving PN.	Monitor fluid and electrolyte balance carefully when initiating therapy. PN volumes may need reduction within weeks. Over-absorption leading to fluid overload is possible, particularly in patients with cardiac or renal comorbidities.
Intestinal obstruction	Cases reported; may reflect underlying SBS anatomy or the effect of increased intestinal motility and tone.	Evaluate for obstruction if symptoms develop. Temporary discontinuation may be required; permanent discontinuation if obstructive symptoms recur.
Biliary and pancreatic disease	Cholecystitis, cholangitis, cholestasis, and pancreatitis reported in post-marketing experience.	Discontinue if these complications develop. Monitor for symptoms especially in patients with prior biliary disease.
Stoma output changes	Patients with stomas may experience significant increases in stoma output with improved absorption.	Monitor stoma output; adjust hydration and PN accordingly.
Acceleration of underlying GI disease	In patients with residual GI disease such as Crohn’s, the trophic effect could theoretically accelerate underlying pathology.	Clinical judgment required; monitor for exacerbation of underlying disease.
Cardiac comorbidity	Fluid retention risk relevant in patients with heart failure or reduced cardiac function.	Use with caution; careful monitoring of fluid status required.
Renal impairment	Dose reduction to 0.025 mg/kg once daily required in patients with moderate to severe renal impairment (eGFR below 60 mL/min/1.73m²).	Check kidney function at baseline and monitor during therapy.
Injection site reactions	Common: redness, pain at the site of subcutaneous injection.	Rotate injection sites.

The Cost Reality: When a Drug Exceeds $700,000 a Year

The current list price for adult dosing of teduglutide exceeds $700,000 per year. For pediatric patients, weight-based dosing produces lower daily doses and somewhat lower annual costs, but still reaches hundreds of thousands of dollars.

To contextualize this against the condition it treats: home parenteral nutrition itself is extremely expensive. Annual PN costs for an SBS patient in the United States range from approximately $150,000 to $300,000 or more per year depending on volume, complexity, and frequency of infusions. The economic case for teduglutide hinges on whether reducing PN dependence produces cost savings that offset the drug’s price.

Published cost-effectiveness modeling is sobering. Seidner et al. found that teduglutide does not meet traditional cost-effectiveness thresholds as a treatment for PN reduction in adult SBS patients compared with standard intestinal rehabilitation. Subpopulations demonstrating maximum benefit could represent cost-saving scenarios, and teduglutide becomes economically reasonable only if its cost is substantially reduced.

In practice, coverage decisions vary substantially by payer. Many commercial insurers cover teduglutide with prior authorization and documented PN dependence. Medicare and Medicaid coverage exists but may require appeals and documentation of medical necessity. For the approximately 12% of treated patients who achieve complete PN independence, the economic calculus shifts dramatically: eliminating the cost of home PN entirely changes the math. For the majority who achieve meaningful PN reduction without full independence, the system is paying more than $700,000 per year for a benefit that is real but falls short of the most transformative outcome.

Takeda’s patient support program provides access and financial assistance navigation for eligible patients. The Oley Foundation, which specifically serves home PN and tube-fed patients, and the National Organization for Rare Disorders are the primary patient community resources.

The Generic and Follow-On Landscape: Why This LOE Is Unique

Gattex’s LOE story has a wrinkle that distinguishes it from both the small-molecule generics (sitagliptin, cladribine) and the biologics (golimumab, omalizumab) in this series. Teduglutide is a recombinant 33-amino acid peptide, which places it in a regulatory category that the FDA has approached differently for different manufacturers over time.

Under the Biologics Price Competition and Innovation Act (BPCIA), large biologics follow the biosimilar aBLA pathway. However, for small peptides, the FDA has also permitted 505(b)(2) NDAs and in some cases standard ANDA pathways where clinical bridging studies can establish equivalence without a full biosimilar data package. The specific pathway for any given teduglutide follow-on product will depend on the FDA’s classification determination for that application. This regulatory ambiguity is not unique to teduglutide: the FDA has published guidance on peptide drug products noting that these determinations are made on a product-by-product basis.

Multiple generic or follow-on manufacturers have filed Paragraph IV patent challenges against Gattex, with seven patent litigation cases filed in total. Two cases remain active. The specific patents challenged cover composition of matter, manufacturing processes, and methods of treatment. The patient population is small enough, and the specialty care infrastructure required to manage SBS complex enough, that competitive launch dynamics here will look nothing like the broad retail pharmacy competition seen with sitagliptin or cladribine.

For patients currently on Gattex: access through Takeda’s specialty pharmacy network will continue unaffected by the LOE. Any formulary transitions to a follow-on product, when they eventually occur, should be managed through the gastroenterology or intestinal rehabilitation team overseeing the patient’s SBS care, not handled at a retail pharmacy level.

What This Means for Patients and Their Families

Short bowel syndrome and intestinal failure exist in a medical ecosystem that most people, including most physicians, have never directly encountered. Patients are managed at specialized intestinal rehabilitation programs at academic medical centers, with multidisciplinary teams including gastroenterologists, dietitians, pharmacists, nurses, and surgeons. The complexity of managing fluid balance, central line care, PN formulation, and the monitoring requirements for teduglutide means that this drug is never managed casually.

For patients currently on Gattex who are responding: treatment should not be discontinued without a specialist’s guidance. The intestinal adaptation that teduglutide has supported may regress over weeks to months after stopping. The colonoscopy surveillance requirement is mandatory throughout treatment, not optional.

For patients or families newly diagnosed with SBS and learning about treatment options: the conversation about teduglutide belongs at a center with intestinal rehabilitation expertise. The drug’s complexity, from the colonoscopy prerequisite to the fluid monitoring to the PN dose adjustments triggered by improving absorption, requires a team that manages this routinely. The Oley Foundation maintains a provider directory and connects SBS patients with peer support networks.

For pediatric patients: the expanded approval to children as young as 1 year old, and the long-term case reports of children weaned from PN dependence with teduglutide, represent a genuinely hopeful development in a disease where neonatal-onset SBS has historically carried sobering long-term outcomes.

For related HED coverage on other pediatric gastroenterological approvals and rare disease drug access, see our post on Linzess (linaclotide) expanding its approval to children as young as 2 years old for functional constipation and our post on Hepcludex (bulevirtide), the first FDA-approved treatment for hepatitis delta, both covering the rare disease treatment access landscape in 2026.

Sources

Gattex FDA approval: FDA approves teduglutide for short bowel syndrome. FDA.gov. December 21, 2012.

Gattex prescribing information: Gattex (teduglutide) Prescribing Information. Takeda Pharmaceuticals. 2024.

Patent expiry and generic interest: GATTEX Loss of Exclusivity. DrugPatentWatch.

GLP-2 discovery and teduglutide engineering: Drucker DJ et al. The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome. ACS Pharmacology and Translational Science. 2019. doi:10.1021/acsptsci.9b00016.

GLP-2 mechanism review: GLP-2 and intestinal adaptation. PMC6720278.

DPP-4 and incretin system: Ahrén B. DPP-4 Inhibition and the Path to Clinical Proof. Frontiers in Endocrinology. 2019. PMC6593050.

STEPS pivotal trial: Jeppesen PB et al. Teduglutide reduces need for parenteral support in patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473–1481. doi:10.1053/j.gastro.2012.09.007. PMID 22982184.

Long-term PN independence data: Drucker DJ et al. ACS Pharmacology and Translational Science. 2019.

SBS epidemiology and PN dependence: Winkler M, Tappenden K. Epidemiology, survival, costs, and quality of life in adults with SBS. Nutr Clin Pract. 2023;38(S1):S17–S26. doi:10.1002/ncp.10964. | Siddiqui MT et al. Short-bowel syndrome: epidemiology, hospitalization trends, in-hospital mortality, and healthcare utilization. JPEN. 2021;45(7):1441–1455. doi:10.1002/jpen.2051.

Cost-effectiveness modeling: Seidner DL et al. Cost-effectiveness of teduglutide in adult patients with SBS. JPEN. 2020. PMC7307185.

Gattex cost reference: Gattex (teduglutide) prices and financial assistance. MedicalNewsToday. June 2025.

SBS StatPearls: Short Bowel Syndrome. StatPearls. NCBI.

Total parenteral nutrition: Total Parenteral Nutrition. StatPearls. NCBI.

PN-associated liver disease: Parenteral Nutrition-Associated Cholestasis. PMC6547003.

Mesenteric ischemia: Mesenteric Ischemia. StatPearls. NCBI.

Necrotizing enterocolitis: Necrotizing Enterocolitis. StatPearls. NCBI.

Crohn’s disease: Crohn’s Disease. NIDDK.

Orphan drug program: Orphan Drug Act. FDA.gov.

BPCIA biosimilar pathway: Biosimilars. FDA.gov.

CLABSI infections: Central Line-Associated Bloodstream Infections. CDC.

NIDDK SBS overview: Short Bowel Syndrome. NIDDK.

HED internal references: LOE Post 4: Januvia/sitagliptin | Linzess pediatric approval post | Hepcludex hepatitis delta post

Patient resources: Oley Foundation | National Organization for Rare Disorders | Gattex patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals, loss of exclusivity events, and health research for educational purposes. This content is not a substitute for professional medical advice. Short bowel syndrome and intestinal failure require management by specialized multidisciplinary intestinal rehabilitation teams. Decisions about initiating, continuing, or transitioning from teduglutide therapy should be made in close collaboration with a gastroenterologist or intestinal rehabilitation specialist experienced in SBS management. Drug pricing information reflects estimates at time of publication and is subject to change.

Mavenclad Takes 20 Days of Pills to Deliver Two Years of Multiple Sclerosis Protection. Its Patents Were Just Ruled Invalid and Generics Launched Earlier Than Anyone Expected. Here Is What the Science Behind This Unusual Therapy Actually Shows.

June 16, 2026

📌 The essentials Mavenclad (cladribine tablets, EMD Serono) is the first and only FDA-approved MS treatment that provides two years of proven disease control with a maximum of 20 days of oral tablet-taking across the entire two-year treatment cycle. Approved in March 2019 for relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS) in patients with inadequate response to or intolerance of an alternate MS therapy. Mechanism: selective immune reconstitution therapy (SIRT). Cladribine is a synthetic purine nucleoside analogue that preferentially depletes B cells and T cells, particularly memory B cells, while largely sparing innate immune cells. This produces durable disease control without continuous immunosuppression. Revenue: Mavenclad generated sales of approximately €1.2 billion in 2025, with North American revenue of €635 million. The patent story: an appeals court upheld a decision by the U.S. Patent Office invalidating two of the dosing regimen patents protecting Mavenclad. Generic launches arrived in December 2025, roughly 10 to 11 months earlier than Merck KGaA anticipated. Merck guided for no U.S. Mavenclad sales from March 2026 onward amid generic competition. Generic pricing: approximately $15,000 to $22,000 per annual treatment course versus brand-name list price of approximately $99,500. CLARITY trial primary endpoint: 57.6% reduction in annualized relapse rate with cladribine 3.5 mg/kg versus placebo (0.14 vs. 0.33; p less than 0.001) at 96 weeks. CLARITY Extension: clinical benefits from the two-year treatment course may be maintained for at least four years in the majority of patients. Boxed warning: embryo-fetal toxicity. Contraception required during treatment and for 6 months after the last dose in both male and female patients.

📚 About this series: the 2026 Loss of Exclusivity Watch This is Post 6 of HED’s 2026 Loss of Exclusivity series, tracking the ten major drugs losing U.S. exclusivity this year. The full series covers: Xolair (omalizumab) • Pomalyst (pomalidomide) • Opsumit (macitentan) • Januvia/Janumet (sitagliptin) • Simponi (golimumab) • Mavenclad (cladribine) • Gattex (teduglutide) • Trintellix (vortioxetine) • Briviact (brivaracetam) • Xeljanz (tofacitinib). Each post follows the same format: what the drug is and how it works, what the clinical evidence shows, who uses it and why, and what the entrance of competition means for patients, prescribers, and the market.

Multiple sclerosis is the most common acquired neurological disease of young adults, affecting roughly one million people in the United States and 2.9 million worldwide. It is a disease that primarily strikes in the prime of life, with most patients receiving their diagnosis between the ages of 20 and 40, and the prospect of decades of progressive disability shapes every treatment decision from the moment of diagnosis.

Most MS therapies require continuous, ongoing treatment. You take the pill daily, or inject yourself weekly, or receive an infusion every month or every six months, indefinitely. The therapy suppresses disease activity while you are taking it; stop taking it, and the disease typically returns.

Mavenclad (cladribine tablets) is the first and only FDA-approved treatment for relapsing-remitting MS and active secondary progressive MS that provides two years of proven efficacy with a maximum of 20 days of oral treatment over a two-year period. Patients take cladribine tablets for a handful of days during two treatment weeks in Year 1, and the same in Year 2, a total of no more than 20 days of actual tablet-taking across the entire two-year treatment cycle. Then, for many patients, no further treatment is needed for at least the following two years.

That is genuinely unlike anything else in the MS formulary. And it is possible because of the biology of what cladribine does inside lymphocytes, a mechanism that produces durable disease control not through continuous immunosuppression, but through something closer to an immune system reset.

Mavenclad generated sales of approximately €1.2 billion in 2025, with North American revenue of €635 million. Then came a dramatic turn. An appeals court upheld a decision by the U.S. Patent Office invalidating two of the dosing regimen patents that had been protecting Mavenclad from generic competition. Generic launches arrived in December 2025, roughly 10 to 11 months earlier than Merck KGaA had anticipated, and Merck’s guidance for 2026 assumed no U.S. Mavenclad sales from March onward amid generic competition.

This post covers the science behind cladribine’s mechanism, what the pivotal CLARITY trials showed, where it fits in the MS treatment landscape, and what the patent invalidation and early generic entry mean for patients and prescribers.

What Multiple Sclerosis Is and Why Relapsing Forms Are the Target

MS is a chronic autoimmune disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord, and over time the nerve fibers themselves. The resulting nerve damage disrupts signals between the brain and body, producing a wide spectrum of symptoms: fatigue, walking difficulty, cognitive problems, vision loss, sensory disturbances, spasticity, bladder dysfunction, and pain.

Relapsing-remitting MS (RRMS) is the most common form at diagnosis, affecting approximately 85% of newly diagnosed patients. It is characterized by discrete episodes of neurological worsening (relapses or attacks) followed by periods of partial or complete recovery. Inflammation is the dominant driver of damage in the relapsing phase.

Active secondary progressive MS (SPMS) develops in a proportion of RRMS patients over time, transitioning from a relapsing pattern to steady, ongoing accumulation of disability with or without superimposed relapses. The FDA approved cladribine specifically for SPMS patients who still have active inflammatory disease, a distinction that matters because not all SPMS patients benefit from anti-inflammatory therapies.

Primary progressive MS (PPMS) involves steady neurological decline from onset, without relapses, and is a distinct biological entity. Cladribine is not indicated for PPMS.

Cladribine’s mechanism, selectively depleting the lymphocytes that drive MS inflammation, is most relevant in the relapsing disease context, where adaptive immune cells (B cells and T cells) are the primary drivers of the inflammatory cascade responsible for relapses and new MRI lesion formation.

The Science: What Cladribine Does and Why 20 Days Generates Years of Effect

Cladribine is a synthetic purine nucleoside analogue, a molecular mimic of deoxyadenosine, one of the building blocks of DNA. Understanding why it works in MS requires understanding why lymphocytes are unusually vulnerable to it.

The main mechanism of action is the induction of a cytotoxic effect on lymphocytes, leading to long-term depletion of peripheral T and B cells. To produce its effects, cladribine must be phosphorylated inside the cell by deoxycytidine kinase (DCK) to its active triphosphate form. Here is the key to cladribine’s selectivity: DCK is expressed at high levels in lymphocytes, far higher than in most other cell types. When cladribine enters a lymphocyte, DCK phosphorylates it into the active form, which then accumulates intracellularly, impairs DNA synthesis and repair, and triggers apoptosis (programmed cell death). Cells that express low levels of DCK, including most cells of the innate immune system such as neutrophils and monocytes, cannot efficiently activate cladribine and are therefore largely spared.

This biochemical selectivity produces a clinically important profile: cladribine preferentially depletes lymphocytes without a major impact on innate immune cells. Within the lymphocyte compartment, it depletes B cells more profoundly and durably than T cells.

Memory B cells, the long-lived immune cells that carry immune memory and drive antigen-specific inflammation, repopulate very slowly after depletion. Unlike immature and mature B cell populations, memory B cells repopulate mostly via germinal center activity, leading to selective long-term loss of peripheral blood memory B cells that may persist for 18 months or longer. In a real-world longitudinal study, after two months CD19 B-lymphocytes were reduced by approximately 85%, CD4 T-lymphocytes by approximately 50%, and CD8 T-lymphocytes by approximately 40% of baseline levels. After 12 months, CD19 B-lymphocytes had largely reconstituted, while CD4 and CD8 T-lymphocytes remained depleted at approximately 40% and 30% of baseline levels respectively.

Lymphocyte population	Depletion at Month 2	Reconstitution at Month 12	Key clinical relevance
CD19+ B cells (total)	approximately 85% reduction	Largely reconstituted	Deep early depletion of cells implicated in MS pathogenesis
Memory B cells specifically	Marked depletion (comparable to alemtuzumab)	Very slow; may remain depleted 18 months or longer	Prolonged memory B cell depletion may underlie durable efficacy
CD4+ T cells	approximately 50% reduction	Remain approximately 40% depleted at 12 months	Slower recovery; contribute to ongoing disease suppression
CD8+ T cells	approximately 40% reduction	Remain approximately 30% depleted at 12 months	Less selectively depleted than B cells
Innate immune cells (neutrophils, monocytes)	Largely spared	Not applicable	Preserves first-line infection defense

Source: Baker D et al. Cladribine treatment of MS is associated with depletion of memory B cells. J Neurol. 2017;264:2052–2060. PMC5937883.

This pattern, deep early depletion of pathogenic lymphocytes followed by gradual immune reconstitution, is the basis for cladribine’s classification as a selective immune reconstitution therapy (SIRT). As a SIRT, cladribine acts as a short-term immunosuppressant rather than a long-term maintenance immunosuppressive. The hypothesis is that depleting autoreactive lymphocytes and allowing the immune system to reconstitute from a cleaner baseline creates a durable window of reduced inflammatory disease activity, without requiring continuous immunosuppressive therapy.

The CLARITY Trials: What the Clinical Evidence Shows

The pivotal clinical program supporting Mavenclad’s approval was the CLARITY trial and its extension, together comprising the most comprehensive dataset for oral cladribine in MS.

CLARITY was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial enrolling 1,326 patients with RRMS. Patients were randomized to cladribine tablets at cumulative doses of 3.5 mg/kg or 5.25 mg/kg body weight, or placebo, administered as short-course annual treatment over 96 weeks.

Outcome at 96 weeks	Placebo	Cladribine 3.5 mg/kg	Cladribine 5.25 mg/kg
Annualized relapse rate	0.33	0.14	0.15
ARR reduction versus placebo	—	57.6% (p less than 0.001)	54.5% (p less than 0.001)
Patients relapse-free	approximately 60%	approximately 80%	approximately 79%
T1 Gd+ lesion reduction	—	approximately 86%	approximately 87%
Active T2 lesion reduction	—	approximately 74%	approximately 77%
Sustained disability progression	Significantly reduced versus placebo for both doses	—	—

Source: Giovannoni G et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. NEJM. 2010;362:416–426. doi:10.1056/NEJMoa0902533. CLARITY trial, NCT00213135.

The MRI data was particularly striking. MRI-measured disease activity was greatly reduced by both doses, with significantly greater proportions of patients remaining lesion-free in cladribine groups versus placebo across all lesion types.

CLARITY Extension was designed to answer the durability question, the most important unknown for any induction therapy. Among patients who had received active cladribine in CLARITY and then received only placebo in the extension, a substantial proportion remained free of relapse and MRI disease activity for at least an additional two years. The CLARITY Extension data demonstrated that in a majority of patients, the clinical benefits of cladribine 3.5 mg/kg given in Years 1 and 2 may be maintained for at least four years, with decisions on further treatment based on monitoring during this period. This durability is the clinical core of the cladribine story: a drug that requires 20 days of tablets and then maintains efficacy for four or more years in a meaningful proportion of patients is a fundamentally different treatment proposition from anything else in MS therapy.

Where Cladribine Fits in the MS Treatment Landscape

The MS disease-modifying therapy landscape in 2026 is one of the most complex in all of neurology. Broadly, DMTs divide into two strategic categories: maintenance therapies and induction therapies.

Maintenance therapies require continuous ongoing treatment to suppress disease activity. Stopping them typically leads to return of disease activity. Examples include interferon betas, glatiramer acetate, natalizumab, ocrelizumab, and ofatumumab.

Induction therapies (or immune reconstitution therapies) aim to achieve durable remission through a time-limited course of treatment that fundamentally alters the immune landscape. Cladribine and alemtuzumab are the two primary examples currently approved for MS. Neither requires indefinite continuous dosing if disease control is achieved.

The regulatory positioning of Mavenclad in the U.S. reflects a second-line designation: it is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate MS drug. In practice, it tends to be used in patients with higher disease activity, either those who have failed a first-line agent or those presenting with highly active disease who require high-efficacy therapy from the start.

Therapy type	Examples	Dosing	Disease activity level	Key consideration
Moderate-efficacy maintenance	Interferons, glatiramer acetate, dimethyl fumarate	Daily, weekly, or biweekly, indefinitely	Low to moderate	Lower side effect burden; lower efficacy ceiling
High-efficacy maintenance	Natalizumab, ocrelizumab, ofatumumab	Monthly or biweekly injections/infusions, indefinitely	Moderate to high	High efficacy; ongoing immunosuppression
Induction/immune reconstitution	Cladribine, alemtuzumab	Short course over 2 years, then monitor	High or highly active	Durable remission possible; distinct safety profile
S1P receptor modulators	Siponimod, ozanimod, fingolimod	Daily oral, indefinitely	Moderate to high	Cardiac monitoring at initiation; rebound risk on discontinuation

The ORACLE-MS study extended cladribine’s evidence base to patients at their first clinical demyelinating event, the earliest stage of MS diagnosis, showing that cladribine tablets significantly reduced the risk of clinically definite MS compared with placebo. This evidence base is relevant for neurologists seeing patients at initial presentation, though the approved U.S. indication remains restricted to relapsing forms with prior inadequate response.

The Safety Profile

Cladribine’s safety profile reflects its mechanism: a drug that depletes lymphocytes will affect the immune system’s ability to fight infections and carries a malignancy risk that requires ongoing attention.

Safety item	Details	Clinical guidance
Lymphopenia	Dose-dependent reduction in lymphocyte counts is expected and is part of the mechanism. Grade 3 lymphopenia occurred in approximately 25% of patients at the 3.5 mg/kg dose; Grade 4 in 0.7%.	Lymphocyte counts must be measured at baseline and during treatment. Do not initiate Year 2 treatment if lymphocyte count has not recovered to the specified threshold.
Serious infections	Increased risk due to lymphocyte depletion, including opportunistic infections and reactivation of latent viruses.	Screen for active infections before initiating. Vaccination status should be reviewed and updated at least 4 to 6 weeks before treatment.
Herpes zoster	Zoster infections occurred at higher rates in cladribine-treated patients than placebo in clinical trials.	Consider prophylactic antiviral therapy. Patients should be vaccinated against varicella-zoster if not immune before starting cladribine. Live zoster vaccine is contraindicated once treatment begins.
Malignancy	Increased risk of malignancy is a class concern for immune reconstitution therapies. A signal was observed in longer-term datasets.	Not recommended in patients with current malignancy. Ongoing cancer screening recommended. Risk-benefit discussion required.
Embryo-fetal toxicity (boxed warning)	Cladribine is teratogenic and genotoxic based on animal studies. May cause fetal harm.	Effective contraception required during treatment and for 6 months after the last dose in both female and male patients. Pregnancy testing required before each treatment cycle. Not for use during pregnancy or breastfeeding.
Renal impairment	Dose adjustment required in patients with moderate-to-severe renal impairment (CrCl below 60 mL/min). Not studied in severe hepatic impairment.	Assess renal function before initiating.
Live vaccines	Contraindicated during treatment due to immunosuppression.	Update all live vaccines before treatment. No live vaccines during the cladribine treatment course.

The teratogenicity boxed warning creates contraception requirements for women and men of reproductive potential extending 6 months after the last dose, reflecting the genotoxicity concern.

The Patent Story: How Generics Arrived Early

Mavenclad’s patent situation is one of the most significant stories in the 2026 LOE landscape, not because it followed the expected course, but because it did not.

Merck KGaA held multiple patents protecting cladribine tablets for MS, including patents covering specific dosing regimens. Multiple generic manufacturers, including Apotex, Aurobindo, and Accord/Intas, filed Paragraph IV certifications challenging those patents as invalid or not infringed. Merck pursued litigation to defend them.

An appeals court upheld a decision by the U.S. Patent Office that two dosing regimen patents for Mavenclad were invalid. Apotex received full FDA approval for its generic version of cladribine tablets, with the first generic launches arriving in December 2025, roughly 10 to 11 months earlier than Merck had anticipated.

In the Merck versus Apotex case, the court invalidated specific claims of U.S. Patent No. 7,713,947 and U.S. Patent No. 8,377,903, both covering cladribine dosing regimens for treating MS. The claims were found invalid as obvious under 35 U.S.C. § 103, following the Federal Circuit’s binding ruling in Merck Serono S.A. v. Hopewell Pharma Ventures, Inc. in 2025. The court found that the specific dosing regimen claimed in the patents was an obvious extension of what skilled practitioners would have arrived at from prior art, not a novel inventive step warranting patent protection.

This outcome has implications beyond Mavenclad. It demonstrates that method-of-use patents, covering how a drug is dosed rather than what the drug is, face a higher obviousness hurdle when the underlying molecule and its general clinical use are already known. Cladribine had been used in medicine for decades before Mavenclad’s development for MS; the composition-of-matter patent on the molecule had long expired. The only protection Merck had was the MS dosing regimen, and the Federal Circuit concluded that regimen was obvious.

The Merck KGaA versus Aurobindo Pharma case, involving three patents covering cladribine treatment regimens for MS, closed February 2, 2026, after 1,116 days of litigation. Multiple additional ANDA filers are in the pipeline, and the competitive generic landscape for cladribine tablets is expected to expand through 2026 and into 2027.

The Pricing and Access Reality

Brand-name Mavenclad costs approximately $99,500 per annual treatment course at list price. Generic cladribine tablets are currently priced at approximately $15,000 to $22,000 per course, though pricing is still stabilizing as additional manufacturers enter.

A discount of 75 to 85% off list price is significant. For uninsured patients or those in health systems where list price matters, the difference between $100,000 and $15,000 to $22,000 per year represents a transformative access change.

For commercially insured patients, the calculation is more nuanced. Brand Mavenclad may actually cost less than generic at the point of care because of manufacturer copay assistance programs. With insurance plus EMD Serono’s copay assistance program, many commercially insured patients pay $0 to $25 per course. This dynamic, where originator copay assistance makes the brand cheaper for insured patients while the system-level cost remains high, is a familiar feature of the specialty pharmaceutical market and partly explains why payer pressure rather than patient demand drives generic conversion in high-cost specialty drugs.

For uninsured patients, Medicare patients who cannot benefit from commercial copay assistance, and patients in markets without robust insurance coverage, generic entry is materially impactful. The MS patient advocacy community has long flagged Mavenclad’s price as an access barrier, and the generic arrival, even at $15,000 to $22,000, is a meaningful step toward broader reach, particularly as generic competition deepens and prices decline further.

What patients currently on Mavenclad should know: generic cladribine tablets are bioequivalent to Mavenclad. The active ingredient, the dose, and the clinical mechanism are identical. A formulary switch from brand to generic cladribine is therapeutically equivalent. As always, confirm the transition with your neurologist, particularly to ensure that the monitoring schedule and contraception requirements are not disrupted during a coverage or formulary change.

What This Means for the MS Treatment Landscape

Mavenclad’s generic availability matters beyond the economics of a single drug. The MS treatment landscape has historically been dominated by drugs requiring indefinite continuous use, with patient adherence, injection burden, infusion logistics, and continuous immunosuppression as consequences. An affordable short-course oral induction therapy opens a clinical and economic niche that previously existed but was priced out of reach for many patients and health systems.

For neurologists managing MS patients: the arrival of generic cladribine creates a moment to revisit whether any patients who have been hesitant due to cost could now access this therapy. Patients with highly active MS who have not responded adequately to first-line agents, and who value the induction treatment model over continuous daily therapy, are the clearest candidates for this conversation.

For patients with MS who have been following the Mavenclad story: the fundamental science behind cladribine, selective immune reconstitution, durable memory B cell depletion, and a finite treatment course rather than indefinite therapy, is unchanged by the patent invalidation. The pill that cost $100,000 per year and the pill that costs $15,000 to $22,000 per year are the same molecule, with the same mechanism, producing the same clinical effect. The landscape has changed; the biology has not.

For related HED coverage on MS treatment advances in 2026, see our post on the FDA approval of Ocrevus (ocrelizumab) for relapsing-remitting MS in pediatric patients aged 10 and older, which covers the OPERETTA 2 trial data and the comparison between ocrelizumab and fingolimod in the pediatric setting.

Sources

Mavenclad FDA approval: FDA approves cladribine tablets for relapsing forms of multiple sclerosis. FDA.gov. March 29, 2019.

Merck KGaA LOE impact statement: Merck KGaA signals end of Mavenclad’s blockbuster era. FirstWord Pharma. March 5, 2026.

Generic cladribine availability: Generic Mavenclad Availability. drugs.com.

Generic pricing: Cladribine 2026: What Patients Need to Know. Medfinder. March 2026. | How to Save Money on Cladribine in 2026. Medfinder. May 2026.

Patent invalidation (Apotex case): Merck vs. Apotex: Cladribine MS Patents Ruled Invalid as Obvious. PatSnap Eureka. February 2026.

Patent litigation (Aurobindo case): Merck KGaA vs. Aurobindo Pharma: Cladribine MS Patent Dispute Closes. PatSnap Eureka. March 2026.

CLARITY trial primary publication: Giovannoni G et al. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. NEJM. 2010;362:416–426. doi:10.1056/NEJMoa0902533.

CLARITY trial registration: NCT00213135. ClinicalTrials.gov.

CLARITY Extension: Giovannoni G et al. Safety and efficacy of cladribine tablets in patients with RRMS: results from the CLARITY extension. Mult Scler. 2018;24:1594–1604. PMID 29307230.

Memory B cell depletion mechanism: Baker D et al. Cladribine treatment of MS is associated with depletion of memory B cells. J Neurol. 2017;264:2052–2060. PMC5937883.

SIRT classification: Baker D et al. Potential mechanisms of action related to the efficacy and safety of cladribine. Multiple Sclerosis and Related Disorders. 2019. PMID 31362145.

Lymphocyte reconstitution kinetics: Comi G et al. Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment. Multiple Sclerosis and Related Disorders. 2021.

ORACLE-MS (clinically isolated syndrome): Leist TP et al. Effect of Oral Cladribine on Time to Conversion to Clinically Definite MS. JAMA Neurol. 2014;71(10):1278–1286. doi:10.1001/jamaneurol.2014.1947.

Cladribine StatPearls: Cladribine. StatPearls. NCBI.

MS overview: Multiple Sclerosis. StatPearls. NCBI.

Interferon betas: Interferon Beta. StatPearls. NCBI.

Alemtuzumab FDA approval: FDA approves alemtuzumab for multiple sclerosis. FDA.gov.

Lymphopenia: Lymphopenia. StatPearls. NCBI.

Herpes zoster: Herpes Zoster. StatPearls. NCBI.

Mavenclad prescribing information: Mavenclad (cladribine) tablets Prescribing Information. EMD Serono.

National MS Society disease types: Types of MS. nationalmssociety.org.

Patient resources: National Multiple Sclerosis Society | Can Do MS | EMD Serono Mavenclad patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals, loss of exclusivity events, and health research for educational purposes. This content is not a substitute for professional medical advice. Multiple sclerosis treatment decisions, including the choice of disease-modifying therapy and transitions between brand-name and generic products, should be made in close collaboration with a board-certified neurologist specializing in MS. Patients must follow all pregnancy prevention and monitoring requirements associated with cladribine therapy.

IgA Nephropathy Silently Damages Kidneys for Years Before Most Patients Know It Is Happening. Trutakna Just Became the First Approved Therapy to Target Its Root Immunological Cause.

Pediatric Psoriasis Has Lacked Good Biologic Options for Younger Children and Smaller Patients. Skyrizi Just Became the First IL-23 Inhibitor Approved Down to Age Six and Under 40 Kilograms.

Keytruda Has Been Approved for More Than 20 Cancers Since 2014. Its New TNBC Approval Is Not Just Another Indication. It Is Also the First Time the Subcutaneous Version Gets to Work Alongside an ADC.

Stem Cell Transplants Can Cure Blood Cancers Like Leukemia. Chronic Graft-Versus-Host Disease Can Make the Cure Almost As Devastating As the Disease. Tregzi Just Changed That Calculus.

HR-Positive, HER2-Positive Breast Cancer Resists Both Its Major Treatments at the Same Time. Palbociclib Just Became the First CDK4/6 Inhibitor Shown to Address That Resistance in Maintenance. Here Is What the PATINA Trial Data Shows.

Triple-Negative Breast Cancer Has Had No Good First-Line Option for Patients Who Cannot Take Immunotherapy. Trodelvy Just Became the First Advance in 20 Years for That Population and the New Standard for Those Who Can. Here Is What the ASCENT-03 and ASCENT-04 Data Shows.

Thyroid Eye Disease Has Had Only One Approved Treatment Since 2020. Lumvoa Just Became the Second, and It’s the First Proven to Work in Both Active and Chronic Disease. Here Is What the THRIVE Trials Show.

Severe Hypertriglyceridemia Has No Good Treatment Options. Tryngolza Just Became the First Approved Therapy Shown to Reduce Acute Pancreatitis Risk. Here Is What the CORE Trial Data Shows.

The Standard Nilotinib Pill and Acid Reducers Don’t Mix. For the 25% of CML Patients on PPIs, That’s Been a Real Problem. Cavhanza Just Solved It.

The FDA Just Approved a Third OTC Naloxone Nasal Spray. Here Is What Rextovy Is, How Naloxone Works, and Why More Competition in This Market Could Finally Move the Price.

IgA Nephropathy Silently Damages Kidneys for Years Before Most Patients Know It Is Happening. Trutakna Just Became the First Approved Therapy to Target Its Root Immunological Cause.

Pediatric Psoriasis Has Lacked Good Biologic Options for Younger Children and Smaller Patients. Skyrizi Just Became the First IL-23 Inhibitor Approved Down to Age Six and Under 40 Kilograms.

Keytruda Has Been Approved for More Than 20 Cancers Since 2014. Its New TNBC Approval Is Not Just Another Indication. It Is Also the First Time the Subcutaneous Version Gets to Work Alongside an ADC.

Triple-Negative Breast Cancer Has Had No Good First-Line Option for Patients Who Cannot Take Immunotherapy. Trodelvy Just Became the First Advance in 20 Years for That Population and the New Standard for Those Who Can. Here Is What the ASCENT-03 and ASCENT-04 Data Shows.

Thyroid Eye Disease Has Had Only One Approved Treatment Since 2020. Lumvoa Just Became the Second, and It’s the First Proven to Work in Both Active and Chronic Disease. Here Is What the THRIVE Trials Show.

Severe Hypertriglyceridemia Has No Good Treatment Options. Tryngolza Just Became the First Approved Therapy Shown to Reduce Acute Pancreatitis Risk. Here Is What the CORE Trial Data Shows.

The FDA Just Approved a Third OTC Naloxone Nasal Spray. Here Is What Rextovy Is, How Naloxone Works, and Why More Competition in This Market Could Finally Move the Price.

Type 1 Diabetes Has Never Had a Disease-Modifying Therapy That Works After Diagnosis. Tzield Just Changed That. Here Is What the PROTECT Trial Data Shows.

Ebglyss Can Now Be Given Every 8 Weeks Instead of Every 4. For Patients With Moderate-to-Severe Atopic Dermatitis, That Is a Meaningful Change. Here Is What the Science Shows.

Hympavzi Just Became Available to Children as Young as 6 and to Patients With Hemophilia Inhibitors — Two of the Groups Who Have Needed It Most. Here Is What the BASIS Trial Data Shows.